{
    "testId": 396304748,
    "parentTestId": null,
    "userId": 4331736,
    "sequenceId": 120,
    "qbankId": 2,
    "isSim": 0,
    "testModeId": 0,
    "testModeName": "Timed",
    "questionModeId": 0,
    "questionModeName": "ALL",
    "testName": "",
    "totalQuestionCorrect": 0,
    "correctToIncorrect": 0,
    "incorrectToCorrect": 0,
    "incorrectToIncorrect": 0,
    "timeInSeconds": 3593,
    "averageTimeSpentInSeconds": 0,
    "otherAverageTimeSpentInSeconds": 62,
    "isStarted": true,
    "isEnded": true,
    "formId": 0,
    "bLockId": 0,
    "subscriptionId": 13863865,
    "lastQuestionVisited": 40,
    "containsMediaQuestion": false,
    "sectionId": 1010,
    "sectionName": "Step 2 Review",
    "difficultyLevelId": null,
    "difficultyLevelName": null,
    "testTypeId": null,
    "testTypeName": null,
    "allottedTime": null,
    "allottedTimeTypeId": null,
    "canResume": null,
    "assignmentId": null,
    "canViewAssignmentResult": null,
    "questionModeIds": "1",
    "testSource": 1,
    "testTypes": "",
    "questionList": [
        {
            "exhibits": null,
            "sequenceId": 1,
            "questionId": 3814,
            "questionIndex": 3814,
            "questionText": "<p>A 34-year-old woman comes to the office for evaluation of 3 months of amenorrhea.&nbsp; She first began experiencing irregular periods a year ago, and now they have stopped completely.&nbsp; The patient has no headaches, visual changes, galactorrhea, hair loss, or fatigue.&nbsp; She has a history of non-Hodgkin lymphoma for which she received chemotherapy 5 years ago; there are no signs of recurrence.&nbsp; The patient currently takes no medications.&nbsp; Family history is noncontributory.&nbsp; Her most recent Pap test was last year and all prior testing was normal.&nbsp; She has no history of sexually transmitted infections.&nbsp; The patient does not use tobacco, alcohol, or recreational drugs.&nbsp; Blood pressure is 120/80 mm Hg and pulse is 78/min.&nbsp; BMI is 28 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Physical examination reveals a nonenlarged thyroid without masses.&nbsp; Cardiopulmonary examination is normal.&nbsp; Pelvic examination reveals dry vaginal mucosa and a small, anteverted, mobile uterus with no adnexal masses.&nbsp; A pregnancy test is negative.&nbsp; Which of the following laboratory findings are most likely present in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t33065\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"5\"><p align=\"center\"><strong>Diagnostic findings of amenorrhea</strong></p></td></tr><tr><td></td><td><p align=\"center\"><strong>FSH</strong></p></td><td><p align=\"center\"><strong>LH</strong></p></td><td><p align=\"center\"><strong>Prolactin</strong></p></td><td><p align=\"center\"><strong>TSH</strong></p></td></tr><tr><td><p><strong>Ovarian failure</strong></p></td><td><p align=\"center\">&#8593;</p></td><td><p align=\"center\">&#8593;</p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">Normal</p></td></tr><tr><td><p><strong>Functional hypothalamic amenorrhea</strong></p></td><td><p align=\"center\">&#8595;</p></td><td><p align=\"center\">&#8595;</p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">Normal</p></td></tr><tr><td><p><strong>Asherman syndrome</strong></p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">Normal</p></td></tr><tr><td><p><strong>Prolactinoma</strong></p></td><td><p align=\"center\">&#8595;</p></td><td><p align=\"center\">&#8595;</p></td><td><p align=\"center\">&#8593;</p></td><td><p align=\"center\">Normal</p></td></tr><tr><td><p><strong>Hypothyroidism</strong></p></td><td><p align=\"center\">&#8595;</p></td><td><p align=\"center\">&#8595;</p></td><td><p align=\"center\">&#8593;</p></td><td><p align=\"center\">&#8593;</p></td></tr></tbody></table></div><p>This patient has a history of cancer, <strong>amenorrhea</strong>, and signs of <strong>estrogen deficiency</strong> (eg, vaginal dryness), consistent with <strong>ovarian failure</strong> secondary to <strong>chemotherapy</strong>.&nbsp; <strong>Hypergonadotropic hypogonadism</strong> in women <strong>age &lt;40</strong>, also known as <strong>primary ovarian insufficiency</strong>, occurs due to the absence of developing follicles.&nbsp; Chemotherapy and radiation target rapidly dividing cancer cells but also affect the proliferating granulosa and theca cells of the ovary.&nbsp; Patients undergoing cancer treatment often have transient amenorrhea but have an overall shortened reproductive capacity even if menses return.&nbsp; Ovarian failure results in decreased estrogen, thereby decreasing negative feedback to the hypothalamus and pituitary and resulting in <strong>increased FSH and LH production</strong>.&nbsp; Treatment with hormone replacement therapy provides menopausal symptom relief and bone loss protection.&nbsp; Fertility preservation may be possible with cryopreservation techniques prior to treatment onset.</p><p><strong>(Choice B)</strong>&nbsp; Functional hypothalamic amenorrhea occurs in patients with relative caloric deficiency (unlikely with a normal BMI) and is characterized by a decrease in GnRH secretion, resulting in decreased FSH and LH levels and suppression of ovarian function.&nbsp; There is no association with chemotherapy.</p><p><strong>(Choice C)</strong>&nbsp; Asherman syndrome is a structural cause of secondary amenorrhea due to intrauterine adhesions from endometrial infection (eg, endometritis) or instrumentation (eg, dilation and curettage).&nbsp; Hormone levels are normal.</p><p><strong>(Choice D)</strong>&nbsp; Prolactinoma is a cause of secondary amenorrhea; elevated prolactin levels negatively inhibit hypothalamic GnRH secretion and result in decreased FSH and LH levels.&nbsp; Symptoms include headache, bilateral hemianopsia, and galactorrhea, which are not seen in this patient.&nbsp; In addition, there is no correlation with history of chemotherapy.</p><p><strong>(Choice E)</strong>&nbsp; Hypothyroidism can present with menstrual dysfunction, fatigue, and hair changes, without signs of hypoestrogenism.&nbsp; Findings include an enlarged thyroid, elevated TSH, and low T3/T4 levels.&nbsp; In hypothyroidism, low T3/T4 increases thyrotropin-releasing hormone (TRH) secretion from the hypothalamus.&nbsp; Increased TRH stimulates prolactin secretion, which has inhibitory effects on GnRH production, thereby decreasing FSH and LH levels.</p><p><strong>Educational objective:</strong><br>Ovarian failure may occur secondary to chemotherapy and presents with amenorrhea and signs of estrogen deficiency (eg, vaginal dryness).&nbsp; Ovarian failure is characterized by increased FSH and LH due to lack of feedback inhibition from estrogen.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 23429,
            "topic": "Amenorrhea",
            "titleId": 23429,
            "title": "Amenorrhea",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "1",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"450\">\n\t<tbody>\n\t\t<tr align=\"center\">\n\t\t\t<td width=\"25%\">\n\t\t\t\t&#8593;\n\t\t\t</td>\n\t\t\t<td width=\"25%\">\n\t\t\t\t&#8593;\n\t\t\t</td>\n\t\t\t<td width=\"25%\">\n\t\t\t\tNormal\n\t\t\t</td>\n\t\t\t<td width=\"25%\">\n\t\t\t\tNormal\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>",
                    "choiceNumber": 1,
                    "correctTaken": 12362,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"450\">\n\t<tbody>\n\t\t<tr align=\"center\">\n\t\t\t<td width=\"25%\">\n\t\t\t\t&#8595;\n\t\t\t</td>\n\t\t\t<td width=\"25%\">\n\t\t\t\t&#8595;\n\t\t\t</td>\n\t\t\t<td width=\"25%\">\n\t\t\t\tNormal\n\t\t\t</td>\n\t\t\t<td width=\"25%\">\n\t\t\t\tNormal\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>",
                    "choiceNumber": 2,
                    "correctTaken": 3090,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"450\">\n\t<tbody>\n\t\t<tr align=\"center\">\n\t\t\t<td width=\"25%\">\n\t\t\t\tNormal\n\t\t\t</td>\n\t\t\t<td width=\"25%\">\n\t\t\t\tNormal\n\t\t\t</td>\n\t\t\t<td width=\"25%\">\n\t\t\t\tNormal\n\t\t\t</td>\n\t\t\t<td width=\"25%\">\n\t\t\t\tNormal\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>",
                    "choiceNumber": 3,
                    "correctTaken": 279,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"450\">\n\t<tbody>\n\t\t<tr align=\"center\">\n\t\t\t<td width=\"25%\">\n\t\t\t\t&#8595;\n\t\t\t</td>\n\t\t\t<td width=\"25%\">\n\t\t\t\t&#8595;\n\t\t\t</td>\n\t\t\t<td width=\"25%\">\n\t\t\t\t&#8593;\n\t\t\t</td>\n\t\t\t<td width=\"25%\">\n\t\t\t\tNormal\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>",
                    "choiceNumber": 4,
                    "correctTaken": 664,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"450\">\n\t<tbody>\n\t\t<tr align=\"center\">\n\t\t\t<td width=\"25%\">\n\t\t\t\t&#8595;\n\t\t\t</td>\n\t\t\t<td width=\"25%\">\n\t\t\t\t&#8595;\n\t\t\t</td>\n\t\t\t<td width=\"25%\">\n\t\t\t\t&#8593;\n\t\t\t</td>\n\t\t\t<td width=\"25%\">\n\t\t\t\t&#8593;\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>",
                    "choiceNumber": 5,
                    "correctTaken": 385,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "703",
                    "mediaDataId": 0,
                    "title": "Evaluation of primary amenorrhea",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27912889",
                    "mediaDataId": 0,
                    "title": "Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27912889",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 3,
            "othersAvgTimeSpent": 73,
            "notes": null,
            "peopleTaken": 16780,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 74,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"450\"><tbody><tr align=\"center\"><td width=\"25%\"><strong>FSH</strong></td><td width=\"25%\"><strong>LH</strong></td><td width=\"25%\"><strong>Prolactin</strong></td><td width=\"25%\"><strong>TSH</strong></td></tr></tbody></table>",
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 3,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 2,
            "questionId": 10918,
            "questionIndex": 12054,
            "questionText": "<p>A 60-year-old woman comes to the clinic due to the persistent feeling of &#x22;always having to go to the bathroom.&#x22;&nbsp; For the past 3 years, the patient has had urinary urgency followed by involuntary loss of urine 2 or 3 times per day.&nbsp; She has dysuria and nocturia and sometimes awakens to find her undergarments wet but she does not lose urine with coughing or sneezing.&nbsp; Menopause occurred at age 52 when a total laparoscopic hysterectomy with bilateral salpingo-oophorectomy was performed for endometrial adenocarcinoma.&nbsp; Medical history is significant for recurrent urinary tract infections during the past year.&nbsp; The patient is not sexually active and takes no medications.&nbsp; On physical examination, the vulvar skin shows reduced elasticity with labia minora retraction.&nbsp; The vaginal epithelium is smooth, dry, and has areas of patchy erythema.&nbsp; On Valsalva maneuver, there is no loss of urine.&nbsp; Urinalysis and postvoid residual urine testing are normal.&nbsp; Which of the following is the most likely cause of this patient&#39;s urinary symptoms?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t31153\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Genitourinary syndrome of menopause</strong></p></td></tr><tr><td><p align=\"center\"><strong>Symptoms</strong></p></td><td><ul><li>Vulvovaginal dryness, irritation, pruritus</li><li>Dyspareunia</li><li>Vaginal bleeding</li><li>Urinary incontinence, recurrent urinary tract infection</li><li>Pelvic pressure</li></ul></td></tr><tr><td><p align=\"center\"><strong>Physical<br />examination</strong></p></td><td><ul><li>Narrowed introitus</li><li>Pale mucosa, &darr;&nbsp;elasticity, &darr;&nbsp;rugae</li><li>Petechiae, fissures</li><li>Loss of labial volume</li></ul></td></tr><tr><td><p align=\"center\"><strong>Treatment</strong></p></td><td><ul><li>Vaginal moisturizer &amp; lubricant</li><li>Topical vaginal estrogen</li></ul></td></tr></tbody></table></div><p>This patient&#39;s urinary symptoms and vulvovaginal atrophy are due to the <strong>genitourinary syndrome of menopause</strong> (or atrophic vaginitis).&nbsp; Both age-related ovarian follicle depletion (ie, menopause) and surgical removal of the ovaries (eg, bilateral salpingo-oophorectomy) result in an <strong>estrogen deficiency</strong> that affects the urogenital tissue and causes the associated urinary symptoms of atrophic vaginitis:</p><ul><li><p>Decreased collagen, elasticity, and blood flow in the bladder trigone and urethra (which are estrogen-sensitive tissues) result in <strong>urogenital atrophy</strong>, which can induce <strong>urgency incontinence</strong> (urgency followed by immediate loss of urine), often causing wet undergarments and nocturia (as seen in this patient).</p></li><li><p>Decreased glycogen content results in loss of vaginal lactobacilli and an elevated vaginal pH, which increase the risk of <strong>recurrent urinary tract infections</strong>.&nbsp; At the vulva, decreased glycogen content results in a thin, easily denuded vulvovaginal epithelium that causes <strong>dysuria</strong> when in contact with urine.</p></li></ul><p>Additional clinical features of atrophic vaginitis include reduced vulvar elasticity; labial retraction; and a smooth, nonrugated vaginal epithelium with areas of patchy erythema.&nbsp; First-line treatment is with nonhormonal moisturizers and lubricants.&nbsp; Vaginal estrogen is indicated in patients with no symptom relief or in those with severe symptoms.</p><p><strong>(Choice A)</strong>&nbsp; Chronic bladder pain syndrome (ie, interstitial cystitis) is an idiopathic bladder pain syndrome associated with urinary frequency and urgency.&nbsp; Patients have bladder pain that worsens with filling and is relieved with emptying.&nbsp; There is typically no associated urinary incontinence, making this diagnosis unlikely.</p><p><strong>(Choice C)</strong>&nbsp; Patients with overflow incontinence have a persistently full, distended bladder that causes continuous loss of urine (dribbling) due to incomplete bladder emptying (ie, high postvoid residual volume).&nbsp; This patient&#39;s postvoid residual is normal.</p><p><strong>(Choice D)</strong>&nbsp; Urethral hypermobility is a cause of stress urinary incontinence, which presents with intermittent urine loss with increased intraabdominal pressure (eg, cough, sneeze).&nbsp; This patient has no loss of urine with Valsalva maneuver, making this diagnosis unlikely.</p><p><strong>(Choice E)</strong>&nbsp; <a href=\"4908\">Vesicovaginal fistula</a> leads to continuous urine leakage through an abnormal connection from the bladder to the vagina, typically presenting within months after pelvic surgery (eg, hysterectomy).&nbsp; This patient does not have continuous leakage of urine.</p><p><strong>Educational objective:</strong><br>Genitourinary syndrome of menopause causes an estrogen deficiency that results in urogenital atrophy and can present with multiple urinary symptoms (eg, dysuria, urgency incontinence, recurrent urinary tract infections).&nbsp; Treatment is with nonhormonal moisturizers; vaginal estrogen is prescribed for nonimproving or severe symptoms.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 14169,
            "topic": "Vaginal atrophy",
            "titleId": 14169,
            "title": "Vaginal atrophy",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "2",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Chronic bladder pain syndrome",
                    "choiceNumber": 1,
                    "correctTaken": 1680,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Estrogen deficiency",
                    "choiceNumber": 2,
                    "correctTaken": 7333,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Incomplete bladder emptying",
                    "choiceNumber": 3,
                    "correctTaken": 2071,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Urethral hypermobility",
                    "choiceNumber": 4,
                    "correctTaken": 3666,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Vesicovaginal fistula formation",
                    "choiceNumber": 5,
                    "correctTaken": 1871,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "57",
                    "mediaDataId": 0,
                    "title": "Genitourinary syndrome of menopause",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26366797",
                    "mediaDataId": 0,
                    "title": "Treatment of the genitourinary syndrome of menopause.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26366797",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26830033",
                    "mediaDataId": 0,
                    "title": "The role of local estrogen therapy in the management of pelvic floor disorders.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26830033",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "29787390",
                    "mediaDataId": 0,
                    "title": "Genitourinary syndrome of menopause.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/29787390",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 72,
            "notes": null,
            "peopleTaken": 16621,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 44,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 3,
            "questionId": 2395,
            "questionIndex": 2395,
            "questionText": "<p>A 16-year-old girl comes to the office for evaluation of painful menstrual periods.&nbsp; The patient underwent menarche at age 13 and initially had irregular menses.&nbsp; Her menstrual cycles now occur every 30 days, with 4 days of moderate bleeding.&nbsp; Her menses have become increasingly painful; lower abdominal pain starts a few hours prior to menses and lasts 1 or 2 days with associated fatigue, dizziness, and diarrhea.&nbsp; She misses school at least 1 day per month due to the pain but is able to maintain her grades and has no pain or other symptoms after completion of menses.&nbsp; The patient has a history of depression, for which she sees a therapist, but has had no recent changes in mood.&nbsp; She recently became sexually active and uses condoms for contraception.&nbsp; Her last menstrual period was a week ago.&nbsp; Vital signs are normal.&nbsp; Pelvic examination shows normal external genitalia and a clear discharge emerging from the cervical os.&nbsp; On bimanual examination, the uterus is mobile, nontender, and normal in size and contour.&nbsp; Bilateral adnexa have no masses or tenderness.&nbsp; Which of the following is the most likely diagnosis in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t35624\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Primary dysmenorrhea </strong></p></td></tr><tr><td><p align=\"center\"><strong>Etiology </strong></p></td><td><ul><li>Excessive prostaglandin production</li></ul></td></tr><tr><td><p align=\"center\"><strong>Risk factors </strong></p></td><td><ul><li>Age &lt;30</li><li>BMI &lt;20 kg/m<sup>2</sup></li><li>Tobacco use</li><li>Menarche at age &lt;12</li><li>Heavy/long menstrual periods</li><li>Sexual abuse</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical features </strong></p></td><td><ul><li>Pain first 2-3 days of menses</li><li>Nausea, vomiting, diarrhea</li><li>Normal pelvic examination</li></ul></td></tr><tr><td><p align=\"center\"><strong>Management </strong></p></td><td><ul><li>Nonsteroidal anti-inflammatory drugs</li><li>Combination&nbsp;oral contraceptive pills</li></ul></td></tr></tbody></table></div><p>At the onset of menarche, adolescents typically have irregular, nonpainful menses due to the lack of ovulation from an immature hypothalamic-pituitary-ovarian axis.&nbsp; As this axis matures, ovulation can cause excessive endometrial prostaglandin release during menses, which results in lower abdominal cramping and other associated symptoms (eg, fatigue, dizziness, diarrhea) known as <strong>primary dysmenorrhea</strong>.&nbsp; Primary dysmenorrhea is common in <strong>adolescents</strong> (up to 90%).&nbsp; Patients typically have <strong>crampy</strong>, <strong>bilateral</strong>, <strong>lower abdominal pain</strong> that begins 1 or 2 days prior to menses (as uterine contractions initiate endometrial sloughing) and <strong>resolves a few days after onset of menses</strong> (as the endometrial lining thins).&nbsp; Patients have a <strong>normal pelvic examination</strong> and no chronic pain symptoms.</p><p>First-line treatment in nonsexually active patients is with <strong>nonsteroidal anti-inflammatory drugs</strong> because they decrease prostaglandin production.&nbsp; In sexually active patients, such as this one, <strong>combination oral contraceptives</strong> are an option because they suppress ovulation, thereby providing contraception as well as decreasing prostaglandin release.&nbsp; Most women have decreasing symptoms with increasing age.</p><p><strong>(Choice A)</strong>&nbsp; <a href=\"1210\">Adenomyosis</a> typically causes dysmenorrhea in women age &gt;40 rather than adolescents.&nbsp; Due to the endometrial glands and stroma within the uterine myometrium, patients typically have a tender, symmetrically enlarged (&#x22;globular&#x22;) uterus, which is not seen in this patient.</p><p><strong>(Choice B)</strong>&nbsp; <a href=\"1139\">Endometriosis</a> may present in adolescents with dysmenorrhea.&nbsp; In contrast to this patient, those with endometriosis have pain that typically begins a few days prior and persists throughout the entire menstrual cycle.&nbsp; In addition, patients may have uterosacral ligament tenderness, cul-de-sac nodularity, or adnexal enlargement (ie, endometrioma) on examination.</p><p><strong>(Choice C)</strong>&nbsp; Adolescents are a high-risk group for sexually transmitted infections.&nbsp; However, pelvic inflammatory disease is unlikely because this patient has no fever, uterine and adnexal tenderness, or purulent cervical discharge.&nbsp; Her clear cervical discharge is likely physiologic.</p><p><strong>(Choice E)</strong>&nbsp; Somatic symptom disorder occurs due to a preoccupation with 1 or more somatic symptoms (ie, pelvic pain) that result in significant dysfunction or distress.&nbsp; Although the patient has some risk factors (eg, depression), this disorder is unlikely due to the temporal pattern of the pain, which causes no significant impairment (eg, no grade changes).</p><p><strong>Educational objective:</strong><br>Primary dysmenorrhea commonly occurs in adolescents after the establishment of ovulatory menstrual cycles.&nbsp; Excessive endometrial prostaglandin production results in lower abdominal cramping and other associated symptoms (eg, fatigue) during menses.&nbsp; Symptoms typically decrease with age.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 104,
            "subject": "Pediatrics",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 21040,
            "topic": "Dysmenorrhea",
            "titleId": 21040,
            "title": "Dysmenorrhea",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "4",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Adenomyosis",
                    "choiceNumber": 1,
                    "correctTaken": 282,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Endometriosis",
                    "choiceNumber": 2,
                    "correctTaken": 2390,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Pelvic inflammatory disease",
                    "choiceNumber": 3,
                    "correctTaken": 308,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Primary dysmenorrhea",
                    "choiceNumber": 4,
                    "correctTaken": 12622,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Somatic symptom disorder",
                    "choiceNumber": 5,
                    "correctTaken": 256,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "58",
                    "mediaDataId": 0,
                    "title": "Primary dysmenorrhea",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "22846528",
                    "mediaDataId": 0,
                    "title": "Adolescent dysmenorrhea.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/22846528",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "24695505",
                    "mediaDataId": 0,
                    "title": "Diagnosis and initial management of dysmenorrhea.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/24695505",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26841639",
                    "mediaDataId": 0,
                    "title": "Primary dysmenorrhea in adolescents: prevalence, impact and recent knowledge.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26841639",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 59,
            "notes": null,
            "peopleTaken": 15859,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 80,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 4,
            "questionId": 3241,
            "questionIndex": 3241,
            "questionText": "<p>A 16-year-old girl comes to the office for emergency contraception.&nbsp; She had unprotected sexual intercourse last night and is worried that she may become pregnant.&nbsp; Her last menstrual period was 1 week ago, and she has had regular menses since menarche.&nbsp; Physical examination is normal and urine pregnancy test is negative.&nbsp; After various emergency contraceptive options are discussed, the patient asks for a pill option and that her parents not be notified about this visit.&nbsp; In most states, which of the following is the most appropriate management of this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t32628\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"4\"><p align=\"center\"><strong>Emergency contraception</strong></p></td></tr><tr><td><p align=\"center\"><strong>Method</strong></p></td><td><p align=\"center\"><strong>Timing after<br />intercourse</strong></p></td><td><p align=\"center\"><strong>Efficacy</strong></p></td><td><p align=\"center\"><strong>Contraindications</strong></p></td></tr><tr><td><p align=\"center\"><strong>Copper-containing<br />intrauterine device</strong></p></td><td><p align=\"center\">0-120 hr</p></td><td><p align=\"center\">&gt;99%</p></td><td><ul><li>Wilson disease</li><li>Active pelvic infection</li><li>Severe uterine cavity distortion</li></ul></td></tr><tr><td><p align=\"center\"><strong>Progestin-releasing<br />intrauterine device</strong></p></td><td><p align=\"center\">0-120 hr</p></td><td><p align=\"center\">&gt;99%</p></td><td><ul><li>Breast cancer</li><li>Active pelvic infection</li><li>Severe uterine cavity distortion</li></ul></td></tr><tr><td><p align=\"center\"><strong>Ulipristal</strong></p></td><td><p align=\"center\">0-120 hr</p></td><td><p align=\"center\">98%-99%</p></td><td><ul><li>None</li></ul></td></tr><tr><td><p align=\"center\"><strong>Oral levonorgestrel</strong></p></td><td><p align=\"center\">0-72 hr</p></td><td><p align=\"center\">92%-98%</p></td><td><ul><li>None</li></ul></td></tr><tr><td><p align=\"center\"><strong>Oral contraceptives*</strong></p></td><td><p align=\"center\">0-72 hr</p></td><td><p align=\"center\">75%-89%</p></td><td><ul><li>None</li></ul></td></tr><tr><td colspan=\"4\"><p>*Combined estrogen/progestin oral contraceptive pills containing levonorgestrel or norgestrel.</p></td></tr></tbody></table></div><p>Patients with recent unprotected intercourse may be candidates for postcoital or <strong>emergency contraception (EC)</strong> for <strong>pregnancy prevention</strong>.&nbsp; Pregnancy status determines eligibility for EC use:</p><ul><li>Patients with a positive pregnancy test are not candidates for EC because implantation has already occurred.</li><li>In contrast, patients with a negative pregnancy test are still at risk for unintended pregnancy and are candidates for EC <strong>(Choice D)</strong>.</li></ul><p>The<strong> levonorgestrel pill</strong>&nbsp;(ie, Plan B) is the most readily available form of EC; the high dose of progestin in these pills prevents pregnancy by inhibiting the LH surge, thereby <strong>delaying ovulation</strong>.&nbsp; Additional mechanisms include cervical mucus thickening and thinning of the endometrial lining.&nbsp; Levonorgestrel pills are highly effective (ie, up to 94%); however, effectiveness decreases over the course of 72 hours (ie, as low as 59%).&nbsp; Therefore, levonorgestrel pills should be <strong>provided as soon as possible</strong> after unprotected intercourse.&nbsp; Most states allow adolescents to receive confidential care for contraception, pregnancy, and sexually transmitted diseases without parental consent <strong>(Choice A)</strong>.</p><p><strong>(Choice B)</strong>&nbsp; In patients with a positive pregnancy test (ie, implanted pregnancy), misoprostol (prostaglandin E1) can be used for medical abortion or pregnancy termination by stimulating uterine contractions.&nbsp; Misoprostol does not prevent pregnancy and, therefore, is not used for EC.</p><p><strong>(Choice E)</strong>&nbsp; Combination oral contraceptives, commonly used for precoital contraception, may also be used for EC by taking multiple pills simultaneously to achieve the progestin level required to delay ovulation.&nbsp; However, the high estrogen content typically causes intolerable side effects (eg, severe nausea), and this method is less effective (ie, 47%-89%) than levonorgestrel pills.</p><p><strong>Educational objective:</strong><br>The levonorgestrel pill (ie, Plan B) are a readily available and effective emergency contraception option that prevent pregnancy by delaying ovulation.&nbsp; In most states, adolescents seeking pregnancy prevention options may receive confidential medical care without parental consent.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 104,
            "subject": "Pediatrics",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 17805,
            "topic": "Contraception",
            "titleId": 17805,
            "title": "Contraception",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "3",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Obtain parental consent prior to providing emergency contraception",
                    "choiceNumber": 1,
                    "correctTaken": 386,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Prescribe misoprostol (prostaglandin E1) pills",
                    "choiceNumber": 2,
                    "correctTaken": 2372,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Provide levonorgestrel pill",
                    "choiceNumber": 3,
                    "correctTaken": 11758,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Reassure patient that pregnancy is unlikely and no emergency contraception is required",
                    "choiceNumber": 4,
                    "correctTaken": 540,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Supply a short course of high-dose oral contraceptives",
                    "choiceNumber": 5,
                    "correctTaken": 1525,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "75",
                    "mediaDataId": 0,
                    "title": "Emergency contraception",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "21836502",
                    "mediaDataId": 0,
                    "title": "Adolescents and emergency contraception: update 2011.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/21836502",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25254919",
                    "mediaDataId": 0,
                    "title": "Emergency contraception review: evidence-based recommendations for clinicians.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25254919",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26287787",
                    "mediaDataId": 0,
                    "title": "Practice bulletin no. 152: emergency contraception.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26287787",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28766313",
                    "mediaDataId": 0,
                    "title": "Interventions for emergency contraception.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28766313",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 37,
            "notes": null,
            "peopleTaken": 16581,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 71,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 5,
            "questionId": 11321,
            "questionIndex": 12474,
            "questionText": "<p>A 13-year-old girl is brought to the office due to lower abdominal pain for the past 4 days.&nbsp; The patient has rectal pain with bowel movements, but no melena or frank blood.&nbsp; She has had this pain several times over the past year, but it usually resolves after 2 or 3 days.&nbsp; She has no fever, chills, nausea, vomiting, loss of appetite, dysuria, hematuria, or abnormal vaginal discharge.&nbsp; The patient has no chronic medical conditions or previous surgeries.&nbsp; She has not reached menarche and has never been sexually active.&nbsp; Temperature is 36.7 C (98 F) and blood pressure is 110/70 mm Hg.&nbsp; BMI is 24 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Physical examination shows a nondistended abdomen without rebound or guarding.&nbsp; There is lower abdominal tenderness to deep palpation in the midline.&nbsp; The external genitalia are Tanner stage 3.&nbsp; On pelvic examination, a smooth, firm mass is protruding between the labia majora.&nbsp; Which of the following is the most likely diagnosis?</p>",
            "questionHeader": "",
            "explanationText": "<p><img draggable=\"false\" id=\"1956\" src=\"https://www.uworld.com/media/L15399.jpg\" ></p><p>An <strong>imperforate hymen</strong>&nbsp;is a common anatomic cause of <strong>primary amenorrhea</strong>.&nbsp; This occurs when the hymen fails to fenestrate during embryonic development.&nbsp; Infants may present with a bulging membrane due to mucus collection, but this typically resolves and patients remain asymptomatic until menarche.&nbsp; Adolescent patients with an imperforate hymen typically present with <strong>cyclic lower abdominal pain</strong> in the absence of apparent vaginal bleeding.&nbsp; When menstruation occurs, blood collects in the vagina behind the hymenal membrane (eg, hematocolpos).&nbsp; The enlarging blood collection with each menstrual period causes increasing pressure on the surrounding pelvic organs, resulting in lower back pain, pelvic pressure, or defecatory rectal pain.</p><p>Pelvic examination typically reveals a blue, <strong>bulging vaginal mass</strong> or membrane that swells with increased intraabdominal pressure (eg, Valsalva).&nbsp; External genitalia and pubic hair development is normal.&nbsp; Treatment is with incision of the hymen and drainage of the hematocolpos.&nbsp; Patients with abnormal genital tract development should be evaluated for associated renal abnormalities with renal ultrasound.</p><p><strong>(Choice A)</strong>&nbsp; A uterine leiomyoma may present with bulk symptoms (eg, rectal pain or pressure), and a cervical leiomyoma presents as a protruding cervical rather than a vaginal mass.&nbsp; Leiomyomata are associated with heavy vaginal bleeding rather than amenorrhea.</p><p><strong>(Choice B)</strong>&nbsp; Choriocarcinoma typically presents with vaginal bleeding, markedly elevated &#946;-hCG levels, and an enlarged uterus.&nbsp; The vagina is a common site of metastasis, presenting as a friable mass.</p><p><strong>(Choice C)</strong>&nbsp; Complete m&uuml;llerian agenesis may present with amenorrhea and a blind vaginal pouch due to the congenital absence of the uterus and cervix.&nbsp; Because the uterus is absent, patients do not have cyclic abdominal pain or associated hematocolpos.</p><p><strong>(Choice D)</strong>&nbsp; A foreign body in the vagina typically presents with abdominal pain, foul-smelling vaginal discharge, and vaginal bleeding, and is seen on examination.</p><p><strong>(Choice F)</strong>&nbsp; Pelvic organ prolapse may present with pelvic pressure and a vaginal bulge that increases with Valsalva.&nbsp; Pelvic organ prolapse is more typical in postmenopausal patients and is not associated with primary amenorrhea.</p><p><strong>(Choice G)</strong>&nbsp; Sarcoma botryoides, a form of rhabdomyosarcoma, typically presents during infancy as a polypoid or &#x22;grapelike&#x22; mass protruding from the vagina with associated vaginal discharge and bleeding.</p><p><strong>Educational objective:</strong><br>Imperforate hymen is an anatomic cause of primary amenorrhea.&nbsp; Pubertal patients typically present with cyclic lower abdominal pain, amenorrhea, and hematocolpos.&nbsp; Pelvic examination typically reveals a smooth, blue, bulging vaginal mass that swells with increased intraabdominal pressure.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 13536,
            "topic": "Imperforate hymen",
            "titleId": 13536,
            "title": "Imperforate hymen",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "5",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Cervical leiomyoma",
                    "choiceNumber": 1,
                    "correctTaken": 123,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Choriocarcinoma",
                    "choiceNumber": 2,
                    "correctTaken": 5,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Complete m&uuml;llerian agenesis",
                    "choiceNumber": 3,
                    "correctTaken": 28,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Foreign body",
                    "choiceNumber": 4,
                    "correctTaken": 65,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Imperforate hymen",
                    "choiceNumber": 5,
                    "correctTaken": 4214,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Pelvic organ prolapse",
                    "choiceNumber": 6,
                    "correctTaken": 302,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Sarcoma botryoides",
                    "choiceNumber": 7,
                    "correctTaken": 310,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "39",
                    "mediaDataId": 0,
                    "title": "Imperforate hymen",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "21686660",
                    "mediaDataId": 0,
                    "title": "Imperforate hymen: a cause of abdominal pain in female adolescents.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/21686660",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 71,
            "notes": null,
            "peopleTaken": 5047,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 83,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 6,
            "questionId": 13741,
            "questionIndex": 15131,
            "questionText": "<p>A 13-year-old girl is brought to the office for evaluation of acne.&nbsp; The patient began to develop acne over her forehead and chin 4 months ago.&nbsp; She used over-the-counter topical salicylic acid, but the acne did not improve.&nbsp; The patient now has painful acne over her face and upper chest.&nbsp; She participates in a soccer league after school, and her mother feels that her exercise regimen is too strenuous and stressful and contributes to her acne.&nbsp; The patient has no medical conditions and has had no surgeries.&nbsp; She has not had a menstrual period.&nbsp; The girl has grown 10.1 cm (4 in) in the past year; her height and weight are at the 70th percentile for age.&nbsp; Vital signs are normal.&nbsp; Nodulocystic acne is present across the face and upper chest.&nbsp; There is no breast bud development.&nbsp; The abdomen is nontender and has no palpable masses.&nbsp; External pelvic examination shows the clitoris protruding from the clitoral hood and bilateral masses in the labia majora.&nbsp; Which of the following is the most likely diagnosis in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_T41330\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>5-&#945; reductase deficiency</strong></p></td></tr><tr><td><p align=\"center\"><strong>Pathogenesis</strong></p></td><td><ul><li>46,XY genotype</li><li>Impaired conversion of testosterone to DHT</li><li>Impaired virilization during embryogenesis</li><li>Normal male testosterone &amp; estrogen levels</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical features</strong></p></td><td><ul><li>Male internal genitalia (eg, testes, vas deferens)</li><li>Female external genitalia (eg, blind-ending vagina)</li><li>Phenotypically female at birth</li><li>Virilization at puberty (&#8593; testosterone)<ul style=\"list-style-type:circle;\"><li>Clitoromegaly</li><li>Increased muscle mass</li><li>Male pattern hair development</li><li>Nodulocystic acne</li></ul></li></ul></td></tr><tr><td colspan=\"2\"><p><strong>DHT</strong> = dihydrotestosterone.</p></td></tr></tbody></table></div><p>During embryogenesis, sexual development in genotypically male fetuses (46,XY) occurs due to testicular hormone production.&nbsp; The testes produce testosterone, which promotes development of the male internal genitalia (eg, vas deferens, epididymis).&nbsp; Testosterone is also converted to dihydrotestosterone (DHT) via 5-alpha reductase; DHT promotes development of the male external genitalia (eg, penis) and prostate.&nbsp; Patients with <strong>5-alpha reductase deficiency</strong> are unable to convert testosterone to DHT; therefore, they have <strong>undescended testes</strong> (eg, bilateral labial masses), have&nbsp;<strong>no male external genitalia</strong> development, and appear <strong>phenotypically female</strong> at birth.</p><p>At puberty, <strong>increased testosterone</strong> levels cause <strong>virilization</strong> of phenotypically female patients, which can manifest as nodulocystic <strong>acne</strong> and <strong>clitoromegaly</strong> (ie, clitoris protruding from the clitoral hood).&nbsp; Additional features of virilization include voice deepening and increased muscle mass.&nbsp; The testosterone levels at puberty are at the normal male range; therefore, patients develop additional normal secondary sexual characteristics (eg, axillary and pubic hair).&nbsp; Patients have <strong>no breast development</strong> because testosterone binds to the breast androgen receptor and inhibits breast tissue proliferation.&nbsp; Diagnosis in adolescents and adults is based on an elevated testosterone/DHT ratio.&nbsp; Management is dependent on age and gender identity.</p><p><strong>(Choice B)</strong>&nbsp; Patients with androgen insensitivity syndrome (AIS) have peripheral testosterone resistance due to a defective androgen receptor.&nbsp; Therefore, in contrast to patients with 5-alpha reductase deficiency, they do not undergo virilization in adolescence (ie, clitoromegaly), and they lack axillary and pubic hair development.&nbsp; Patients with AIS also have breast development at puberty due to aromatization of testosterone to estrogen and because breast tissue proliferation is not inhibited by a defective androgen receptor.</p><p><strong>(Choice C)</strong>&nbsp; Ovarian hyperthecosis can present in women with virilization; however, patients are typically postmenopausal and have bilaterally enlarged ovaries.</p><p><strong>(Choice D)</strong>&nbsp; Patients with polycystic ovary syndrome have hyperandrogenism (eg, acne, hirsutism) but not virilization (eg, clitoromegaly).</p><p><strong>(Choice E)</strong>&nbsp; Sertoli-Leydig cell tumors are testosterone-producing ovarian tumors that can result in virilization.&nbsp; However, patients have a unilateral, solid adnexal mass rather than bilateral undescended testes.</p><p><strong>Educational objective:</strong><br>5-Alpha reductase deficiency causes impaired conversion of testosterone to dihydrotestosterone.&nbsp; In a male fetus, this impaired conversion during embryogenesis causes development of male internal genitalia and female external genitalia, resulting in a phenotypically female infant.&nbsp; During puberty, the increased testosterone level results in virilization (eg, clitoromegaly).</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 23429,
            "topic": "Amenorrhea",
            "titleId": 23429,
            "title": "Amenorrhea",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "1",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "5-Alpha reductase deficiency",
                    "choiceNumber": 1,
                    "correctTaken": 9033,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Androgen insensitivity syndrome",
                    "choiceNumber": 2,
                    "correctTaken": 4583,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Ovarian hyperthecosis",
                    "choiceNumber": 3,
                    "correctTaken": 560,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Polycystic ovary syndrome",
                    "choiceNumber": 4,
                    "correctTaken": 444,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Sertoli-Leydig cell tumor",
                    "choiceNumber": 5,
                    "correctTaken": 1944,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "67",
                    "mediaDataId": 0,
                    "title": "5-alpha reductase deficiency",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "23513070",
                    "mediaDataId": 0,
                    "title": "Diagnosis of 5a -reductase 2 deficiency: is measurement of dihydrotestosterone essential?",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/23513070",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25321150",
                    "mediaDataId": 0,
                    "title": "5-Alpha reductase deficiency: a 40-year retrospective review.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25321150",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27224879",
                    "mediaDataId": 0,
                    "title": "Steroid 5a-reductase 2 deficiency.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27224879",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 65,
            "notes": null,
            "peopleTaken": 16565,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 55,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 7,
            "questionId": 4756,
            "questionIndex": 4756,
            "questionText": "<p>A 37-year-old woman comes to the office for evaluation of infertility.&nbsp; The patient and her 39-year-old husband have been unable to conceive after 18 months of unprotected and frequent intercourse.&nbsp; Menstrual cycles occur every 28 days and last 5 days; she has heavy bleeding and cramping on the first day.&nbsp; The patient had a miscarriage at age 27 that required a dilation and curettage.&nbsp; The couple had another spontaneous pregnancy 6 years later that resulted in an uncomplicated term vaginal delivery.&nbsp; The patient feels well and has no medical conditions.&nbsp; She is an aerobics instructor and teaches 2 hour-long classes daily.&nbsp; Blood pressure is 120/80 mm Hg and pulse is 84/min.&nbsp; BMI is 23 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; She has no thyromegaly.&nbsp; Breast examination shows no palpable masses, axillary lymphadenopathy, or expressed nipple discharge.&nbsp; Pelvic examination reveals normal external genitalia, a well-rugated vagina, a mobile uterus, and normal ovaries.&nbsp; Which of the following is the most likely underlying cause of this couple&#39;s inability to conceive?</p>",
            "questionHeader": "",
            "explanationText": "<p><img  draggable=\"false\" id=\"6038\" src=\"https://www.uworld.com/media/highresdefault/L31095.png\"  ></p><p>Spontaneous pregnancy rates decrease with increasing female age.&nbsp; Women are born with a lifetime supply of oocytes, and a sharp decline in conception rates is notable at age 35.&nbsp; Due to this decline, lack of conception after &#8805;6 months of unprotected intercourse in women age &#8805;35 is considered <strong>infertility</strong>.&nbsp; In women with regular menstrual cycles, infertility can occur due to <strong>diminished ovarian reserve</strong>, characterized by <strong>decreased oocyte number and quality</strong>.&nbsp; <strong>Regular menstrual periods</strong> still occur due to continuing ovulation, but fecundability (ie, conception rate) decreases due to diminished oocyte quality.</p><p>As ovarian reserve and function decline, estradiol and inhibin production decreases, and the normal negative feedback mechanism is suppressed.&nbsp; This causes FSH levels to become increasingly elevated as ovarian function decreases.&nbsp; Therefore, day 3 (early follicular phase) FSH testing can be performed to assess ovarian function.&nbsp; Assisted reproductive techniques (eg, in vitro fertilization, oocyte/embryo donation) are available to couples with age-related infertility.</p><p><strong>(Choice B)</strong>&nbsp; Hypothalamic dysfunction (eg, hypogonadotropic hypogonadism) due to intense exercise and relative caloric deficiency can cause anovulation and result in amenorrhea.&nbsp; This is unlikely to be the cause of infertility in the setting of normal menses.</p><p><strong>(Choice C)</strong>&nbsp; Hypothyroidism is associated with infertility but presents with irregular menses.</p><p><strong>(Choice D)</strong>&nbsp; Primary ovarian insufficiency refers to menopause before age 40.&nbsp; Patients with primary ovarian insufficiency have amenorrhea, hot flashes, and vaginal atrophy (eg, minimal rugation).&nbsp; The condition is associated with concomitant autoimmune disorders or Turner syndrome.</p><p><strong>(Choices E and F)</strong>&nbsp; <a href=\"26490\">Uterine synechiae</a> (eg, Asherman syndrome) and uterine leiomyomas are anatomic factors that may decrease conception rates.&nbsp; Uterine synechiae can occur after dilation and curettage; however, this patient has normal menses (as opposed to light menses/amenorrhea from endometrial scarring) and had a subsequent normal pregnancy following surgery, which makes this condition unlikely.&nbsp; Leiomyomas typically cause heavy menstrual bleeding throughout the entirety of menses (as opposed to heavy bleeding on day 1).&nbsp; In addition, physical examination may show an enlarged, irregularly contoured uterus (not seen in this patient), which makes this diagnosis less likely.</p><p><strong>Educational objective:</strong><br>Inability to conceive after 6 months of unprotected intercourse in women age &#8805;35 is considered infertility.&nbsp; This can occur due to diminished ovarian reserve, characterized by regular menstrual cycles and decreased oocyte number and quality.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 7389,
            "topic": "Infertility",
            "titleId": 7389,
            "title": "Infertility",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "1",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Decreased ovarian reserve",
                    "choiceNumber": 1,
                    "correctTaken": 10472,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Hypothalamic dysfunction",
                    "choiceNumber": 2,
                    "correctTaken": 1533,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Hypothyroidism",
                    "choiceNumber": 3,
                    "correctTaken": 36,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Primary ovarian insufficiency",
                    "choiceNumber": 4,
                    "correctTaken": 817,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Uterine leiomyomata",
                    "choiceNumber": 5,
                    "correctTaken": 887,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Uterine synechiae",
                    "choiceNumber": 6,
                    "correctTaken": 2843,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "632",
                    "mediaDataId": 0,
                    "title": "Infertility",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27382229",
                    "mediaDataId": 0,
                    "title": "Poor ovarian reserve.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27382229",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 69,
            "notes": null,
            "peopleTaken": 16588,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 63,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 8,
            "questionId": 13938,
            "questionIndex": 15336,
            "questionText": "<p>A 29-year-old woman comes to the emergency department due to fever, chills, and lower abdominal pain.&nbsp; Two days ago, the patient underwent dilation and curettage for a 9-week missed abortion.&nbsp; After the procedure, she initially had light spotting, but within the last few hours, the bleeding has become increasingly heavy and malodorous.&nbsp; The patient has also developed increasing abdominal pain and a fever unrelieved by acetaminophen.&nbsp; She has no chronic medical conditions and has had no other surgeries.&nbsp; Temperature is 39.4 C (102.9 F), blood pressure is 88/50 mm Hg, and pulse is 118/min.&nbsp; On speculum examination, the cervix is 1 cm dilated and has purulent discharge at the os.&nbsp; The uterus is enlarged and has cervical motion tenderness.&nbsp; Transvaginal ultrasound reveals a thickened endometrial stripe.&nbsp; Urine pregnancy test is positive.&nbsp; The patient is prescribed broad-spectrum intravenous antibiotics and undergoes a suction uterine curettage.&nbsp; Compared to the general population, this patient is at greatest risk for which of the following conditions?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_T43083\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Intrauterine adhesions</strong></p></td></tr><tr><td><p align=\"center\"><strong>Risk factors</strong></p></td><td><ul><li>Infection (eg, septic abortion, endometritis)</li><li>Intrauterine surgery (eg, curettage, myomectomy)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical features</strong></p></td><td><ul><li>Abnormal uterine bleeding</li><li>Amenorrhea</li><li>Infertility</li><li>Cyclic pelvic pain</li><li>Recurrent pregnancy loss</li></ul></td></tr><tr><td><p align=\"center\"><strong>Evaluation</strong></p></td><td><ul><li>Hysteroscopy</li></ul></td></tr></tbody></table></div><p>This patient&#39;s fever, lower abdominal pain, and purulent cervical discharge shortly after dilation and curettage for a missed abortion are likely due to a <strong>septic abortion</strong>, a polymicrobial infection of retained products of conception.</p><p>When dilation and curettage (eg, performed for a missed abortion) do not completely evacuate the uterus, ascending vaginal flora can seed the uterus and retained products of conception through the dilated cervix, resulting in infection.&nbsp; Treatment of septic abortion is broad-spectrum antibiotics and prompt <strong>uterine evacuation</strong> with <strong>suction curettage</strong> to remove the infected retained products of conception.</p><p>During this procedure, the endometrium can be removed with the products of conception, particularly if infection is present (eg, septic abortion)&nbsp;because the infected tissues are more adherent to one another.&nbsp; The uterus becomes softer and more enlarged.&nbsp; This often results in an <strong>unintentionally more aggressive</strong> curettage, which <strong>denudes</strong> the <strong>endometrial basalis</strong> layer and causes an <strong>inflamed</strong>, obliterated uterine cavity prone to <strong>intrauterine adhesion development</strong> (ie,&nbsp;<a href=\"26490\">Asherman syndrome</a>).</p><p><strong>(Choice B)</strong>&nbsp; During uterine curettage, the endometrial basalis (ie, the regenerative layer of the endometrium) can be injured; therefore, endometrial overgrowth (ie, endometrial hyperplasia) is unlikely.&nbsp; Endometrial hyperplasia most often develops as a result of excess estrogen (eg, adiposity, anovulation) in a patient without a damaged endometrial basalis.</p><p><strong>(Choice C)</strong>&nbsp; Endometriosis (implantation of endometrial tissue outside of the uterus) is not associated with intrauterine surgery or infection.</p><p><strong>(Choice D)</strong>&nbsp; Sheehan syndrome (infarction of the pituitary gland) can occur due to obstetric blood loss (eg, postpartum hemorrhage).&nbsp; Pituitary enlargement does not occur until after 20 weeks gestation; therefore, the pituitary gland is not prone to ischemia in patients with first-trimester spontaneous abortions regardless of hemodynamic instability.</p><p><strong>(Choice E)</strong>&nbsp; Gestational trophoblastic neoplasia (GTN) is the malignant transformation of trophoblastic tissue that often arises following a complete hydatidiform mole pregnancy.&nbsp; On ultrasonography, these often have a &#x22;snowstorm&#x22; appearance rather than a missed abortion (ie, fetus with no cardiac activity) or a thickened endometrial stripe (as seen in this patient).&nbsp; Although &#946;-hCG levels are elevated in GTN, a positive pregnancy test due to retained products of conception is common.&nbsp; In addition, suction curettage is not a risk factor for malignant transformation.</p><p><strong>Educational objective:</strong><br>Asherman syndrome (the development of intrauterine adhesions) is a possible complication of intrauterine surgery (eg, suction curettage) caused by scarring and obliteration of endometrial tissue.&nbsp; The risk for adhesion formation increases with a concomitant intrauterine infection (eg, septic abortion).</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 23429,
            "topic": "Amenorrhea",
            "titleId": 23429,
            "title": "Amenorrhea",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "1",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Development of intrauterine adhesions",
                    "choiceNumber": 1,
                    "correctTaken": 12406,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Hyperplastic overgrowth of the endometrium",
                    "choiceNumber": 2,
                    "correctTaken": 369,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Implantation of ectopic endometrial tissue",
                    "choiceNumber": 3,
                    "correctTaken": 967,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Infarction of the pituitary gland",
                    "choiceNumber": 4,
                    "correctTaken": 422,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Malignant transformation of trophoblastic tissue",
                    "choiceNumber": 5,
                    "correctTaken": 2472,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "64",
                    "mediaDataId": 0,
                    "title": "Intrauterine adhesions",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "24373209",
                    "mediaDataId": 0,
                    "title": "The management of Asherman syndrome: a review of literature.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/24373209",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25932831",
                    "mediaDataId": 0,
                    "title": "Treating spontaneous and induced septic abortions.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25932831",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28582327",
                    "mediaDataId": 0,
                    "title": "A comprehensive review of Asherman&#39;s syndrome: causes, symptoms and treatment options.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28582327",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 61,
            "notes": null,
            "peopleTaken": 16636,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 75,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 9,
            "questionId": 10991,
            "questionIndex": 12130,
            "questionText": "<p>A 31-year-old woman, gravida 3 aborta 3, comes to the office for an annual examination and discussion of contraceptive options.&nbsp; Seven months ago, she experienced her third spontaneous miscarriage and underwent a recurrent miscarriage work-up.&nbsp; Results were consistent with antiphospholipid antibody syndrome, and the patient was informed that she is at increased risk for another miscarriage.&nbsp; Due to these risks, the patient and her husband have elected to adopt.&nbsp; The patient&#39;s menses occur every 30 days with 4-5 days of moderate bleeding.&nbsp; She takes no medications and does not use tobacco, alcohol, or recreational drugs.&nbsp; Blood pressure is 115/60 mm Hg and pulse is 88/min.&nbsp; BMI is 22 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; On bimanual pelvic examination, the uterus is in a significantly retroverted position.&nbsp; Hemoglobin is 13 g/dL.&nbsp; Which of the following is the most appropriate contraceptive option for this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_T50515\" style=\"overflow-x:auto;\"><table class=\"table-default-style\" style=\"width:370px\"><tbody><tr><td><p align=\"center\"><strong>Absolute contraindications to<br>combined hormonal contraceptive pills</strong></p></td></tr><tr><td><ul><li>Active breast cancer</li><li>Migraines with aura</li><li>Uncontrolled hypertension</li><li>Active hepatitis, severe cirrhosis, liver cancer</li><li>Age &#8805;35 &amp; &#8805;15 cigarettes/day</li><li>Ischemic heart disease, stroke</li><li>&lt;3 weeks postpartum</li><li>Prolonged immobilization</li><li>Thrombophilia (eg, factor V Leiden,<br>antiphospholipid antibody syndrome)</li><li>Venous thromboembolism</li></ul></td></tr></tbody></table></div><p>This patient has <strong>antiphospholipid antibody syndrome</strong> (APS), an autoimmune thrombophilia that increases the risk for arterial and venous thrombosis.&nbsp; With <strong>pregnancy or exogenous estrogen use</strong>, women with APS and other thrombophilic disorders are at even higher risk for thromboembolism because <strong>estrogen has hypercoagulable properties</strong>.&nbsp; As a result, patients with APS commonly have pregnancy complications (eg, recurrent miscarriages, preeclampsia, fetal growth restriction) likely related to thrombosis of the placental vessels.</p><p>The same hypercoagulable properties make <strong>estrogen-containing hormonal contraceptives</strong> (eg, combination oral contraceptive pills, vaginal ring, transdermal patch) <strong>contraindicated</strong> in patients with APS and other thrombophilias due to an unacceptably high thromboembolic risk <strong>(Choices A and E)</strong>.&nbsp; Nonhormonal options can be offered, such as barrier methods (eg, condoms), <strong>copper-containing intrauterine device (IUD)</strong>, and permanent sterilization (eg, tubal ligation).&nbsp; IUDs can be placed in patients with challenging uterine positions (eg, <a href=\"49870\">retroverted, retroflexed uterus</a>) because uterine position typically does not affect insertion, expulsion, or failure rates.</p><p>Although heavy menses are a potential adverse effect, the copper-containing IUD is an appropriate option for patients with normal hemoglobin levels, such as this woman.&nbsp; Patients with thrombophilias are also candidates for low-dose <strong>progestin-only contraceptives</strong> (eg, progestin-releasing IUD, progestin-only pill), which carry a lower risk for thromboembolism compared to estrogen-containing options.&nbsp; For patients who have heavy menses at baseline or who have heavy menses due to anticoagulation, the benefits of progestin-only contraception (eg, reduced menstrual blood loss, anemia prevention) generally outweigh the risks.</p><p><strong>(Choice B)</strong>&nbsp; Condoms with spermicide are a hormone-free option with low efficacy (87% with typical use).&nbsp; Because unplanned pregnancy could lead to life-threatening vascular thrombosis in this patient, a more efficacious method (eg, IUD) is recommended.</p><p><strong>(Choice D)</strong>&nbsp; Endometrial ablation is the surgical destruction of the endometrium to treat heavy menstrual bleeding.&nbsp; Although it incapacitates most of the uterine lining, endometrial ablation is not an acceptable contraceptive method because pregnancy prevention is not guaranteed; furthermore, pregnancies conceived following the procedure are at high risk for obstetric complications (eg, spontaneous abortion, placenta accreta).&nbsp; Therefore, candidates for endometrial ablation do not desire future fertility but still require contraception.</p><p><strong>Educational objective:</strong><br>Antiphospholipid antibody syndrome and other thrombophilias are absolute contraindications to estrogen-containing hormonal contraceptives due to the increased risk for thromboembolism.&nbsp; These patients can be offered nonhormonal (eg, copper-containing intrauterine device) or progestin-only methods.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 17805,
            "topic": "Contraception",
            "titleId": 17805,
            "title": "Contraception",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "3",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Combination oral contraceptive pills",
                    "choiceNumber": 1,
                    "correctTaken": 401,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Condoms with spermicide",
                    "choiceNumber": 2,
                    "correctTaken": 534,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Copper-containing intrauterine device",
                    "choiceNumber": 3,
                    "correctTaken": 8449,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Endometrial ablation",
                    "choiceNumber": 4,
                    "correctTaken": 506,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Vaginal contraceptive ring",
                    "choiceNumber": 5,
                    "correctTaken": 1090,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "53",
                    "mediaDataId": 0,
                    "title": "Contraception",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25162263",
                    "mediaDataId": 0,
                    "title": "Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25162263",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25228006",
                    "mediaDataId": 0,
                    "title": "Antiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatment.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25228006",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "29745237",
                    "mediaDataId": 0,
                    "title": "Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/29745237",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 43,
            "notes": null,
            "peopleTaken": 10980,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 77,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 10,
            "questionId": 22904,
            "questionIndex": 106987,
            "questionText": "<p>A 29-year-old woman, gravida 0 para 0, comes to the office due to an 8-month history of irregular menses.&nbsp; For more than 12 months, she has been unable to conceive despite frequent sexual intercourse without contraception.&nbsp; Menses previously occurred at regular 28-day intervals and lasted 5 days.&nbsp; The patient has no headache or visual changes.&nbsp; She takes no medication.&nbsp; Temperature is 36.9 C (98.4 F), blood pressure is 120/72 mm Hg, and pulse is 70/min.&nbsp; Height is 165 cm (5 ft 5 in) and weight is 75 kg (165.6 lb).&nbsp; BMI is 28 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Physical examination, including pelvic examination, is normal.&nbsp; Serum laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td>Pregnancy test</td><td>negative</td></tr><tr><td>TSH</td><td>30 &#956;U/mL (normal: 0.5-5.0)</td></tr><tr><td>Free thyroxine</td><td>0.4 ng/dL (normal: 0.9-1.7)</td></tr><tr><td>LH</td><td>4 IU/L (normal: 5-25)</td></tr><tr><td>FSH</td><td>5 IU/L (normal: 5-25)</td></tr><tr><td>Prolactin</td><td>45 ng/mL (normal: &lt;25)</td></tr></tbody></table><p>Which of the following is the most appropriate next step in management of this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p><img  draggable=\"false\" id=\"19897\" src=\"https://www.uworld.com/media/highresdefault/L45228.jpg\"  ></p><p>This patient has primary hypothyroidism (ie, low free thyroxine [T4], high TSH) associated with an elevated prolactin level.&nbsp; Both <strong>hypothyroidism</strong> and <strong>hyperprolactinemia</strong> (individually or in conjunction) can cause <strong>central hypogonadism</strong>, manifesting with menstrual abnormalities and infertility, via multiple mechanisms:</p><ul><li><p>Hypothyroidism causes decreased responsiveness of the pituitary to GnRH, leading to decreased gonadotropin (ie, FSH, LH) secretion.</p></li><li><p>Thyrotropin-releasing hormone, which is upregulated in hypothyroidism, stimulates the pituitary secretion of prolactin.</p></li><li><p>Hyperprolactinemia, whether due to hypothyroidism or as an isolated disorder, further suppresses gonadotropin secretion.</p></li></ul><p>In addition to mild to moderate hyperprolactinemia (serum prolactin &lt;100 ng/mL), laboratory findings in patients with hypothyroid-related hypogonadism include <strong>low FSH and LH</strong> and low serum estradiol (low testosterone in men).</p><p>When patients have primary hypothyroidism and hyperprolactinemia, the thyroid disorder is usually the primary condition; hyperprolactinemia does not cause hypothyroidism.&nbsp; Therefore, <strong>levothyroxine therapy</strong> should be initiated first, which usually corrects prolactin levels and restores reproductive function.&nbsp; However, if prolactin levels are <a href=\"54903\">unusually high</a> (ie, &#8805;100 ng/dL) or do not normalize with the treatment of hypothyroidism, prolactinoma should be suspected and may require cranial imaging (ie, MRI) and dopamine agonist (eg, cabergoline) therapy <strong>(Choices A and D)</strong>.</p><p><strong>(Choice C)</strong>&nbsp; Although a small amount of T3 is released from the thyroid, T3 is generated primarily by deiodination of T4 in peripheral tissues.&nbsp; Serum T3 levels are useful in evaluating hyperthyroidism but not primary hypothyroidism.</p><p><strong>(Choice E)</strong>&nbsp; The GnRH stimulation test (ie, serial measurement of LH following administration of a GnRH agonist) is typically used in the evaluation of central precocious puberty.&nbsp; This patient&#39;s gonadotropin abnormalities are due to primary hypothyroidism, so a GnRH stimulation test would not be helpful.</p><p><strong>Educational objective:</strong><br>Menstrual irregularities (eg, irregular menses, infertility) are common in hypothyroidism.&nbsp; Typical laboratory findings include elevated prolactin and low FSH and LH levels with low serum estradiol (low testosterone in men).&nbsp; Reproductive function usually normalizes with levothyroxine therapy.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 7389,
            "topic": "Infertility",
            "titleId": 7389,
            "title": "Infertility",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "2",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Begin treatment with cabergoline",
                    "choiceNumber": 1,
                    "correctTaken": 364,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Begin treatment with levothyroxine",
                    "choiceNumber": 2,
                    "correctTaken": 1926,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Measure serum total T3 level",
                    "choiceNumber": 3,
                    "correctTaken": 115,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Order an MRI of the pituitary",
                    "choiceNumber": 4,
                    "correctTaken": 2312,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Perform a GnRH stimulation test",
                    "choiceNumber": 5,
                    "correctTaken": 298,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "632",
                    "mediaDataId": 0,
                    "title": "Infertility",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "31259157",
                    "mediaDataId": 0,
                    "title": "Effect of adequate thyroid hormone replacement on the hypothalamo-pituitary-gonadal axis in premenopausal women with primary hypothyroidism.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/31259157",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 83,
            "notes": null,
            "peopleTaken": 5015,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 38,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 11,
            "questionId": 4767,
            "questionIndex": 4767,
            "questionText": "<p>A 15-year-old girl is brought to the office due to irregular menstrual periods.&nbsp; Menarche was at age 13, and since then her periods have been irregular with cycle lengths varying from 3 to 8 weeks.&nbsp; Her last menstrual period ended 6 weeks ago.&nbsp; The patient has no chronic medical conditions, has had no surgeries, and takes no medications.&nbsp; Her mother and older sister have polycystic ovary syndrome, and both take oral contraceptive pills.&nbsp; The patient has never been sexually active.&nbsp; Vital signs are normal.&nbsp; BMI is 21 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Physical examination shows normal hair distribution with Tanner stage 5 secondary sexual characteristics.&nbsp; Abdominal examination is normal, and there are no abnormalities seen on inspection of the external genitalia.&nbsp; Serum prolactin and TSH levels are normal.&nbsp; Administration of a short course of oral progesterone results in withdrawal bleeding 3 days after stopping the medication.&nbsp; Pelvic ultrasound reveals normal ovaries and uterus.&nbsp; Which of the following is the most likely explanation for this patient&#39;s irregular menstrual periods?</p>",
            "questionHeader": "",
            "explanationText": "<p><img  draggable=\"false\" id=\"2990\" src=\"https://www.uworld.com/media/highresdefault/L24345.jpg\"  ></p><p>The initial menstrual cycles in adolescent girls are <strong>irregular</strong> and <strong>anovulatory</strong>.&nbsp; The <strong>abnormal uterine bleeding (AUB)</strong> that follows menarche is due to <strong>immaturity of the developing hypothalamic-pituitary-gonadal axis</strong> that produces inadequate quantities and proportions of GnRH, and subsequently FSH and LH, required to induce ovulation.&nbsp; In the <a href=\"5965\">absence of ovulation</a>, menstrual cycles lack periodicity.&nbsp; The endometrium builds up under the influence of estrogen, but without the influence of progesterone the endometrium never differentiates into secretory endometrium and continues to proliferate; menstrual-like bleeding then occurs due to estrogen breakthrough bleeding.&nbsp; Progesterone is normally produced in greater amounts by the corpus luteum following ovulation, and withdrawal of this progesterone as the corpus luteum degenerates results in a complete and synchronous shedding of the endometrium (ie, menses).</p><p>In patients with AUB, bleeding after exogenous progesterone administration confirms normal endogenous estrogen production and proliferative endometrium.&nbsp; It also eliminates causes of estrogen deficiency (eg, primary ovarian insufficiency), endometrial abnormalities (eg, intrauterine adhesions), and outlet tract abnormalities (eg, imperforate hymen).&nbsp; Treatment of AUB in adolescents with either progestin-only or combination estrogen/progestin oral contraceptive pills is indicated when bleeding disrupts activities or results in anemia.&nbsp; Anovulation typically resolves 1-4 years postmenarche, after which menstrual cycles normalize.</p><p><strong>(Choices A and B)</strong>&nbsp; Excess androgen and LH secretion are characteristic of polycystic ovary syndrome.&nbsp; Clinical features include irregular menses, signs of hirsutism, and multiple small, &#x22;pearl-string&#x22; ovarian cysts on ultrasound.&nbsp; This patient has no signs of hirsutism and has normal-appearing ovaries on ultrasound, making this diagnosis unlikely.</p><p><strong>(Choice C)</strong>&nbsp; Inadequate endometrial proliferation occurs in the absence of estrogen (eg, primary ovarian insufficiency).&nbsp; Patients lacking estrogen do not have proliferative endometrium; therefore, they do not have withdrawal bleeding following a course of oral progesterone.&nbsp; This patient had bleeding following a <a href=\"67928\">progesterone withdrawal challenge</a>, making this diagnosis unlikely.</p><p><strong>(Choice E)</strong>&nbsp; Intrauterine adhesions (eg, Asherman syndrome) are a cause of secondary amenorrhea typically due to previous uterine instrumentation (eg, dilation and curettage) or infection (eg, endometritis).&nbsp; In these patients, progesterone withdrawal bleeding does not occur due to scarring of endometrial tissue.</p><p><strong>Educational objective:</strong><br>The initial menstrual cycles in adolescent girls are irregular and anovulatory due to hypothalamic-pituitary-gonadal axis immaturity and insufficient secretion of GnRH.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 21633,
            "topic": "Anovulation",
            "titleId": 21633,
            "title": "Anovulation",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "4",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Excess androgen secretion",
                    "choiceNumber": 1,
                    "correctTaken": 337,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Excess LH secretion",
                    "choiceNumber": 2,
                    "correctTaken": 645,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Inadequate endometrial proliferation",
                    "choiceNumber": 3,
                    "correctTaken": 764,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Insufficient gonadotropin secretion",
                    "choiceNumber": 4,
                    "correctTaken": 3278,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Intrauterine adhesions",
                    "choiceNumber": 5,
                    "correctTaken": 21,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "54",
                    "mediaDataId": 0,
                    "title": "Evaluation of abnormal uterine bleeding",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "29537383",
                    "mediaDataId": 0,
                    "title": "Abnormal uterine bleeding in adolescents.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/29537383",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "24192679",
                    "mediaDataId": 0,
                    "title": "Dysfunctional uterine bleeding in adolescent girls and evaluation of their response to treatment.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/24192679",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 89,
            "notes": null,
            "peopleTaken": 5045,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 65,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 12,
            "questionId": 11284,
            "questionIndex": 12439,
            "questionText": "<p>A 45-year-old woman comes to the office due to increasing difficulty sleeping for the past few months.&nbsp; She is unable to concentrate at work and is not exercising due to fatigue.&nbsp; The patient reports a 4.5-kg (9.9-lb) weight gain and is now unable to wear her normally fitting clothing.&nbsp; She has no mood changes, hair loss, weakness, or changes in bowel or bladder function.&nbsp; She has no chronic medical problems or previous surgeries.&nbsp; The patient&#39;s menstrual periods have become irregular over the last 2 years; her last period was 3 months ago.&nbsp; She is currently sexually active.&nbsp; She does not use tobacco, alcohol, or illicit drugs.&nbsp; Blood pressure is 120/70 mm Hg and pulse is 80/min.&nbsp; BMI is 31 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; The patient has moist mucous membranes with normal capillary refill.&nbsp; There is no acanthosis nigricans.&nbsp; The abdomen is obese; there is no hepatosplenomegaly or ascites.&nbsp; On bimanual examination, the uterus is symmetrically enlarged.&nbsp; There are no palpable adnexal masses.&nbsp; Which of the following is the best next step in management of this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p>This patient has <strong>insomnia</strong>, fatigue, weight gain, <strong>amenorrhea</strong>, and an <strong>enlarged uterus</strong> consistent with <strong>pregnancy</strong>.&nbsp; Women begin the menopausal transition (ie, perimenopause) years before the final menstrual period and onset of menopause (average age 51).&nbsp; Ovulation still occurs during this time, and women may become pregnant despite lower conception rates.&nbsp; Symptoms of perimenopause include irregular menstrual periods, insomnia, fatigue, and weight gain, which often overlap with symptoms of early pregnancy.&nbsp; All women of reproductive age with amenorrhea and signs of pregnancy should be evaluated with an <strong>hCG level</strong>.</p><p><strong>(Choice A)</strong>&nbsp; Ovarian cancer may present with fatigue, increased abdominal circumference due to ascites, and weight loss (rather than weight gain).&nbsp; Physical examination findings include ascites and an adnexal mass, rather than a uniformly enlarged uterus.&nbsp; Evaluation of ovarian cancer includes an abdominal CT scan and pelvic ultrasound.</p><p><strong>(Choice B)</strong>&nbsp; Menopause can cause symptoms similar to those of pregnancy.&nbsp; However, patients typically have a decreased uterine size.&nbsp; Decreased ovarian function from menopause can be confirmed with an elevated FSH level.</p><p><strong>(Choice D)</strong>&nbsp; Nocturnal polysomnography evaluates for the presence of sleep disorders (eg, sleepwalking, nocturnal epilepsy).&nbsp; This patient&#39;s insomnia and fatigue are common in pregnancy and require no further evaluation.</p><p><strong>(Choice E)</strong>&nbsp; Thyroid disorders may present with fatigue and menstrual disturbances; diagnosis is with abnormal TSH levels.&nbsp; This patient does not have other typical symptoms of hypothyroidism - mood changes, hair loss, weakness, and changes in bowel function.&nbsp; In addition, thyroid disorders do not cause uterine enlargement.</p><p><strong>Educational objective:</strong><br>Pregnancy can present in a perimenopausal woman with insomnia, fatigue, weight gain, amenorrhea, and an enlarged uterus.&nbsp; Patients with amenorrhea and other signs of pregnancy should be evaluated with an hCG level.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 22520,
            "topic": "Undiagnosed pregnancy",
            "titleId": 22520,
            "title": "Undiagnosed pregnancy",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "3",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Abdominal CT scan",
                    "choiceNumber": 1,
                    "correctTaken": 424,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "FSH level",
                    "choiceNumber": 2,
                    "correctTaken": 2288,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "hCG level",
                    "choiceNumber": 3,
                    "correctTaken": 10768,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Nocturnal polysomnography",
                    "choiceNumber": 4,
                    "correctTaken": 325,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "TSH level",
                    "choiceNumber": 5,
                    "correctTaken": 2934,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "700",
                    "mediaDataId": 0,
                    "title": "Evaluation of secondary amenorrhea",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "14644814",
                    "mediaDataId": 0,
                    "title": "Perimenopausal conception.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/14644814",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 61,
            "notes": null,
            "peopleTaken": 16739,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 64,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 13,
            "questionId": 14127,
            "questionIndex": 15530,
            "questionText": "<p>A 16-year-old girl comes to the office due to recurrent, intermittent lower abdominal pain.&nbsp; The pain typically begins the day before the onset of menses and subsides on the second day of bleeding.&nbsp; She has associated nausea and diarrhea during this time; her last episode of pain occurred 2 weeks ago.&nbsp; These symptoms began 5 months ago and have progressively worsened, causing the patient to miss 2 days of school last month.&nbsp; Menarche was at age 13; menses were irregular until 6 months ago but now occur every 28 days with 4 or 5 days of moderate bleeding.&nbsp; The patient recently became sexually active and uses condoms for contraception.&nbsp; She has had some increased clear vaginal discharge between menses but no pain with intercourse; her last menstrual period was 2 weeks ago.&nbsp; Vital signs are normal.&nbsp; On speculum examination, a small amount of clear discharge is noted throughout the vaginal vault, and the cervix is nonfriable.&nbsp; The uterus is small, mobile, and nontender.&nbsp; Wet mount microscopy of the vaginal discharge is normal.&nbsp; A urine pregnancy test is negative.&nbsp; Which of the following is the most likely cause of this patient&#39;s pain?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_T35624\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Primary dysmenorrhea</strong></p></td></tr><tr><td><p align=\"center\"><strong>Etiology</strong></p></td><td><ul><li>Excessive prostaglandin production</li></ul></td></tr><tr><td><p align=\"center\"><strong>Risk factors</strong></p></td><td><ul><li>Age &lt;30</li><li>BMI &lt;20 kg/m<sup>2</sup></li><li>Tobacco use</li><li>Menarche at age &lt;12</li><li>Heavy/long menstrual periods</li><li>Sexual abuse</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical features</strong></p></td><td><ul><li>Pain first 2-3 days of menses</li><li>Nausea, vomiting, diarrhea</li><li>Normal pelvic examination</li></ul></td></tr><tr><td><p align=\"center\"><strong>Management</strong></p></td><td><ul><li>Nonsteroidal anti-inflammatory drugs</li><li>Combination oral contraceptive pills</li></ul></td></tr></tbody></table></div><p>This patient&#39;s regular, painful menses and normal pelvic examination are consistent with <strong>primary dysmenorrhea</strong>, which is common in <strong>adolescents</strong> after the establishment of ovulatory menstrual cycles.&nbsp; During menses, the endometrium produces and releases prostaglandins, which stimulate uterine contractions and promote endometrial sloughing.&nbsp; Patients with primary dysmenorrhea have <strong>increased endometrial prostaglandin production</strong>, which causes <strong>uterine hypercontractility</strong>, hypertonicity, <strong>vasoconstriction</strong>, and <strong>resultant ischemia</strong>.&nbsp; Classic symptoms include:</p><ul><li><p>Cramping, midline lower abdominal pain beginning 1 or 2 days prior to menses and radiating to the lower back and thighs (ie, uterine hypercontractility and hypertonicity)</p></li><li><p>Systemic symptoms such as nausea, vomiting, and diarrhea (ie, prostaglandin-induced stimulation of the gastrointestinal tract)</p></li></ul><p>First-line treatment is with <strong>nonsteroidal anti-inflammatory drugs</strong>, which inhibit prostaglandin synthesis.&nbsp; Combined hormonal contraception (eg, estrogen-progestin oral contraceptive pills) also reduces endometrial prostaglandin production by inhibiting both ovulation and endometrial decidualization; it is another first-line treatment for sexually active patients.</p><p><strong>(Choice A)</strong>&nbsp; Adenomyosis can cause dysmenorrhea due to the presence of endometrial stroma and glands within the uterine myometrium; however, adenomyosis causes a symmetrically enlarged (globular), tender uterus, which is not seen in this patient.&nbsp; In addition, it typically occurs in women age &gt;40.</p><p><strong>(Choice B)</strong>&nbsp; Endometriosis (extrauterine endometrial gland implants) can cause dysmenorrhea.&nbsp; However, patients typically have pelvic pain throughout the duration of menses rather than improved symptoms 1 or 2 days after menses onset.&nbsp; In addition, endometriosis causes chronic intraperitoneal inflammation, which can result in pelvic adhesions (eg, immobile, fixed uterus) and chronic pelvic pain that persists outside menses.&nbsp; In contrast, this patient has a small, mobile uterus and pain associated with menses only.</p><p><strong>(Choice D)</strong>&nbsp; <a href=\"5096\">Ovarian torsion</a>, intermittent compression of the ovarian vessels, can cause intermittent lower abdominal pain; however, the pain is usually unilateral rather than midline and does not occur monthly with menses.</p><p><strong>(Choice E)</strong>&nbsp; Mittelschmerz pain, caused by peritoneal inflammation from ovarian follicle rupture, occurs during <a href=\"15005\">ovulation</a>, approximately 2 weeks prior to menses, rather than during menses.</p><p><strong>(Choice F)</strong>&nbsp; Endometritis, a polymicrobial infection within the endometrial cavity, can present with pelvic pain; however, patients typically have abnormal uterine bleeding (eg, postcoital, intermenstrual), cervical motion tenderness, and uterine tenderness, none of which are seen in this patient.</p><p><strong>Educational objective:</strong><br>Primary dysmenorrhea occurs due to increased endometrial prostaglandin production during menses that causes uterine hypercontractility and ischemia.&nbsp; Patients classically have midline lower abdominal pain with associated systemic symptoms (eg, nausea, diarrhea).&nbsp; First-line treatment is with nonsteroidal anti-inflammatory drugs.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 21040,
            "topic": "Dysmenorrhea",
            "titleId": 21040,
            "title": "Dysmenorrhea",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "3",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Endometrial stroma and glands within the uterine muscle",
                    "choiceNumber": 1,
                    "correctTaken": 847,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Implanted endometrial glands outside the uterus",
                    "choiceNumber": 2,
                    "correctTaken": 4060,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Increased endometrial prostaglandin production",
                    "choiceNumber": 3,
                    "correctTaken": 10490,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Intermittent compression of the ovarian vessels",
                    "choiceNumber": 4,
                    "correctTaken": 306,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Peritoneal inflammation from a ruptured ovarian follicle",
                    "choiceNumber": 5,
                    "correctTaken": 841,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Polymicrobial infection within the endometrial cavity",
                    "choiceNumber": 6,
                    "correctTaken": 119,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "58",
                    "mediaDataId": 0,
                    "title": "Primary dysmenorrhea",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "30461694",
                    "mediaDataId": 0,
                    "title": "ACOG committee opinion no. 760: dysmenorrhea and endometriosis in the adolescent.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/30461694",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "32041388",
                    "mediaDataId": 0,
                    "title": "Dysmenorrhea, endometriosis and chronic pelvic pain in adolescents.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/32041388",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "34749716",
                    "mediaDataId": 0,
                    "title": "Prevalence, risk factors, and management practices of primary dysmenorrhea among young females.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/34749716",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 75,
            "notes": null,
            "peopleTaken": 16663,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 63,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 14,
            "questionId": 12938,
            "questionIndex": 14257,
            "questionText": "<p>A 41-year-old woman, gravida 1 para 1, comes to the office to discuss possible contraceptive options.&nbsp; She was recently diagnosed with hypertension and prescribed an ACE inhibitor.&nbsp; The patient was counseled about the risk of ACE inhibitors in pregnancy and the need for reliable contraception.&nbsp; She has not used contraception for the past year because she was breastfeeding until a month ago.&nbsp; Her husband does not think he wants more children, but the patient is unsure about future pregnancy.&nbsp; She has no other chronic medical conditions and takes no other daily medications.&nbsp; Menses are monthly, with 4 days of light bleeding and mild cramping on the first day.&nbsp; The patient does not use tobacco, alcohol, or illicit drugs.&nbsp; Blood pressure is 122/78 mm Hg and pulse is 70/min.&nbsp; BMI is 19 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; On pelvic examination, the cervix is parous and has no visible lesions.&nbsp; The uterus is mobile and nontender.&nbsp; Which of the following is the most appropriate contraceptive option for this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p><img  draggable=\"false\" id=\"2558\" src=\"https://www.uworld.com/media/highresdefault/L23852.jpg\"  ></p><p>Contraceptive counseling should be patient-centered and take into consideration patient-specific factors (eg, medical history), the risk/benefit profiles of various contraception methods, and the patient&#39;s future fertility desires.&nbsp; In this patient with medication-controlled hypertension, the best option is the <strong>copper-containing intrauterine device (IUD)</strong> for several reasons, including the following:</p><ul><li><p><strong>No effect on hypertension</strong>:&nbsp; This is in contrast to estrogen-containing contraceptives, which can elevate blood pressure and increase the risk for stroke or acute myocardial infarction.</p></li><li><p><strong>High efficacy (&gt;99%)</strong> for pregnancy prevention:&nbsp; The effectiveness of the copper-containing IUD is due to high patient compliance (ie, ease and duration of use, with reinsertion every 10 years) and its multiple mechanisms of action (ie, impaired sperm function, fertilization, and implantation).&nbsp; Contraceptive efficacy is particularly important for patients taking teratogenic medications (eg, ACE inhibitors).</p></li><li><p><strong>No effect on future fertility</strong>:&nbsp; The copper-containing IUD can be removed at any time the patient desires pregnancy, with immediate return of fertility.</p></li></ul><p>Although the copper-containing IUD does not help (and may worsen) menstrual bleeding, patients, such as this one, with light bleeding and mild cramping are ideal candidates because they typically experience minimal adverse effects.</p><p><strong>(Choices A and E)</strong>&nbsp; Bilateral tubal ligation and vasectomy are surgical procedures that induce permanent sterility and should not be undertaken by those considering future fertility.&nbsp; Although reversal of tubal ligation and vasectomy is possible, it involves an additional surgery and is not always successful; success rates are between 50% and 70% and decline with increased time between procedures.</p><p><strong>(Choices B and D)</strong>&nbsp; Combined estrogen/progestin oral contraceptive pills and the estrogen/progestin <a href=\"24758\">vaginal ring</a> can worsen preexisting hypertension due to estrogen-induced angiotensinogen synthesis.&nbsp; Therefore, estrogen-containing contraceptives are an absolute contraindication in patients with severe hypertension and a relative contraindication in patients with mild or medication-controlled hypertension, such as this patient.</p><p><strong>Educational objective:</strong><br>Long-acting, reversible contraceptives (eg, copper-containing intrauterine devices) are highly effective for pregnancy prevention and can be used in patients with contraindications to estrogen-containing contraceptives (eg, hypertension).</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 17805,
            "topic": "Contraception",
            "titleId": 17805,
            "title": "Contraception",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "3",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Bilateral tubal ligation",
                    "choiceNumber": 1,
                    "correctTaken": 74,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Combined estrogen/progestin oral contraceptive pills",
                    "choiceNumber": 2,
                    "correctTaken": 2341,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Copper-containing intrauterine device",
                    "choiceNumber": 3,
                    "correctTaken": 12227,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Estrogen/progestin vaginal ring",
                    "choiceNumber": 4,
                    "correctTaken": 667,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Vasectomy in husband",
                    "choiceNumber": 5,
                    "correctTaken": 834,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "53",
                    "mediaDataId": 0,
                    "title": "Contraception",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "30681544",
                    "mediaDataId": 0,
                    "title": "ACOG practice bulletin no. 206: use of hormonal contraception in women with coexisting medical conditions.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/30681544",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27467196",
                    "mediaDataId": 0,
                    "title": "U.S. medical eligibility criteria for contraceptive use, 2016.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27467196",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 60,
            "notes": null,
            "peopleTaken": 16143,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 76,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 15,
            "questionId": 19674,
            "questionIndex": 21161,
            "questionText": "<p>A 62-year-old woman comes to the office for evaluation of postmenopausal bleeding.&nbsp; The patient had a single episode of light vaginal bleeding with wiping 1 week ago.&nbsp; She has had no pelvic pain or recurrence of bleeding.&nbsp; The patient&#39;s last menstrual period was at age 48, and she has never used hormone therapy for menopausal symptoms.&nbsp; Vital signs are normal.&nbsp; BMI is 34 kg/m&sup2;.&nbsp; Vulvovaginal atrophy is noted on physical examination.&nbsp; There are no cervical lesions.&nbsp; Transvaginal ultrasonography shows a normal-sized uterus with a slightly thickened endometrium and a 1.7-cm intracavitary lesion consistent with an endometrial polyp.&nbsp; There are no adnexal masses.&nbsp; Endometrial biopsy reveals atrophic endometrium with no evidence of hyperplasia.&nbsp; Which of the following is the best next step in management of this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_T93882\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Endometrial polyps</strong></p></td></tr><tr><td><p align=\"center\"><strong>Pathogenesis</strong></p></td><td><ul><li>Localized hyperplastic growths of endometrial glands &amp; stroma that form projections</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical presentation</strong></p></td><td><ul><li>Abnormal uterine bleeding (intermenstrual bleeding)</li><li>Postmenopausal bleeding</li><li>Asymptomatic</li></ul></td></tr><tr><td><p align=\"center\"><strong>Indications for removal</strong></p></td><td><ul><li>Postmenopausal</li><li>Premenopausal with:<ul style=\"list-style-type:circle;\"><li>Abnormal uterine bleeding</li><li>Infertility</li><li>Risk factors for endometrial cancer*</li></ul></li></ul></td></tr><tr><td colspan=\"2\"><p>*Anovulation, obesity, Lynch syndrome, tamoxifen therapy.</p></td></tr></tbody></table></div><p>Evaluation of the endometrium (eg, ultrasonography, endometrial biopsy) is required in all patients with <strong>postmenopausal bleeding</strong> because it is a common clinical presentation of endometrial hyperplasia/cancer.&nbsp; Other etiologies of postmenopausal bleeding include cervical dysplasia/cancer, endometrial polyps, and vulvovaginal atrophy.</p><p>This patient&#39;s ultrasound examination reveals an <strong>endometrial polyp</strong>, a highly friable hyperplastic growth of endometrial glands and stroma that projects into the uterine cavity.&nbsp; Although the vast majority of endometrial polyps are benign, they may contain focal areas of hyperplasia/carcinoma.&nbsp; This underlying risk is best predicted by <strong>patient age</strong> and <strong>bleeding symptoms</strong> (ie, risk increases with age and with abnormal uterine bleeding).</p><ul><li><p>In premenopausal patients, polyps are typically benign and warrant no further evaluation unless bleeding is abnormal/persistent or the patient has risk factors for endometrial cancer (eg, unopposed estrogen [obesity], tamoxifen use) <strong>(Choice D)</strong>.</p></li><li><p>In contrast, <strong>postmenopausal patients</strong> are at <strong>increased risk for malignancy</strong>; therefore, <strong>all polyps</strong> (symptomatic or asymptomatic) <strong>require histologic evaluation</strong>.</p></li></ul><p>Histologic sampling is often performed with an <a href=\"64090\">endometrial biopsy</a>, which has high sensitivity when &gt;50% of the endometrium is abnormal.&nbsp; However, endometrial biopsy has poor sensitivity (ie, increased false negatives) in patients with focal malignant lesions (eg, polyps).&nbsp; Despite this patient&#39;s negative endometrial biopsy (ie, endometrial atrophy with no hyperplasia), the presence of a focal lesion that is&nbsp;inaccessible to the endometrial biopsy catheter (eg, within the&nbsp;polyp)&nbsp;cannot be ruled out.&nbsp; Therefore, this patient requires <strong>hysteroscopic polyp removal</strong> to completely evaluate for underlying malignancy.</p><p><strong>(Choice A)</strong>&nbsp; Estrogen-containing transdermal patches are used to treat vasomotor symptoms of menopause.&nbsp; If the hormone replacement therapy does not include progestins, the unopposed estrogen dramatically increases the risk for endometrial cancer.&nbsp; For patients with suspected or known endometrial cancer, exogenous estrogens are contraindicated.</p><p><strong>(Choice B)</strong>&nbsp; Hysterectomy with bilateral salpingectomy may be indicated for benign conditions (eg, fibroids).&nbsp; In contrast, patients with endometrial cancer typically undergo hysterectomy with bilateral salpingo-oophorectomy for cancer staging.&nbsp; This patient requires hysteroscopic polyp removal to complete the evaluation before hysterectomy is considered; if the polyp is benign, hysterectomy may not be indicated.</p><p><strong>(Choice E)</strong>&nbsp; Progestins can inhibit and potentially reverse abnormal endometrial proliferation; therefore, progestin-containing intrauterine devices (IUDs) can be used to treat endometrial hyperplasia or prevent recurrence of endometrial polyps.&nbsp; However, this patient requires polypectomy for adequate evaluation prior to IUD placement.</p><p><strong>Educational objective:</strong><br>In postmenopausal patients, endometrial polyps (with or without associated postmenopausal bleeding) require hysteroscopic polypectomy for adequate evaluation of endometrial hyperplasia/cancer.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 19922,
            "topic": "Endometrial polyps",
            "titleId": 19922,
            "title": "Endometrial polyps",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "3",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Estrogen-containing transdermal patch",
                    "choiceNumber": 1,
                    "correctTaken": 960,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Hysterectomy with bilateral salpingectomy",
                    "choiceNumber": 2,
                    "correctTaken": 993,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Hysteroscopic polyp removal",
                    "choiceNumber": 3,
                    "correctTaken": 10082,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Observation and reassurance only",
                    "choiceNumber": 4,
                    "correctTaken": 8527,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Progestin-containing intrauterine device",
                    "choiceNumber": 5,
                    "correctTaken": 420,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "79",
                    "mediaDataId": 0,
                    "title": "Endometrial polyp",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "23090515",
                    "mediaDataId": 0,
                    "title": "Risk factors for developing endometrial cancer after benign endometrial sampling.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/23090515",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "31105939",
                    "mediaDataId": 0,
                    "title": "Endometrial polyps: pathogenesis, sequelae and treatment.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/31105939",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "31391756",
                    "mediaDataId": 0,
                    "title": "Study of the efficacy of pipelle biopsy technique to diagnose endometrial diseases in abnormal uterine bleeding.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/31391756",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 52,
            "notes": null,
            "peopleTaken": 20982,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 48,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 16,
            "questionId": 17289,
            "questionIndex": 18742,
            "questionText": "<p>A 26-year-old woman comes to the office to discuss a different form of contraception.&nbsp; The patient recently started combination oral contraceptive pills but frequently forgot to take them every day and discontinued them 3 months ago.&nbsp; She has regular monthly menses with 5 days of moderate bleeding and 2 days of mild cramping.&nbsp; The patient typically has bloating and breast soreness 2-3 days prior to the onset of menses that resolve on the first day of her period.&nbsp; She has had 2 urinary tract infections in the past year and takes no daily medications.&nbsp; The patient is sexually active with a male partner and has no history of sexually transmitted infections.&nbsp; She would like to have children but not for several years.&nbsp; Vital signs are normal.&nbsp; BMI is 22 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; On pelvic examination, the uterus has an irregular contour.&nbsp; Pelvic ultrasound reveals a divergent endometrial cavity with an indented fundus and normal ovaries bilaterally.&nbsp; Urine pregnancy testing is negative.&nbsp; Which of the following is the best contraceptive option for this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p>Contraceptive counseling takes into consideration patient-specific factors (eg, medical history), the risk/benefit profiles of various contraception methods, and the patient&#39;s future fertility desires.&nbsp; In this patient, the most appropriate contraceptive option is <strong>depot medroxyprogesterone acetate</strong> (DMPA) because it takes the following into consideration:</p><ul><li><p>Preference and ease of use (eg, <strong>inability to adhere to a daily pill schedule</strong>)</p></li><li><p><strong>Uterine cavity distortion</strong>, such as this patient&#39;s bicornuate uterus (divergent endometrial cavity and indented fundus), which is a contraindication to an intrauterine device (IUD)</p></li><li><p><strong>Desire for future fertility</strong>, which is possible with DMPA cessation and return to fertility (variable from 6-18 months) when the patient desires pregnancy</p></li></ul><p>DMPA is an effective, injectable contraceptive that does not require daily administration.&nbsp; It is <strong>safe for most women</strong>, particularly those who have contraindications to intrauterine devices and/or estrogen-containing contraceptives.&nbsp; DMPA is given as an injection every 3 months.&nbsp; A common side effect is light, irregular vaginal bleeding (eg, amenorrhea).</p><p><strong>(Choice A)</strong>&nbsp; The copper-containing IUD is a highly effective nonhormonal, long-acting, reversible contraceptive.&nbsp; It is contraindicated in women with distorted uterine anatomy (eg, <a href=\"2431\">bicornuate uterus</a>, large fibroids) because of the risk of malposition, perforation, and expulsion.</p><p><strong>(Choice C)</strong>&nbsp; Diaphragm and spermicide are placed pericoitally and have a high failure rate (12%).&nbsp; In addition, it is not recommended in women with frequent urinary tract infections, such as this patient.&nbsp; The spermicide decreases the amount of normal vaginal flora, making patients more susceptible to bacteriuria from coliform bacteria (eg, <em>Escherichia coli</em>).</p><p><strong>(Choice D)</strong>&nbsp; Hysterectomy is performed in women for medical indications (eg, uterine leiomyomata, adenomyosis) who do not desire future fertility.&nbsp; It is not used as contraception due to the risk of complications (eg, bleeding, urinary tract injury) and irreversibility.</p><p><strong>(Choice E)</strong>&nbsp; Because they are safe and have few contraindications, progestin-only contraceptive pills are commonly used in women who are breastfeeding.&nbsp; However, they do not consistently inhibit ovulation and have a high failure rate (eg, 6%) because of a short half-life that requires strict adherence to a daily schedule (eg, &gt;3 hr late requires backup contraception).</p><p><strong>Educational objective:</strong><br>Depot medroxyprogesterone acetate is an effective, injectable contraceptive that does not require daily administration.&nbsp; It is a safe choice for most women, particularly those who have contraindications to intrauterine devices and/or estrogen-containing contraceptives.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 17805,
            "topic": "Contraception",
            "titleId": 17805,
            "title": "Contraception",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "2",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Copper-containing intrauterine device",
                    "choiceNumber": 1,
                    "correctTaken": 2406,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Depot medroxyprogesterone acetate",
                    "choiceNumber": 2,
                    "correctTaken": 13578,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Diaphragm and spermicide",
                    "choiceNumber": 3,
                    "correctTaken": 263,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Hysterectomy",
                    "choiceNumber": 4,
                    "correctTaken": 46,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Progestin-only contraceptive pill",
                    "choiceNumber": 5,
                    "correctTaken": 502,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "53",
                    "mediaDataId": 0,
                    "title": "Contraception",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 59,
            "notes": null,
            "peopleTaken": 16795,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 81,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 17,
            "questionId": 4480,
            "questionIndex": 4480,
            "questionText": "<p>A 19-year-old woman comes to the office due to a 6-month history of amenorrhea.&nbsp; Menarche occurred at age 11, and her menstrual cycles were regular until 9 months ago.&nbsp; The patient has had no changes in vision or recent weight loss.&nbsp; She has no medical conditions or previous surgeries.&nbsp; The patient is in her first semester of college, where she has transitioned to collegiate-level soccer.&nbsp; She is taking extra classes and exercising with her team twice daily.&nbsp; The patient is sexually active, has no history of sexually transmitted infection, and uses condoms for contraception.&nbsp; She does not use tobacco, alcohol, or recreational drugs.&nbsp; Blood pressure is 120/70 mm Hg and pulse is 78/min.&nbsp; BMI is 20 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; On pelvic examination, the uterus is small, mobile, and nontender.&nbsp; The adnexa are not palpable.&nbsp; Pregnancy test result is negative.&nbsp; Prolactin and TSH levels are normal.&nbsp; A 10-day challenge with medroxyprogesterone acetate is initiated; no menstrual bleeding occurs.&nbsp; Compared to the general population, this patient is at greatest risk for which of the following?</p>",
            "questionHeader": "",
            "explanationText": "<p><img  draggable=\"false\" id=\"7250\" src=\"https://www.uworld.com/media/highresdefault/L17430.jpg\"  ></p><p>This athlete with increased life stressors, intensive exercise, new-onset secondary amenorrhea, and normal prolactin and TSH levels most likely has <strong>functional hypothalamic amenorrhea (FHA)</strong> (ie, hypogonadotropic hypogonadism).</p><p>Patients with FHA have decreased gonadotropin-releasing hormone (GnRH) secretion due to <strong>relative calorie deficiency</strong> (from increased energy expenditure and/or reduced calorie intake) and <strong>stress</strong> (from strenuous exercise and/or chronic illness).&nbsp; Decreased GnRH secretion leads to abnormal gonadotropin (FSH/LH) pulses and a <strong>low estrogen level</strong>.&nbsp; The low estrogen level can be confirmed with a <a href=\"67928\">progesterone challenge test</a> (eg, medroxyprogesterone acetate); the presence of estrogen causes proliferation of the endometrium, with subsequent sloughing after the withdrawal of progesterone.&nbsp; Patients without adequate estrogen will have no or minimal bleeding because there is no endometrial lining to shed.</p><p>Patients with estrogen deficiency are at risk of <strong>decreased bone mineral density</strong> despite the bone-building effects of physical activity.&nbsp; Estrogen inhibits osteoclastic-mediated bone resorption, and <strong>decreased estrogen leads to increased bone resorption</strong>.&nbsp; Although estrogen repletion can offset bone loss, <strong>increasing calorie intake</strong> and/or decreasing exercise is a more effective way to increase bone density in patients with FHA.</p><p><strong>(Choice B)</strong>&nbsp; A failed progesterone challenge test can indicate intrauterine adhesions (eg, Asherman syndrome) in a patient with prior uterine instrumentation (eg, dilation and curettage).&nbsp; Patients with a history of tubal surgery or pelvic inflammatory disease are at increased risk for ectopic pregnancy.&nbsp; This patient has none of these risk factors.</p><p><strong>(Choice C)</strong>&nbsp; Endometrial hyperplasia is a risk for those with unopposed estrogen stimulation from chronic anovulation, which occurs with polycystic ovary syndrome (PCOS).&nbsp; Patients with PCOS will have withdrawal bleeding after a progesterone challenge test due to high levels of estrogen causing endometrial proliferation.</p><p><strong>(Choice D)</strong>&nbsp; A risk factor for epithelial ovarian cancer is repeated ovulation; trauma to the ovarian surface with each ovulatory cycle can result in malignant transformation.&nbsp; This patient has a decreased risk of ovarian cancer due to anovulation.</p><p><strong>(Choice E)</strong>&nbsp; Patients with FHA have decreased estrogen levels but no vasomotor symptoms (eg, hot flashes, night sweats) or vaginal atrophy due to low basal levels of estrogen produced by the normal (yet unstimulated) ovaries.&nbsp; Patients with amenorrhea, vasomotor symptoms, and vaginal atrophy are more likely to have primary ovarian insufficiency.</p><p><strong>Educational objective:</strong><br>Functional hypothalamic amenorrhea results from suppression of the hypothalamic-pituitary-ovarian axis by strenuous exercise, calorie restriction, increased stress, or chronic illness.&nbsp; Patients are at risk for decreased bone mineral density due to estrogen deficiency.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 23429,
            "topic": "Amenorrhea",
            "titleId": 23429,
            "title": "Amenorrhea",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "1",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Decreased bone mineral density",
                    "choiceNumber": 1,
                    "correctTaken": 12805,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Ectopic pregnancy",
                    "choiceNumber": 2,
                    "correctTaken": 326,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Endometrial hyperplasia",
                    "choiceNumber": 3,
                    "correctTaken": 2156,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Epithelial ovarian cancer",
                    "choiceNumber": 4,
                    "correctTaken": 510,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Vasomotor symptoms",
                    "choiceNumber": 5,
                    "correctTaken": 895,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "700",
                    "mediaDataId": 0,
                    "title": "Evaluation of secondary amenorrhea",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "32843957",
                    "mediaDataId": 0,
                    "title": "Current understanding of hypothalamic amenorrhoea.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/32843957",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "2041389",
                    "mediaDataId": 0,
                    "title": "Where have the periods gone? The evaluation and management of functional hypothalamic amenorrhea.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/2041389",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 60,
            "notes": null,
            "peopleTaken": 16692,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 77,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 18,
            "questionId": 13720,
            "questionIndex": 15110,
            "questionText": "<p>A 12-year-old girl is brought to the office for evaluation of increasing lower abdominal pain.&nbsp; The patient has had intermittent lower abdominal pain for the last 6 months, but the pain would resolve after a few days without intervention.&nbsp; Last week when the pain began, it was initially colicky but relieved with ibuprofen.&nbsp; Now the pain has progressed and is severe, constant, and exacerbated by bowel movements with a sense of incomplete evacuation.&nbsp; The patient has had a decreased appetite for the last month and has lost 2.5 kg (5.5 lb), but she has had no fever, vomiting, diarrhea, or bloody stool.&nbsp; She has no chronic medical conditions or prior surgeries.&nbsp; The patient has never been sexually active and has not reached menarche.&nbsp; BMI is 19 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; There is a tender, symmetric suprapubic mass just above the pelvic brim.&nbsp; External genitalia are normal and breast and pubic hair development is Tanner stage 3.&nbsp; There is a bulge between the labia that increases with Valsalva.&nbsp; Rectal examination reveals an anterior tender, central mass.&nbsp; Which of the following is the best next step in management of this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_T41508\" style=\"overflow-x:auto;\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Imperforate hymen</strong></p></td></tr><tr><td><p align=\"center\"><strong>Pathogenesis</strong></p></td><td><ul><li>Incomplete degeneration of hymen</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical features</strong></p></td><td><ul><li>Cyclic lower abdominal pain</li><li>Bulk symptoms (defecatory &amp; urinary dysfunction)</li><li>Primary amenorrhea</li><li>Suprapubic mass (uterus)</li><li>Blue-tinged vaginal mass</li></ul></td></tr><tr><td><p align=\"center\"><strong>Management</strong></p></td><td><ul><li>Hymenal incision &amp; drainage</li></ul></td></tr></tbody></table></div><p>This patient&#39;s cyclic lower abdominal pain and <a href=\"1956\">interlabial bulge</a> are consistent with an <strong>imperforate hymen</strong>, an <strong>isolated genital outflow tract defect</strong>.&nbsp; Girls with a complete imperforate hymen are typically asymptomatic until menarche, when they begin to have <strong>cyclic lower abdominal pain</strong> due to uterine cramping and obstructed menstruation.</p><p>As blood volume in the vagina increases (ie, <strong>hematocolpos</strong>), the vagina (and sometimes uterus) becomes markedly distended (eg, <strong>enlarged suprapubic mass</strong>), causing bulk symptoms that include constant lower abdominal pain.&nbsp; Posterior expansion of the <a href=\"3835\">hematocolpos</a> causes increased rectal pressure, and patients can present with defecatory pain, <strong>sense of incomplete evacuation</strong>, and a tender anterior rectal mass.</p><p>Treatment is with <strong>hymenal incision and drainage</strong> of the entrapped material.&nbsp; As the uterus and hematocolpos empty, the abdominal pain resolves and the vagina and uterus (suprapubic mass) return to normal size.</p><p><strong>(Choice A)</strong>&nbsp; A colonoscopy may be indicated in pediatric patients with signs consistent with inflammatory bowel disease (eg, bloody stools, weight loss, tenesmus).&nbsp; Although this patient exhibits some of these symptoms, her pain is predominantly cyclic with no bloody stools.&nbsp; In addition, the tender anterior rectal and suprapubic mass are most consistent with hematocolpos.</p><p><strong>(Choice B)</strong>&nbsp; This patient&#39;s suprapubic mass is due to hematocolpos and uterine enlargement and will resolve with hymenal incision and drainage.&nbsp; If the pelvic mass and chronic pelvic pain do not resolve with incision and drainage, a diagnostic laparoscopy may be performed to evaluate for other pathologies (eg, endometriosis).</p><p><strong>(Choice C)</strong>&nbsp; FSH, TSH, and prolactin levels are part of the evaluation of primary amenorrhea (eg, lack of menses by age 13 with no breast development [or by age 15 with breast development]).&nbsp; This patient is age 12 with breast development and does not require this workup.</p><p><strong>(Choice E)</strong>&nbsp; A hysterosalpingogram can be used to evaluate for uterine anomalies (eg, unicornuate uterus); however, uterine anomalies are not associated with an imperforate hymen, which is an isolated defect.</p><p><strong>(Choice F)</strong>&nbsp; Pessaries are a surgical-sparing treatment for pelvic organ prolapse, which is rare in pediatric patients due to the lack of risk factors (eg, pregnancy).&nbsp; Despite an interlabial mass that increases with Valsalva, pelvic organ prolapse is not associated with severe abdominal pain or painful bowel movements.</p><p><strong>Educational objective:</strong><br>Imperforate hymen is a defect in the female genital outflow tract, resulting in hematocolpos.&nbsp; The accumulated material causes pain and sometimes difficulty with defecation.&nbsp; Treatment is with hymenal incision and drainage.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 23429,
            "topic": "Amenorrhea",
            "titleId": 23429,
            "title": "Amenorrhea",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "4",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Colonoscopy",
                    "choiceNumber": 1,
                    "correctTaken": 128,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Diagnostic laparoscopy",
                    "choiceNumber": 2,
                    "correctTaken": 274,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "FSH, TSH, and prolactin levels",
                    "choiceNumber": 3,
                    "correctTaken": 55,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Hymenal incision and drainage",
                    "choiceNumber": 4,
                    "correctTaken": 4434,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Hysterosalpingogram",
                    "choiceNumber": 5,
                    "correctTaken": 95,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Pessary placement",
                    "choiceNumber": 6,
                    "correctTaken": 154,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "39",
                    "mediaDataId": 0,
                    "title": "Imperforate hymen",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "19960149",
                    "mediaDataId": 0,
                    "title": "Imperforate hymen:  cause of lower abdominal pain in teenage girls.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/19960149",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25438708",
                    "mediaDataId": 0,
                    "title": "Obstructive reproductive tract anomalies.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25438708",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25737786",
                    "mediaDataId": 0,
                    "title": "Abdominal tumor in a 14-year-old adolescent:  imperforate hymen, resulting in hematocolpos-a case report and review of the literature.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25737786",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 81,
            "notes": null,
            "peopleTaken": 5140,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 86,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 19,
            "questionId": 3359,
            "questionIndex": 3359,
            "questionText": "<p>A 19-year-old nulligravid woman comes to the office for a routine checkup.&nbsp; She is concerned about having gained 4.5 kg (10 lb) over the past year and believes it is related to her oral contraceptive pills (OCPs).&nbsp; Six months ago, the patient started taking a low-dose combined ethinyl estradiol-norethindrone contraceptive pill daily.&nbsp; Prior to starting the pills, she had regular, heavy periods lasting 4-5 days.&nbsp; The patient missed school every month due to severe cramping on the first day of her period.&nbsp; Pain symptoms resolved 3 months after she started taking the pills.&nbsp; She takes no other medications.&nbsp; The patient became sexually active at age 18 and has had 2 partners since then.&nbsp; The patient and her current partner use condoms inconsistently.&nbsp; Vital signs are normal.&nbsp; BMI is 27 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Physical examination is unremarkable.&nbsp; Which of the following is the most appropriate response to this patient&#39;s concern?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_T85559\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\" style=\"width:65.0%;\"><p align=\"center\"><strong>Combined estrogen/progestin oral contraceptive pills</strong></p></td></tr><tr><td style=\"width:35.0%;\"><p align=\"center\"><strong>Adverse effects</strong><br>(most due to estrogen component)</p></td><td style=\"width:65.0%;\"><ul><li>Irregular, unscheduled bleeding</li><li>Breast tenderness, nausea, bloating</li><li>Amenorrhea</li><li>Hypertension</li><li>Venous thromboembolic disease</li><li>Liver disorders (eg, hepatic adenoma)</li><li>&#8593; Serum triglycerides</li></ul></td></tr><tr><td style=\"width:35.0%;\"><p align=\"center\"><strong>Benefits</strong></p></td><td style=\"width:65.0%;\"><ul><li>Pregnancy prevention</li><li>Menstrual cycle regulation</li><li>&#8595; Dysmenorrhea</li><li>&#8595; Hyperandrogenism (eg, acne, hirsutism)</li></ul></td></tr><tr><td style=\"width:35.0%;\"><p align=\"center\"><strong>Risk augmentation</strong></p></td><td style=\"width:65.0%;\"><ul><li>&#8595; Risk of ovarian &amp; endometrial cancer (if ever used)</li><li>&#8593; Risk of cervical cancer (only if currently or recently used)</li></ul></td></tr></tbody></table></div><p>Weight gain following initiation of <strong>combined estrogen/progestin oral contraceptive pills (OCPs)</strong> is a frequent patient concern.&nbsp; However, weight gain over time is multifactorial and common in patients regardless of contraception method.&nbsp; Several studies have shown <strong>no significant weight gain</strong> associated with OCPs, particularly <strong>low-dose</strong> formulations.&nbsp; Therefore, this patient can be reassured that her weight gain is unlikely related to her contraception method.&nbsp; Other potential causes should be discussed, and the patient should be provided additional education on the adverse effects and benefits of combined OCPs.</p><p>Early adverse effects of OCPs (typically arising in the first few months of use) include nausea, bloating, and breast tenderness; these symptoms usually subside with continued use.&nbsp; <strong>Irregular, unscheduled bleeding</strong> is the most common adverse effect and is typically associated with pills containing lower estrogen doses.&nbsp; Other adverse effects of OCPs include <strong>hypertension</strong> and <strong>venous thromboembolism</strong>.</p><p>This patient has <strong>primary dysmenorrhea</strong>, or recurrent lower abdominal pain associated with menstruation.&nbsp; Combined OCPs are <strong>first-line treatment</strong> for dysmenorrhea in sexually active patients.&nbsp; They relieve dysmenorrhea by thinning the endometrial lining, reducing prostaglandin release, and thereby decreasing uterine contractions (ie, menstrual cramping).</p><p><strong>(Choice A)</strong>&nbsp; Nonsteroidal anti-inflammatory drugs are first-line treatment in primary dysmenorrhea in non&ndash;sexually active patients.&nbsp; Discontinuing contraception in this sexually active patient increases her risk of unintended pregnancy.</p><p><strong>(Choice C)</strong>&nbsp; Copper intrauterine devices (IUDs) are associated with fewer systemic adverse effects compared with OCPs.&nbsp; However, copper IUDs are not recommended for patients with dysmenorrhea because they produce a local inflammatory reaction in the uterus (toxic to sperm and impairing to implantation), which may worsen pain symptoms.</p><p><strong>(Choice D)</strong>&nbsp; Medroxyprogesterone can induce amenorrhea and decrease menstrual cramping.&nbsp; However, it is not a good option for this patient because of its association with weight gain.&nbsp; This effect is likely due to the high dose of progesterone, which may stimulate appetite.</p><p><strong>(Choice E)</strong>&nbsp; Adverse effects of combined OCPs (eg, hypertension) are largely due to the estrogen component.&nbsp; Progestin-only pills have relatively fewer adverse effects but are less effective for dysmenorrhea treatment and contraception because they do not consistently inhibit ovulation.</p><p><strong>Educational objective:</strong><br>Combined oral contraceptive pills are first-line therapy for primary dysmenorrhea in sexually active patients.&nbsp; Adverse effects include irregular, unscheduled bleeding; hypertension; and venous thromboembolism.&nbsp; Studies have not demonstrated significant weight gain associated with combined OCP use.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 17805,
            "topic": "Contraception",
            "titleId": 17805,
            "title": "Contraception",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "2",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Discontinue the combined OCP and start a nonsteroidal anti-inflammatory drug",
                    "choiceNumber": 1,
                    "correctTaken": 299,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Reassure her that the weight gain is unlikely to be caused by the combined OCPs",
                    "choiceNumber": 2,
                    "correctTaken": 8830,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Recommend switching from the combined OCP to a copper intrauterine device",
                    "choiceNumber": 3,
                    "correctTaken": 2478,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Recommend switching from the combined OCP to a medroxyprogesterone injection",
                    "choiceNumber": 4,
                    "correctTaken": 1998,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Recommend switching from the combined OCP to a progestin-only pill",
                    "choiceNumber": 5,
                    "correctTaken": 3096,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "53",
                    "mediaDataId": 0,
                    "title": "Contraception",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "21507999",
                    "mediaDataId": 0,
                    "title": "The long-term influence of combined oral contraceptives on body weight.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/21507999",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "24156617",
                    "mediaDataId": 0,
                    "title": "Weight and body composition changes during oral contraceptive use in obese and normal weight women.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/24156617",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "24477630",
                    "mediaDataId": 0,
                    "title": "Combination contraceptives: effects on weight.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/24477630",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 60,
            "notes": null,
            "peopleTaken": 16701,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 53,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 20,
            "questionId": 15164,
            "questionIndex": 16588,
            "questionText": "<p>A 27-year-old woman comes to the office for advice regarding contraception.&nbsp; The patient has been using condoms consistently but now wants something more reliable.&nbsp; She has regular monthly menses, typically with 6 days of bleeding that requires wearing both a pad and a tampon simultaneously to prevent blood from getting on her clothing.&nbsp; Last year, the patient&#39;s mother was diagnosed with a pulmonary embolus and found to be a heterozygous factor V Leiden carrier.&nbsp; At that time, the patient also underwent screening and was also found to be a heterozygous factor V Leiden carrier.&nbsp; She has no personal history of venous thromboembolism and no other medical conditions.&nbsp; The patient does not use tobacco, alcohol, or illicit drugs.&nbsp; Blood pressure is 120/76 mm Hg and pulse is 70/min.&nbsp; BMI is 20 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Physical examination is normal.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td colspan=\"2\" style=\"vertical-align:middle;\">Complete blood count</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Hemoglobin</td><td style=\"vertical-align:middle;\">10 g/dL</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Hematocrit</td><td style=\"vertical-align:middle;\">30%</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Platelets</td><td style=\"vertical-align:middle;\">280,000/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Leukocytes</td><td style=\"vertical-align:middle;\">4,100/mm<font size=\"2\"><sup>3</sup></font></td></tr></tbody></table><p>Which of the following is the most appropriate contraceptive option for this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t52179\"><table class=\"table-default-style\" style=\"width:100.0%\"><tbody><tr><td colspan=\"2\" style=\"width:100.0%;\"><p align=\"center\"><strong>Contraindications for the use of combined hormonal contraceptives</strong></p></td></tr><tr><td style=\"width:50.0%;\"><p align=\"center\"><strong>Absolute</strong></p></td><td style=\"width:50.0%;\"><p align=\"center\"><strong>Relative</strong></p></td></tr><tr><td style=\"width:50.0%;\"><ul><li>Migraines with aura</li><li>Severe hypertension</li><li>Ischemic heart disease, stroke</li><li>Age &#8805;35 &amp; smoking &#8805;15 cigarettes/day</li><li>&lt;3 weeks postpartum</li><li>Thromboembolism</li><li>Thrombophilia (eg, factor V Leiden, antiphospholipid-antibody syndrome)</li><li>Active breast cancer</li><li>Active or severe liver disease</li></ul></td><td style=\"width:50.0%;\"><ul><li>Mild or medication-controlled hypertension</li><li>Age &#8805;35 &amp; smoking &lt;15 cigarettes/day</li><li>Certain medications (eg, lamotrigine, rifampin)</li><li>Inherited thrombophilia carrier (&amp; family member with thrombophilia plus thromboembolism)</li></ul></td></tr></tbody></table></div><p>Contraceptive counseling should be patient-centered and take into consideration patient-specific factors (eg, medical history), the risk/benefit profiles of various contraception methods, and the patient&#39;s future fertility desires.&nbsp; In this patient, the most appropriate contraceptive option is the <strong>progestin-releasing intrauterine device (IUD)</strong> because it takes into consideration this patient&#39;s:</p><ul><li><strong>increased risk of thromboembolism</strong> because she is a heterozygous <strong>factor V Leiden carrier</strong> who has a <strong>family member</strong> with inherited thrombophilia and prior thromboembolism.&nbsp; Estrogen-containing contraceptives are avoided in patients at increased risk of thromboembolism due to estrogen-induced hypercoagulability <strong>(Choices C and D)</strong>.&nbsp; In contrast, the <a href=\"2448\">progestin-releasing IUD</a> does not affect thromboembolic risk.</li></ul><ul><li><strong>heavy menstrual bleeding associated with anemia</strong>, which will not improve or may potentially worsen with the use of certain contraception methods such as the <a href=\"2558\">copper-containing IUD</a>&nbsp;<strong>(Choice A)</strong>.&nbsp; The progestin-releasing IUD causes endometrial atrophy, which treats heavy vaginal bleeding and anemia.</li></ul><ul><li><strong>desire for future fertility</strong>, which is possible with IUD removal at any time the patient desires pregnancy.</li></ul><p>In addition, the progestin-releasing IUD is one of the most effective methods of pregnancy prevention, with an efficacy of &gt;99% and duration of use up to 8 years.</p><p><strong>(Choice B)</strong>&nbsp; A diaphragm with spermicide is a nonhormonal barrier method that does not affect thromboembolic risk.&nbsp; However, it has poor contraceptive efficacy, making it an inferior option for this patient seeking reliable contraception.</p><p><strong>Educational objective:</strong><br>Estrogen-containing contraception methods are contraindicated in patients at increased risk for thromboembolism.&nbsp; Progestin-only contraceptives (eg, levonorgestrel-releasing intrauterine device) may be offered to these patients.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 17805,
            "topic": "Contraception",
            "titleId": 17805,
            "title": "Contraception",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "5",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Copper-containing intrauterine device",
                    "choiceNumber": 1,
                    "correctTaken": 3475,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Diaphragm and spermicide",
                    "choiceNumber": 2,
                    "correctTaken": 577,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Estrogen-progestin oral contraceptives",
                    "choiceNumber": 3,
                    "correctTaken": 501,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Estrogen-progestin vaginal ring",
                    "choiceNumber": 4,
                    "correctTaken": 123,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Progestin-releasing intrauterine device",
                    "choiceNumber": 5,
                    "correctTaken": 11994,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "53",
                    "mediaDataId": 0,
                    "title": "Contraception",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25162263",
                    "mediaDataId": 0,
                    "title": "Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25162263",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27467196",
                    "mediaDataId": 0,
                    "title": "US medical eligibility criteria for contraceptive use, 2016.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27467196",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "30681544",
                    "mediaDataId": 0,
                    "title": "ACOG practice bulletin no. 206: use of hormonal contraception in women with coexisting medical conditions.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/30681544",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 49,
            "notes": null,
            "peopleTaken": 16670,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 72,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 21,
            "questionId": 2392,
            "questionIndex": 2392,
            "questionText": "<p>A 34-year-old woman, gravida 1 para 1, comes to the clinic for evaluation of her contraception method.&nbsp; Eight months ago, she had a subdermal progestin implant placed.&nbsp; Since then, the patient has experienced unpredictable bleeding and now she would like to have the implant removed.&nbsp; She previously used combined oral contraceptive pills and would like to return to that method.&nbsp; The patient has primary hypertension that was diagnosed last year and that has been well controlled with medication.&nbsp; She takes no other medications and has no allergies.&nbsp; Her father and brother have type 2 diabetes mellitus.&nbsp; The patient does not use tobacco, alcohol, or recreational drugs.&nbsp; BMI is 24 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Blood pressure is 130/75 mm Hg.&nbsp; Physical examination is normal.&nbsp; Combined oral contraceptive pills would increase the patient&#39;s risk for which of the following?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_T77660\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\" style=\"width:65.0%;\"><p align=\"center\"><strong>Contraindications to combined estrogen/progestin contraceptive pills</strong></p></td></tr><tr><td style=\"width:35.0%;\"><p align=\"center\"><strong>&#8593; Venous thromboembolism risk</strong></p></td><td style=\"width:65.0%;\"><ul><li>Tobacco use</li><li>Prolonged immobilization</li><li>Prior venous thromboembolism</li><li>Thrombophilia (eg, antiphospholipid antibody syndrome)</li><li>&lt;3 weeks postpartum</li></ul></td></tr><tr><td style=\"width:35.0%;\"><p align=\"center\"><strong>&#8593; Cardiovascular disease &amp; stroke</strong></p></td><td style=\"width:65.0%;\"><ul><li>Migraines with aura</li><li>Uncontrolled hypertension</li><li>Ischemic heart disease</li><li>Prior stroke</li></ul></td></tr><tr><td style=\"width:35.0%;\"><p align=\"center\"><strong>Medical conditions negatively affected by &#8593; estrogen</strong></p></td><td style=\"width:65.0%;\"><ul><li>Active breast cancer</li><li>Active liver disease (eg, acute hepatitis, liver cancer)</li></ul></td></tr></tbody></table></div><p>Combined estrogen/progestin <strong>oral contraceptive pills (OCPs)</strong> have risks and benefits that should be discussed with patients prior to the start of therapy.&nbsp; Although most women have no blood pressure changes from taking OCPs, <strong>hypertension</strong> is a potential risk of OCP use due to increased angiotensinogen synthesis by estrogen during hepatic first-pass metabolism.&nbsp; Therefore, women who have controlled hypertension may take combined OCPs with close blood pressure monitoring to ensure ongoing control.</p><p>Other adverse effects of OCPs include an increased risk of <strong>thromboembolism</strong> due to the hypercoagulable properties of estrogen.&nbsp; Women with uncontrolled hypertension, hypertension with associated end-organ damage, or who are age &#8805;35 and use tobacco should not take combined OCPs because the compounding of these factors results in an increased risk of <strong>myocardial infarction</strong> and <strong>stroke</strong>.&nbsp; The elimination of a modifiable risk factor such as OCP use can decrease the overall risk of these conditions for this patient population.</p><p><strong>(Choice A)</strong>&nbsp; OCPs appear to decrease the risk of benign breast disease (particularly benign proliferative epithelial lesions), the most common of which is breast fibroadenoma.&nbsp; The progestin component is likely critical to this effect because estrogen tends to promote fibroadenoma growth (eg, increased size).&nbsp; Active breast cancer is a contraindication to OCP use.</p><p><strong>(Choices B and C)</strong>&nbsp; OCPs reduce the risk of endometrial and ovarian cancer.&nbsp; The decreased risk of endometrial cancer is due to progestin, which counteracts the effect of estrogen on endometrial proliferation.&nbsp; The decreased risk of ovarian cancer is attributed to chronic suppression of ovulation.</p><p><strong>(Choice D)</strong>&nbsp; OCP use has been associated with glucose intolerance and increased insulin resistance in some studies and in some patient populations (eg, those with polycystic ovary syndrome), but it has not been directly linked to the development of type 2 diabetes mellitus.</p><p><strong>Educational objective:</strong><br>Combined oral contraceptive pills (OCPs) can worsen hypertension.&nbsp; Patients with well-controlled hypertension may use OCPs but require close blood pressure monitoring.&nbsp; Poorly controlled hypertension is a contraindication to OCP use due to increased risk of myocardial infarction and stroke.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 17805,
            "topic": "Contraception",
            "titleId": 17805,
            "title": "Contraception",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "5",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Breast fibroadenoma",
                    "choiceNumber": 1,
                    "correctTaken": 1344,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Endometrial cancer",
                    "choiceNumber": 2,
                    "correctTaken": 2222,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Ovarian cancer",
                    "choiceNumber": 3,
                    "correctTaken": 502,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Type 2 diabetes mellitus",
                    "choiceNumber": 4,
                    "correctTaken": 248,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Worsening hypertension",
                    "choiceNumber": 5,
                    "correctTaken": 11597,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "53",
                    "mediaDataId": 0,
                    "title": "Contraception",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "32955577",
                    "mediaDataId": 0,
                    "title": "Hormonal contraception in women with hypertension.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/32955577",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26700034",
                    "mediaDataId": 0,
                    "title": "Progestin and breast cancer risk: a systematic review.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26700034",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 41,
            "notes": null,
            "peopleTaken": 15913,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 73,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 22,
            "questionId": 8882,
            "questionIndex": 8899,
            "questionText": "<p>A 42-year-old woman comes to the office due to recurrent episodes of fatigue and hot flashes.&nbsp; The patient&#39;s most recent symptoms began 4 days ago; she says she feels &#x22;extremely cranky.&#x22;&nbsp; She also has intermittent bloating, and her symptoms sometimes cause her to miss work.&nbsp; Her last menstrual period was 3 weeks ago.&nbsp; Menses occur every 30 days, with 2 days of heavy bleeding followed by 4 days of moderate flow.&nbsp; The patient had 2 vaginal deliveries in her 30s and stopped taking combined oral contraceptives last year after undergoing bilateral tubal ligation.&nbsp; She smokes cigarettes socially but does not use alcohol or illicit drugs.&nbsp; She takes no medications and has no known drug allergies.&nbsp; Vital signs and physical examination are normal.&nbsp; Which of the following is the best next step in management for this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t61253\"><table class=\"table-default-style\" style=\"width:480px\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Premenstrual syndrome &amp;</strong></p><p align=\"center\"><strong>premenstrual dysphoric disorder</strong></p></td></tr><tr><td><p align=\"center\"><strong>Clinical<br />features</strong></p></td><td><ul><li>Symptoms occur during luteal phase</li><li>Physical: bloating, fatigue, headaches, hot flashes, breast tenderness</li><li>Affective: anxiety, irritability, mood swings, decreased interest; more severe in premenstrual dysphoric disorder</li></ul></td></tr><tr><td><p align=\"center\"><strong>Evaluation</strong></p></td><td><ul><li>Symptom/menstrual diary</li></ul></td></tr><tr><td><p align=\"center\"><strong>Treatment</strong></p></td><td><ul><li>Selective serotonin reuptake inhibitor</li></ul></td></tr></tbody></table></div><p>This patient&#39;s recurrent episodes of fatigue, bloating, and mood changes may be due to <strong>premenstrual syndrome</strong> (PMS), which causes both <strong>physical</strong> (eg, headaches, hot flashes) and <strong>affective symptoms</strong> (eg, irritability, anxiety) that compromise the patient&#39;s quality of life (eg, missing work).&nbsp; Although PMS usually is diagnosed when women are in their 20s, some patients develop severe symptoms in their later reproductive years and are at increased risk for mood disorders in the perimenopausal period.</p><p>In patients with vague symptoms, such as this woman, evaluation aims to distinguish PMS from mood disorders (eg, major depressive disorder) or medical conditions (eg, hypothyroidism), which typically are not related to menses.&nbsp; For this reason, the diagnosis of PMS is supported by a <strong>symptom diary</strong> created by the patient over 2 <a href=\"3250\">menstrual cycles</a> that reveals recurring symptoms during the luteal phase <strong>(1-2 weeks prior to menses)</strong> that resolve during the follicular phase (with onset of menses).&nbsp; If this pattern is confirmed, patients may opt for treatment with <strong>selective serotonin reuptake inhibitors</strong> taken daily or only during the luteal phase.</p><p><strong>(Choice A)</strong>&nbsp; Benzodiazepines (eg, lorazepam) may be used acutely to treat certain mood disorders (eg, panic disorder).&nbsp; Although PMS causes affective symptoms (eg, irritability), the pattern is cyclic with menses and includes physical symptoms that do not resolve with benzodiazepines.</p><p><strong>(Choice B)</strong>&nbsp; An FSH level can be measured to confirm menopause, which is unlikely in this regularly menstruating patient.</p><p><strong>(Choice C)</strong>&nbsp; Pelvic ultrasound is used to evaluate abnormal uterine bleeding or an adnexal mass, which may cause fatigue and bloating.&nbsp; This patient has regular menses and a normal physical examination; therefore, imaging is not indicated.</p><p><strong>(Choice D)</strong>&nbsp; Combined estrogen-progestin oral contraceptives are commonly used to treat PMS by inducing anovulation.&nbsp; However, this patient&#39;s age (&#8805;35) and smoking history are relative contraindications to estrogen-containing medications due to the increased risk of thromboembolism.&nbsp; A symptom diary should be obtained prior to initiating treatment.</p><p><strong>Educational objective:</strong><br>Premenstrual syndrome causes both physical and affective symptoms, which commonly include fatigue, bloating, hot flashes, mood swings, and irritability.&nbsp; Diagnosis is supported with a symptom diary that reveals recurring symptoms in the luteal phase (ie, 1-2 weeks prior to menses) that resolve with menses.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 19187,
            "topic": "Premenstrual syndrome",
            "titleId": 19187,
            "title": "Premenstrual syndrome",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "5",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Benzodiazepine therapy",
                    "choiceNumber": 1,
                    "correctTaken": 54,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "FSH level",
                    "choiceNumber": 2,
                    "correctTaken": 6106,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Pelvic ultrasound",
                    "choiceNumber": 3,
                    "correctTaken": 909,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Restart combined oral contraceptives",
                    "choiceNumber": 4,
                    "correctTaken": 1650,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Symptom diary",
                    "choiceNumber": 5,
                    "correctTaken": 8012,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "61",
                    "mediaDataId": 0,
                    "title": "Premenstrual syndrome and premenstrual dysphoric disorder",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "22010771",
                    "mediaDataId": 0,
                    "title": "Premenstrual syndrome and premenstrual dysphoric disorder.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/22010771",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 61,
            "notes": null,
            "peopleTaken": 16731,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 48,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 23,
            "questionId": 8876,
            "questionIndex": 8892,
            "questionText": "<p>A 32-year-old woman, gravida 3 para 3, comes to the office due to abnormal uterine bleeding.&nbsp; Menarche was at age 13, and her menstrual cycles were monthly until a year ago.&nbsp; The patient then began to have irregular menses that occurred every 45-60 days with heavy bleeding and passage of clots but no cramping.&nbsp; She has not had a menstrual period for the last 4 months.&nbsp; The patient has no hot flushes, acne, or abnormal hair growth.&nbsp; She takes levothyroxine for hypothyroidism and her only surgery was a tubal ligation after her last delivery.&nbsp; Height is 160 cm (5 ft 3 in) and weight is 120.2 kg (265 lb).&nbsp; Speculum examination is normal and bimanual examination is limited by body habitus.&nbsp; Urine pregnancy test is negative.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td>TSH</td><td>2.9 &micro;U/mL (normal: 0.5-5.0)</td></tr><tr><td>Prolactin</td><td>16 ng/mL (normal: &lt;20)</td></tr><tr><td>FSH</td><td>20 mIU/mL (normal: 5-30)</td></tr></tbody></table><p>Which of the following is the most likely diagnosis in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p><img draggable=\"false\" id=\"18342\" src=\"https://www.uworld.com/media/L43276.jpg\" ></p><p>This patient&#39;s chronic (&#8805;6 months) abnormal uterine bleeding is likely secondary to excess adipose tissue associated with <strong>obesity</strong>.&nbsp; Excess adipose tissue affects the <strong>hypothalamic-pituitary-ovarian axis</strong> by 2 major mechanisms:</p><ul><li>Obesity causes increased insulin resistance and hyperglycemia, which decrease the production of sex hormone&ndash;binding globulin, causing elevated free androgen (eg, androstenedione) levels.</li><li>The increased free androgens are <strong>aromatized in the adipose tissue to estrone</strong> (a type of estrogen), which leads to persistently elevated estrone levels.</li></ul><p>In these patients, the high estrone levels affect GnRH pulses at the level of the hypothalamus, resulting in high-frequency, short-interval GnRH pulses.&nbsp; These pulses preferentially produce LH, resulting in an imbalance in LH and FSH release from the anterior pituitary (although the overall change in concentration is minimal).&nbsp; The LH/FSH imbalance results in a lack of LH surge, causing <strong>anovulation</strong> and subsequent <strong>abnormal uterine bleeding</strong>.&nbsp; Treatment options include weight loss and combination oral contraceptives, which regulate menstrual cycles and protect the endometrium.</p><p><strong>(Choice A)</strong>&nbsp; Patients with <a href=\"1210\">adenomyosis</a> typically have heavy monthly menstrual bleeding with dysmenorrhea, which is not seen in this patient.</p><p><strong>(Choice C)</strong>&nbsp; <a href=\"4775\">Endometrial polyps</a> are common in obese patients because the estrogen receptor on the endometrium responds to estrogen excess.&nbsp; However, patients with endometrial polyps typically have bleeding between regular, monthly menstrual cycles.&nbsp; Endometrial polyps do not cause amenorrhea, making this diagnosis unlikely.</p><p><strong>(Choice D)</strong>&nbsp; Patients with hypothyroidism can have abnormal uterine bleeding because the increased release of thyrotropin-releasing hormone from the hypothalamus causes increased prolactin levels.&nbsp; The elevated prolactin level inhibits FSH and LH release from the pituitary, leading to anovulation and abnormal uterine bleeding.&nbsp; However, this patient&#39;s TSH is normal, making this diagnosis unlikely.</p><p><strong>(Choice E)</strong>&nbsp; Primary ovarian insufficiency is a type of hypergonadotropic hypogonadism (eg, menopause) in women age &lt;40 that causes anovulation and subsequent abnormal uterine bleeding.&nbsp; In contrast to this patient, those with primary ovarian insufficiency have vasomotor symptoms (eg, hot flushes) and an elevated FSH level (&gt;40 mIU/mL).</p><p><strong>(Choice F)</strong>&nbsp; <a href=\"2335\">Uterine leiomyomas</a> (fibroids) cause heavy, regular menstrual bleeding rather than irregular menses or amenorrhea, making this diagnosis unlikely.</p><p><strong>Educational objective:</strong><br>The increased adipose tissue associated with obesity increases the peripheral conversion of androgens to estrone, a type of estrogen.&nbsp; Chronically elevated estrone levels disrupt the hypothalamic-pituitary-ovarian axis and result in anovulation and abnormal uterine bleeding.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 21633,
            "topic": "Anovulation",
            "titleId": 21633,
            "title": "Anovulation",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "2",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Adenomyosis",
                    "choiceNumber": 1,
                    "correctTaken": 1248,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Anovulation",
                    "choiceNumber": 2,
                    "correctTaken": 9655,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Endometrial polyp",
                    "choiceNumber": 3,
                    "correctTaken": 904,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Hypothyroidism",
                    "choiceNumber": 4,
                    "correctTaken": 326,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Primary ovarian insufficiency",
                    "choiceNumber": 5,
                    "correctTaken": 1864,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Uterine leiomyoma",
                    "choiceNumber": 6,
                    "correctTaken": 1987,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "54",
                    "mediaDataId": 0,
                    "title": "Evaluation of abnormal uterine bleeding",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28050960",
                    "mediaDataId": 0,
                    "title": "Obesity and anovulatory infertility:  a review.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28050960",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27317009",
                    "mediaDataId": 0,
                    "title": "Bariatric surgery in obese women of reproductive age improves conditions that underlie fertility and pregnancy outcomes:  retrospective cohort study of UK National Bariatric Surgery Registry (NBSR).",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27317009",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 82,
            "notes": null,
            "peopleTaken": 15984,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 60,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 24,
            "questionId": 14129,
            "questionIndex": 15532,
            "questionText": "<p>A 15-year-old girl is brought to the office for evaluation of her menstrual periods.&nbsp; The patient underwent menarche at age 12 and initially had irregular, heavy, nonpainful menses.&nbsp; Menses now occur monthly and consist of 4 days of light bleeding.&nbsp; For the past 3 months, the girl has developed malaise and dizziness 2 days prior to her menstrual period and has had associated, continuous lower abdominal pain that radiates to her thighs.&nbsp; Symptoms resolve on the second day of menses.&nbsp; She has no chronic medical conditions and takes no daily medications.&nbsp; The patient is not sexually active.&nbsp; Her last menstrual period was a week ago.&nbsp; Vital signs are normal.&nbsp; The abdomen is soft, nontender, and nondistended and has no palpable masses.&nbsp; Pelvic examination is deferred.&nbsp; Which of the following is the best next step in management of this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t35624\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Primary dysmenorrhea </strong></p></td></tr><tr><td><p align=\"center\"><strong>Etiology </strong></p></td><td><ul><li>Excessive prostaglandin production</li></ul></td></tr><tr><td><p align=\"center\"><strong>Risk factors </strong></p></td><td><ul><li>Age &lt;30</li><li>BMI &lt;20 kg/m<sup>2</sup></li><li>Tobacco use</li><li>Menarche at age &lt;12</li><li>Heavy/long menstrual periods</li><li>Sexual abuse</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical features </strong></p></td><td><ul><li>Pain first 2-3 days of menses</li><li>Nausea, vomiting, diarrhea</li><li>Normal pelvic examination</li></ul></td></tr><tr><td><p align=\"center\"><strong>Management </strong></p></td><td><ul><li>Nonsteroidal anti-inflammatory drugs</li><li>Combination&nbsp;oral contraceptive pills</li></ul></td></tr></tbody></table></div><p>This adolescent&#39;s regular, painful menses after the establishment of ovulatory menstrual cycles is consistent with <strong>primary dysmenorrhea</strong>.&nbsp; During menses, the endometrium produces and releases prostaglandins, stimulating uterine contractions and promoting endometrial sloughing.&nbsp; Patients with primary dysmenorrhea have <strong>increased endometrial prostaglandin production</strong>, which causes uterine hypercontractility and hypertonicity and resultant ischemia.&nbsp; Therefore, <strong>lower abdominal pain</strong> (which can radiate to the back and thighs) is typical, usually beginning 1 or 2 days prior to menses (as uterine contractions initiate endometrial sloughing) and resolving a few days after onset of menses (as the endometrial lining thins).&nbsp; Patients also often have associated <strong>malaise</strong>, <strong>dizziness</strong>, and gastrointestinal symptoms.&nbsp; Pelvic examination is normal and can be deferred in patients who are not sexually active, as in this case.</p><p>First-line treatment in nonsexually active patients, such as this one, with primary dysmenorrhea is <strong>nonsteroidal anti-inflammatory drugs</strong> because they <strong>inhibit prostaglandin synthesis</strong>.&nbsp; In sexually active patients, combination oral contraceptives are an option because they suppress ovulation, providing contraception as well as decreasing prostaglandin release.</p><p><strong>(Choice A)</strong>&nbsp; A copper-containing intrauterine device is not used for the treatment of primary dysmenorrhea because a common side effect of this is painful, heavy menses.</p><p><strong>(Choice B)</strong>&nbsp; Gonadotropin-releasing hormone agonists (eg, leuprolide) can be used in the treatment of endometriosis by suppressing ovulation.&nbsp; In contrast to this patient, those with endometriosis have pain throughout the menstrual cycle and often have chronic pelvic pain.</p><p><strong>(Choice D)</strong>&nbsp; Progestin-only pills are not as effective as nonsteroidal anti-inflammatory drugs or combination oral contraceptives because they do not decrease endometrial prostaglandin synthesis.</p><p><strong>(Choice E)</strong>&nbsp; A selective serotonin reuptake inhibitor is first-line treatment in patients with premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD).&nbsp; Although this patient has associated malaise, she does not have enough (5) systemic symptoms to meet PMS/PMDD criteria.</p><p><strong>(Choice F)</strong>&nbsp; Tranexamic acid is used in women who have heavy, regular bleeding and for whom combination oral contraceptives are contraindicated (eg, thromboembolism).&nbsp; This patient has light bleeding.</p><p><strong>Educational objective:</strong><br>Primary dysmenorrhea occurs due to increased endometrial prostaglandin production during menses that causes uterine hypercontractility (eg, crampy lower abdominal pain) and associated systemic symptoms (eg, malaise).&nbsp; First-line treatment is with nonsteroidal anti-inflammatory drugs, which inhibit prostaglandin synthesis.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 21040,
            "topic": "Dysmenorrhea",
            "titleId": 21040,
            "title": "Dysmenorrhea",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "3",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Copper-containing intrauterine device",
                    "choiceNumber": 1,
                    "correctTaken": 178,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Gonadotropin-releasing hormone agonist",
                    "choiceNumber": 2,
                    "correctTaken": 208,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Nonsteroidal anti-inflammatory drugs",
                    "choiceNumber": 3,
                    "correctTaken": 12790,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Progestin-only pills",
                    "choiceNumber": 4,
                    "correctTaken": 1696,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Selective serotonin reuptake inhibitor",
                    "choiceNumber": 5,
                    "correctTaken": 1026,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Tranexamic acid",
                    "choiceNumber": 6,
                    "correctTaken": 190,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "58",
                    "mediaDataId": 0,
                    "title": "Primary dysmenorrhea",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26224322",
                    "mediaDataId": 0,
                    "title": "Nonsteroidal anti-inflammatory drugs for dysmenorrhoea.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26224322",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "24695505",
                    "mediaDataId": 0,
                    "title": "Diagnosis and initial management of dysmenorrhea.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/24695505",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 56,
            "notes": null,
            "peopleTaken": 16088,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 80,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 25,
            "questionId": 2394,
            "questionIndex": 2394,
            "questionText": "<p>An 18-year-old woman comes to the office due to lower abdominal pain that radiates to her lower back and thighs during menses.&nbsp; The patient had no pain while on oral contraceptives but stopped taking them 5 months ago due to unscheduled breakthrough bleeding.&nbsp; Menstrual periods now occur every 30 days with 5 days of bleeding.&nbsp; The pain and bleeding are worse on the second day, requiring the patient to change her pad every 4 hours.&nbsp; She also has nausea and fatigue during the first 2 days of menses.&nbsp; The patient is sexually active with a male partner and uses condoms inconsistently.&nbsp; She has no intermenstrual bleeding or pain with intercourse.&nbsp; Vital signs are normal.&nbsp; BMI is 19.5 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Pelvic examination reveals a small, mobile uterus and no palpable adnexal masses.&nbsp; Which of the following is the most likely diagnosis in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t35624\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Primary dysmenorrhea </strong></p></td></tr><tr><td><p align=\"center\"><strong>Etiology </strong></p></td><td><ul><li>Excessive prostaglandin production</li></ul></td></tr><tr><td><p align=\"center\"><strong>Risk factors </strong></p></td><td><ul><li>Age &lt;30</li><li>BMI &lt;20 kg/m<sup>2</sup></li><li>Tobacco use</li><li>Menarche at age &lt;12</li><li>Heavy/long menstrual periods</li><li>Sexual abuse</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical features </strong></p></td><td><ul><li>Pain first 2-3 days of menses</li><li>Nausea, vomiting, diarrhea</li><li>Normal pelvic examination</li></ul></td></tr><tr><td><p align=\"center\"><strong>Management </strong></p></td><td><ul><li>Nonsteroidal anti-inflammatory drugs</li><li>Combination&nbsp;oral contraceptive pills</li></ul></td></tr></tbody></table></div><p>This patient, who had resumption of ovulation after discontinuing oral contraceptive use, now has increased painful lower abdominal cramping associated with menses, suggestive of&nbsp;<strong>primary dysmenorrhea</strong>.&nbsp; Primary (ie, physiologic) dysmenorrhea (painful menses) is common, particularly among adolescents.&nbsp;&nbsp;<strong>Excessive prostaglandin production</strong>&nbsp;during menses can stimulate uterine contractions and result in <strong>lower abdominal pain</strong> that can radiate to the back and thighs.&nbsp; Some patients may also develop gastrointestinal symptoms (eg, <strong>nausea</strong>, vomiting, bloating, diarrhea) from prostaglandin-induced gastrointestinal stimulation.&nbsp; Symptoms are typically worse during the first few days of menses and can interfere with daily activities.&nbsp; Patients have a <strong>normal pelvic examination</strong> because the pelvic pain occurs without an identifiable pathologic cause.</p><p>The first-line treatment for primary dysmenorrhea is <strong>nonsteroidal antiinflammatory drugs</strong> (NSAIDs), which reduce prostaglandin synthesis.&nbsp; For patients who are sexually active or in whom NSAIDs are ineffective or&nbsp;cannot be tolerated, <strong>combination oral contraceptives</strong>&nbsp;(COCs) can be used.&nbsp; Although this patient previously had unscheduled breakthrough bleeding as a side effect of COCs, she can be prescribed another formulation that limits this side effect.</p><p><strong>(Choice A)</strong>&nbsp; <a href=\"1210\">Adenomyosis</a> can cause painful menses; however, this diagnosis is less likely because this patient does not have a tender, symmetrically enlarged (ie, &#x22;globular&#x22;) uterus.</p><p><strong>(Choice B)</strong>&nbsp; Endometriosis is a common cause of painful menses.&nbsp; However, patients often have additional pain during urination (dysuria), bowel movements (dyschezia), and sexual activity (dyspareunia).&nbsp; In contrast to this patient, those with endometriosis often have a fixed, immobile uterus or adnexal masses due to the ectopic endometrial glands and stroma.</p><p><strong>(Choice C)</strong>&nbsp; Intermittent ovarian torsion can cause lower abdominal pain and nausea; however, patients typically have an adnexal mass, and symptoms are not confined to the menstrual period.</p><p><strong>(Choice D)</strong>&nbsp; Pelvic congestion syndrome typically presents as a dull, ill-defined pelvic ache that worsens with intercourse or during long periods of standing.&nbsp; In contrast to this patient, those with pelvic congestion syndrome have pain prior to menses that is then relieved by menses.</p><p><strong>(Choice F)</strong>&nbsp; Uterine leiomyoma can cause pelvic pain secondary to bulk symptoms.&nbsp; Most patients have heavy, prolonged menses (eg, soaking a pad every 1-2 hours, passage of clots) and an enlarged, irregular uterus.</p><p><strong>Educational objective:</strong><br>Patients with primary dysmenorrhea have cyclic, lower abdominal pain during menses and a normal pelvic examination.&nbsp; First-line treatment is with nonsteroidal anti-inflammatory drugs.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 21040,
            "topic": "Dysmenorrhea",
            "titleId": 21040,
            "title": "Dysmenorrhea",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "5",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Adenomyosis",
                    "choiceNumber": 1,
                    "correctTaken": 535,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Endometriosis",
                    "choiceNumber": 2,
                    "correctTaken": 3775,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Intermittent ovarian torsion",
                    "choiceNumber": 3,
                    "correctTaken": 115,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Pelvic congestion syndrome",
                    "choiceNumber": 4,
                    "correctTaken": 1129,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Primary dysmenorrhea",
                    "choiceNumber": 5,
                    "correctTaken": 10703,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Uterine leiomyoma",
                    "choiceNumber": 6,
                    "correctTaken": 444,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "58",
                    "mediaDataId": 0,
                    "title": "Primary dysmenorrhea",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26224322",
                    "mediaDataId": 0,
                    "title": "Nonsteroidal anti-inflammatory drugs for dysmenorrhoea.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26224322",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "24695505",
                    "mediaDataId": 0,
                    "title": "Diagnosis and initial management of dysmenorrhea.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/24695505",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 62,
            "notes": null,
            "peopleTaken": 16701,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 64,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 26,
            "questionId": 3368,
            "questionIndex": 3368,
            "questionText": "<p>A 34-year-old woman, gravida 1 para 1, comes to the office for infertility evaluation.&nbsp; She has been trying to conceive for the past year, but her cycles have become increasingly irregular.&nbsp; Her last menstrual period was more than 3 months ago.&nbsp; Menses previously occurred every 27 days and lasted 4 days.&nbsp; The patient feels fatigued and has been waking at night due to feeling too warm.&nbsp; She has been married for 6 years and has a 4-year-old daughter who was delivered vaginally without complications.&nbsp; The patient has hypothyroidism, for which she takes levothyroxine.&nbsp; She has no previous surgeries.&nbsp; The patient smokes a pack of cigarettes daily but does not use alcohol or recreational drugs.&nbsp; Both parents have type 2 diabetes mellitus.&nbsp; BMI is 24 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Vital signs are normal.&nbsp; Pelvic examination shows normal external genitalia; a small, mobile uterus; and normal bilateral ovaries.&nbsp; TSH is normal and a pregnancy test is negative.&nbsp; Which of the following would most likely be seen in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_T31316\"><table class=\"table-default-style\"><tbody><tr><td></td><td><p align=\"center\"><strong>GnRH</strong></p></td><td><p align=\"center\"><strong>FSH</strong></p></td><td><p align=\"center\"><strong>Estrogen</strong></p></td></tr><tr><td><p><strong>Hypothalamic hypogonadism</strong></p></td><td><p align=\"center\">&#8595;</p></td><td><p align=\"center\">&#8595;</p></td><td><p align=\"center\">&#8595;</p></td></tr><tr><td><p><strong>Primary ovarian insufficiency</strong></p></td><td><p align=\"center\">&#8593;</p></td><td><p align=\"center\">&#8593;</p></td><td><p align=\"center\">&#8595;</p></td></tr><tr><td><p><strong>Polycystic ovary syndrome</strong></p></td><td><p align=\"center\">&#8593;</p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">&#8593;</p></td></tr><tr><td><p><strong>Normal ovulation </strong></p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">Normal</p></td></tr><tr><td><p><strong>Exogenous estrogen use</strong></p></td><td><p align=\"center\">&#8595;</p></td><td><p align=\"center\">&#8595;</p></td><td><p align=\"center\">&#8593;</p></td></tr></tbody></table></div><p><strong>Primary ovarian insufficiency (POI)</strong>, a form of <strong>hypergonadotropic hypogonadism</strong>, is the cessation of ovarian function at age &lt;40.&nbsp; The condition is characterized by amenorrhea or oligomenorrhea and symptoms of decreased estrogen (eg, hot flashes, fatigue).&nbsp; Initial presentation is with irregular menses or <strong>infertility</strong>.&nbsp; Patients typically have a history of an autoimmune disorder (eg, hypothyroidism) or Turner syndrome.&nbsp; The decreased ovarian function results in <strong>low estrogen levels</strong>; this prevents the physiologic negative feedback mechanism, thereby causing <strong>increased levels of</strong> gonadotropin-releasing hormone <strong>(GnRH) and FSH</strong> at the hypothalamus and the pituitary, respectively.&nbsp; Infertility treatment for POI consists of either in vitro fertilization or oocyte/embryo donation.</p><p><strong>(Choice A)</strong>&nbsp; Hypothalamic hypogonadism is characterized by low GnRH secretion and resultant low levels of FSH and estrogen.&nbsp; Typical presentation is also with oligomenorrhea or amenorrhea, but the condition is more likely in the setting of relative caloric insufficiency from decreased caloric intake (eg, eating disorders) or strenuous exercise.&nbsp; Patients with hypothalamic hypogonadism do not have associated menopausal symptoms because although estrogen is low, the ovaries often produce enough estrogen to offset vasomotor symptoms.</p><p><strong>(Choice C)</strong>&nbsp; Polycystic ovary syndrome (PCOS) causes infertility by anovulation.&nbsp; Patients with PCOS have elevated GnRH, normal FSH, and elevated estrogen.&nbsp; In patients with PCOS, these hormone levels occur due to increased peripheral conversion of androgen to estrone.&nbsp; This leads to persistently elevated (ie, continuous high-frequency pulses) GnRH levels at the hypothalamus, which causes a preference for LH production (and normal to decreased FSH levels) at the pituitary.&nbsp; These patients typically have irregular menses, obesity, and signs of hyperandrogenism (eg, hirsutism, acne).&nbsp; Physical examination may show bilaterally enlarged ovaries.</p><p><strong>(Choice D)</strong>&nbsp; Normal hormone levels would indicate ovulation, unlikely in a patient with irregular menses.&nbsp; Likely etiologies of infertility with normal laboratory values and normal menses are tubal blockage or male factor infertility.</p><p><strong>(Choice E)</strong>&nbsp; Exogenous estrogen use decreases GnRH and FSH levels through negative feedback, thereby preventing ovulation.&nbsp; This patient has signs of hypoestrogenism (eg, hot flashes), not hyperestrogenism (eg, breast tenderness).</p><p><strong>Educational objective:</strong><br>Primary ovarian insufficiency, cessation of ovarian function at age &lt;40, may present with infertility, irregular menses, and menopausal symptoms.&nbsp; It is characterized by elevated levels of gonadotropin-releasing hormone and FSH and low estrogen levels.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 23429,
            "topic": "Amenorrhea",
            "titleId": 23429,
            "title": "Amenorrhea",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "2",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "<table cellpadding=\"0\" cellspacing=\"0\" style=\"width:450px;\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"width:33%;text-align:center;\">\n\t\t\t\t&#8595;\n\t\t\t</td>\n\t\t\t<td style=\"width:33%;text-align:center;\">\n\t\t\t\t&#8595;\n\t\t\t</td>\n\t\t\t<td style=\"width:33%;text-align:center;\">\n\t\t\t\t&#8595;\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>",
                    "choiceNumber": 1,
                    "correctTaken": 3373,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "<table cellpadding=\"0\" cellspacing=\"0\" style=\"width:450px;\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"width:33%;text-align:center;\">\n\t\t\t\t&#8593;\n\t\t\t</td>\n\t\t\t<td style=\"width:33%;text-align:center;\">\n\t\t\t\t&#8593;\n\t\t\t</td>\n\t\t\t<td style=\"width:33%;text-align:center;\">\n\t\t\t\t&#8595;\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>",
                    "choiceNumber": 2,
                    "correctTaken": 11796,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "<table cellpadding=\"0\" cellspacing=\"0\" style=\"width:450px;\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"width:33%;text-align:center;\">\n\t\t\t\t&#8593;\n\t\t\t</td>\n\t\t\t<td style=\"width:33%;text-align:center;\">\n\t\t\t\tNormal\n\t\t\t</td>\n\t\t\t<td style=\"width:33%;text-align:center;\">\n\t\t\t\t&#8593;\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>",
                    "choiceNumber": 3,
                    "correctTaken": 146,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "<table cellpadding=\"0\" cellspacing=\"0\" style=\"width:450px;\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"width:33%;text-align:center;\">\n\t\t\t\tNormal\n\t\t\t</td>\n\t\t\t<td style=\"width:33%;text-align:center;\">\n\t\t\t\tNormal\n\t\t\t</td>\n\t\t\t<td style=\"width:33%;text-align:center;\">\n\t\t\t\tNormal\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>",
                    "choiceNumber": 4,
                    "correctTaken": 448,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "<table cellpadding=\"0\" cellspacing=\"0\" style=\"width:450px;\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"width:33%;text-align:center;\">\n\t\t\t\t&#8595;\n\t\t\t</td>\n\t\t\t<td style=\"width:33%;text-align:center;\">\n\t\t\t\t&#8595;\n\t\t\t</td>\n\t\t\t<td style=\"width:33%;text-align:center;\">\n\t\t\t\t&#8593;\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>",
                    "choiceNumber": 5,
                    "correctTaken": 881,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "55",
                    "mediaDataId": 0,
                    "title": "Primary ovarian insufficiency",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27513024",
                    "mediaDataId": 0,
                    "title": "Primary ovarian insufficiency.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27513024",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 73,
            "notes": null,
            "peopleTaken": 16644,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 71,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": "<table cellpadding=\"0\" cellspacing=\"0\" style=\"width:450px;\"><tbody><tr><td style=\"width:33%;text-align:center;\"><strong>GnRH</strong></td><td style=\"width:33%;text-align:center;\"><strong>FSH</strong></td><td style=\"width:33%;text-align:center;\"><strong>Estrogen</strong></td></tr></tbody></table>",
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 27,
            "questionId": 12664,
            "questionIndex": 13941,
            "questionText": "<p>A 14-year-old girl is brought to the office by her parents to discuss her menstrual periods.&nbsp; The patient was born at 25 weeks gestation and spent 4 months in the neonatal intensive care unit.&nbsp; She has cerebral palsy, and her mobility is limited due to spasticity.&nbsp; She has no intellectual disabilities.&nbsp; The patient started menstruating a year ago and has monthly bleeding that lasts 8 days with passage of clots.&nbsp; Her parents often need to change the patient&#39;s pads every hour during menses.&nbsp; She has mild intermittent asthma and migraines with aura.&nbsp; On examination, the patient is in a wheelchair and has multiple contractures in the bilateral lower extremities that allow for minimal active and passive range of motion.&nbsp; The abdomen is soft and nontender and has no palpable masses.&nbsp; Pelvic examination is deferred.&nbsp; The patient and her parents desire help in managing her heavy menstrual periods.&nbsp; Which of the following is the best treatment option for this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p><img  draggable=\"false\" id=\"4937\" src=\"https://www.uworld.com/media/highresdefault/L25373.jpg\"  ></p><p>The pubertal transition can be complicated by physical and intellectual disabilities.&nbsp; <strong>Adolescents with disabilities</strong> may become dependent on caregivers for <strong>menstrual hygiene</strong>, limiting their independence and creating embarrassment, especially when there is <strong>heavy menstrual bleeding</strong> (eg, hourly pad changes, large clots) or severe dysmenorrhea.</p><p>Menstrual management with <strong>hormonal contraception</strong> can be used to minimize menstrual bleeding volume and/or frequency, thereby improving a patient&#39;s quality of life and treating possible associated complications (eg, anemia).&nbsp; However, estrogen-containing contraception (eg, combined estrogen/progestin oral contraceptive pills) is contraindicated in patients with migraine with aura due to the increased risk for stroke.&nbsp; They are also contraindicated in patients with limited mobility because of the increased risk for thromboembolism <strong>(Choice A)</strong>.</p><p>A <strong>progestin-releasing subdermal implant</strong> is a long-acting (up to 3 years), reversible contraceptive that reduces menstrual bleeding in 50% of patients and causes amenorrhea in 20% of patients.&nbsp; Because it is easily placed in the upper arm, it is an ideal contraceptive option for adolescents (who do not require a pelvic examination for use) and in those with physical difficulties (eg, lower extremity contractures).&nbsp; In addition, progestin-only contraception has a much lower risk of thromboembolism than estrogen-containing contraception; in this patient, the risks are outweighed by the benefits of menstrual regulation.</p><p><strong>(Choice B)</strong>&nbsp; The copper-containing intrauterine device (IUD) is a highly effective form of nonhormonal contraception, but it is not recommended in patients with heavy menses because it can increase bleeding.&nbsp; In addition, an IUD may be difficult to insert in this patient with lower extremity contractures.</p><p><strong>(Choice C)</strong>&nbsp; Endometrial ablation cauterizes the endometrial lining to treat heavy menstrual bleeding, causing endometrial scarring and possible amenorrhea,.&nbsp; However, in patients who may desire future fertility (eg, adolescents) it is contraindicated due to the increased risk for future obstetric complications (eg, placenta accreta).&nbsp; In addition, adolescents should not be forced to decide between future fertility and menstrual control.</p><p><strong>(Choice D)</strong>&nbsp; <a href=\"64343\">GnRH agonist therapy</a> (eg, leuprolide) treats heavy, regular menses by acting on the pituitary to decrease pulsatile FSH and LH release, thereby producing a hypoestrogenic state leading to amenorrhea.&nbsp; However, it is not recommended for long-term use because of its adverse effects (eg, decreased bone density) and is particularly avoided in patients at higher risk for bone density abnormalities (eg, adolescents, patients in wheelchairs).</p><p><strong>Educational objective:</strong><br>Hormonal contraception, such as the progestin-releasing subdermal implant, can be used for menstrual hygiene (eg, to decrease menstrual bleeding) in adolescents with disabilities.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 17805,
            "topic": "Contraception",
            "titleId": 17805,
            "title": "Contraception",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "5",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Combined estrogen/progestin oral contraceptive pills",
                    "choiceNumber": 1,
                    "correctTaken": 3045,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Copper-containing intrauterine device",
                    "choiceNumber": 2,
                    "correctTaken": 860,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Endometrial ablation",
                    "choiceNumber": 3,
                    "correctTaken": 508,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "GnRH agonist therapy",
                    "choiceNumber": 4,
                    "correctTaken": 1058,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Progestin-releasing subdermal implant",
                    "choiceNumber": 5,
                    "correctTaken": 11141,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "53",
                    "mediaDataId": 0,
                    "title": "Contraception",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25004333",
                    "mediaDataId": 0,
                    "title": "Menstrual and reproductive issues in adolescents with physical and developmental disabilities.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25004333",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26542013",
                    "mediaDataId": 0,
                    "title": "Adolescents with special needs: clinical challenges in reproductive health care.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26542013",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27325636",
                    "mediaDataId": 0,
                    "title": "Menstrual management for adolescents with disabilities.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27325636",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 51,
            "notes": null,
            "peopleTaken": 16612,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 67,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 28,
            "questionId": 3480,
            "questionIndex": 3480,
            "questionText": "<p>A 16-year-old girl comes to the emergency department due to left lower quadrant abdominal pain that suddenly started overnight.&nbsp; The pain does not radiate and is 5/10 in severity.&nbsp; The patient does not report fever, vomiting, dysuria, diarrhea, or vaginal bleeding.&nbsp; She is sexually active with her boyfriend and is using condoms with spermicide for contraception.&nbsp; Her last menstrual period was 2 weeks ago.&nbsp; Menses occurs every 28 days with 5 days of moderate bleeding and some associated cramping on the first 2 days.&nbsp; Temperature is 37.2 C (99 F), blood pressure is 110/66 mm Hg, and pulse is 80/min.&nbsp; BMI is 22 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Abdominal examination shows mild left lower quadrant tenderness with no rebound.&nbsp; Pelvic examination shows a small, anteverted uterus with tenderness over a slightly enlarged left adnexa; the right adnexa is normal.&nbsp; Urine pregnancy test is negative.&nbsp; Pelvic ultrasound shows the&nbsp;left ovary with a 3-cm cyst with several subcentimeter cysts in the periphery.&nbsp; There is normal Doppler blood flow with a small amount of free fluid in the posterior cul-de-sac.&nbsp; Which of the following is the most likely diagnosis for this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p><img draggable=\"false\" id=\"1127\" src=\"https://www.uworld.com/media/highresdefault/L17431.png\" ></p><p>This patient has sudden left lower quadrant pain and an enlarged left adnexa; in reproductive-aged women with these findings, initial evaluation includes a pregnancy test and transvaginal ultrasound to rule out gynecologic emergencies (eg, ectopic pregnancy, ovarian torsion).</p><p>This patient&#39;s negative pregnancy test and an ultrasound that shows a <strong>simple ovarian cyst</strong> with a small amount of free fluid in the pelvis suggest a benign etiology.&nbsp; With the timing of the patient&#39;s last menstrual period 2 weeks ago (eg, <strong>late follicular phase of menses</strong>), the most likely cause of her symptoms is <strong>ovulation</strong> (ie, <strong>Mittelschmerz</strong>).&nbsp; In women with ovulatory menstrual cycles, a dominant follicle (ie, a large cyst with multiple smaller cysts) is formed during the follicular phase (resulting in an <strong>enlarged adnexa</strong>); when the oocyte is released during ovulation, pain can develop due to <strong>rupture of the follicle</strong> and subsequent release of a small amount of blood and fluid that irritates the peritoneum.&nbsp; Most patients can be managed with reassurance and pain management (eg, nonsteroidal anti-inflammatory medications).</p><p><strong>(Choice A)</strong>&nbsp; An ectopic pregnancy can present with abdominal pain and a large adnexa; however, patients typically have a complex adnexal mass and a positive pregnancy test, making this diagnosis unlikely.</p><p><strong>(Choice B)</strong>&nbsp; An <a href=\"49026\">endometrioma</a> arises from ectopic endometrium within the ovary that bleeds and forms a hematoma, which appears on ultrasound as a homogenous ovarian cyst with a ground-glass appearance.</p><p><strong>(Choice D)</strong>&nbsp; <a href=\"5096\">Ovarian torsion</a> results from a large ovarian mass twisting around the infundibulopelvic ligament causing occlusion of the ovarian vessels, resulting in ovarian ischemia.&nbsp; It often presents with severe unilateral pain with associated nausea and vomiting; however, ultrasound typically shows absent blood flow to the adnexa, making this diagnosis less likely.</p><p><strong>(Choice E)</strong>&nbsp; Polycystic ovary syndrome is characterized by menstrual irregularities, hyperandrogenism, and polycystic ovaries on ultrasound.&nbsp; This patient has normal menstrual cycles; in addition, the large follicle with multiple subcentimeter follicles on ultrasound is consistent with normal postovulatory ovarian changes.</p><p><strong>(Choice F)</strong>&nbsp; A tuboovarian abscess presents with fever, diffuse lower abdominal pain, and a complex, multicystic adnexal mass with thickened walls on ultrasound.&nbsp; This is an unlikely diagnosis in this patient without fever and with imaging that shows a simple ovarian cyst.</p><p><strong>Educational objective:</strong><br>Mittelschmerz is a physiologic cause of unilateral abdominal pain in young women.&nbsp; The pain occurs in the middle of the menstrual cycle (ie, follicular phase), corresponding with ovulation.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 21575,
            "topic": "Menstrual cycles",
            "titleId": 21575,
            "title": "Menstrual cycles",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "3",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Ectopic pregnancy",
                    "choiceNumber": 1,
                    "correctTaken": 466,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Endometrioma",
                    "choiceNumber": 2,
                    "correctTaken": 1644,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Mittelschmerz",
                    "choiceNumber": 3,
                    "correctTaken": 8792,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Ovarian torsion",
                    "choiceNumber": 4,
                    "correctTaken": 2144,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Polycystic ovary syndrome",
                    "choiceNumber": 5,
                    "correctTaken": 1933,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Tuboovarian abscess",
                    "choiceNumber": 6,
                    "correctTaken": 1775,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "19584789",
                    "mediaDataId": 0,
                    "title": "Mittelschmerz mimicking appendicitis.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/19584789",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 74,
            "notes": null,
            "peopleTaken": 16754,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 52,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 29,
            "questionId": 10884,
            "questionIndex": 12020,
            "questionText": "<p>A 42-year-old woman, gravida 2 para 2, comes to the office for evaluation of pelvic pain.&nbsp; The patient&#39;s menses are painful, with heavy bleeding that requires her to change her tampon every hour during the first 2 days.&nbsp; She did not have painful menstrual periods until a few years ago.&nbsp; The pelvic pain used to subside after menses but has become constant over the past few months and is unrelieved by ibuprofen.&nbsp; Her menstrual cycles are regular, occur every 28-30 days, and last 4 days.&nbsp; She has had no dysuria, urinary frequency, or constipation.&nbsp; The patient had a tubal ligation after her last delivery.&nbsp; She has not had cervical cancer screening within the past 5 years and is not sexually active.&nbsp; Temperature is 36.7 C (98 F), blood pressure is 120/70 mm Hg, and pulse is 78/min.&nbsp; Examination shows a boggy uterus that is tender to palpation.&nbsp; Which of the following additional findings is most likely present in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p><img draggable=\"false\" id=\"1210\" src=\"https://www.uworld.com/media/L18075.jpg\" ></p><p>This patient&#39;s chronic pelvic pain and heavy menstrual bleeding are most likely due to <strong>adenomyosis</strong>, a condition in which endometrial glands and stroma accumulate abnormally within the uterine myometrium.&nbsp; Adenomyosis typically occurs in <strong>multiparous women age &gt;40</strong> and is characterized by new-onset <strong>dysmenorrhea</strong> due to the cyclic shedding of the endometrium within the myometrium.&nbsp; The continued accumulation of endometrial tissue within the myometrium causes an increase in the endometrial cavity surface area (resulting in <strong>heavy menstrual bleeding</strong>) and progression to <strong>chronic pelvic pain</strong>.&nbsp; The entrapped endometrial tissue within the uterine myometrium results in a <strong>boggy</strong>, <strong>tender uterus</strong> on examination; it also induces myometrium hypertrophy, which causes a concentric or <strong>symmetrically enlarged uterus</strong>.</p><p>The initial workup of suspected adenomyosis consists of pelvic ultrasonography and/or MRI.&nbsp; A definitive diagnosis is made histologically after hysterectomy, which is also the treatment for patients who do not improve with conservative management (eg, oral contraceptives, progestin-releasing intrauterine device).</p><p><strong>(Choice A)</strong>&nbsp; An exophytic cervical mass due to <a href=\"8311\">cervical cancer</a> may cause heavy vaginal bleeding; however, the bleeding is typically irregular rather than cyclic as with menstruation.</p><p><strong>(Choice B)</strong>&nbsp; An enlarged, irregularly shaped uterus is common with <a href=\"1140\">uterine leiomyomata</a> (fibroids).&nbsp; Fibroids can cause heavy menstrual bleeding; however, the uterus is typically firm (not boggy) and nontender.</p><p><strong>(Choice C)</strong>&nbsp; Pelvic inflammatory disease can cause chronic pelvic pain and mucopurulent cervical discharge.&nbsp; It does not cause heavy menstrual bleeding and is unlikely in patients who are not sexually active.</p><p><strong>(Choices D and F)</strong>&nbsp; Posterior cul-de-sac nodularity and adnexal masses (ie, <a href=\"1139\">endometriomas</a>) can occur in women with endometriosis due to endometrial implants outside the uterus.&nbsp; This condition typically presents with dysmenorrhea and chronic pelvic pain in younger women (age 25-35).&nbsp; Because endometriosis causes endometrial implants outside (rather than within) the uterine musculature, it does not cause a boggy uterus.</p><p><strong>Educational objective:</strong><br>Adenomyosis typically presents in women age &gt;40 and is characterized by dysmenorrhea; heavy menstrual bleeding; progressive chronic pelvic pain; and a boggy, tender, symmetrically enlarged uterus.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 21040,
            "topic": "Dysmenorrhea",
            "titleId": 21040,
            "title": "Dysmenorrhea",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "5",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Exophytic cervical mass",
                    "choiceNumber": 1,
                    "correctTaken": 331,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Large, irregularly shaped uterus",
                    "choiceNumber": 2,
                    "correctTaken": 4394,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Mucopurulent cervical discharge",
                    "choiceNumber": 3,
                    "correctTaken": 338,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Posterior cul-de-sac nodularity",
                    "choiceNumber": 4,
                    "correctTaken": 1284,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Symmetrically enlarged uterus",
                    "choiceNumber": 5,
                    "correctTaken": 10064,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Unilateral adnexal mass",
                    "choiceNumber": 6,
                    "correctTaken": 316,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "48",
                    "mediaDataId": 0,
                    "title": "Adenomyosis",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "54",
                    "mediaDataId": 0,
                    "title": "Evaluation of abnormal uterine bleeding",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26427702",
                    "mediaDataId": 0,
                    "title": "Adenomyosis: a clinical review of a challenging gynecologic condition.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26427702",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27810281",
                    "mediaDataId": 0,
                    "title": "Adenomyosis and abnormal uterine bleeding (AUB-A)—pathogenesis, diagnosis, and management.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27810281",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 68,
            "notes": null,
            "peopleTaken": 16730,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 60,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 30,
            "questionId": 2390,
            "questionIndex": 2390,
            "questionText": "<p>A 16-year-old girl comes to the emergency department with heavy vaginal bleeding for 3 days.&nbsp; The patient&#39;s menses have been irregular since menarche at age 14 and occur every 4-5 months; her previous menstrual period was almost 4 months ago.&nbsp; She has no medical problems and has had no surgeries.&nbsp; She does not use tobacco, alcohol, or recreational drugs.&nbsp; The patient is sexually active and uses condoms for contraception.&nbsp; Temperature is 37.2 C (99 F), blood pressure is 110/60 mm Hg, pulse is 90/min, and respirations are 16/min.&nbsp; On pelvic examination, there is a moderate amount of blood in the vaginal vault and active bleeding from the cervical os.&nbsp; Bimanual examination shows a small uterus and no adnexal masses.&nbsp; Pelvic ultrasound reveals a small uterus with a thick endometrial stripe and normal ovaries.&nbsp; Urine pregnancy test is negative.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td colspan=\"2\" style=\"vertical-align:middle;\">Complete blood count</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp; &nbsp; &nbsp; &nbsp; Hemoglobin</td><td style=\"vertical-align:middle;\">10 g/dL</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp; &nbsp; &nbsp; &nbsp; Mean corpuscular volume</td><td style=\"vertical-align:middle;\">76 &micro;m<font size=\"2\"><sup>3</sup></font></td></tr><tr><td style=\"vertical-align:middle;\">&nbsp; &nbsp; &nbsp; &nbsp; Platelets</td><td style=\"vertical-align:middle;\">320,000/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td colspan=\"2\" style=\"vertical-align:middle;\"></td></tr><tr><td colspan=\"2\" style=\"vertical-align:middle;\">Coagulation studies</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp; &nbsp; &nbsp; &nbsp; PT</td><td style=\"vertical-align:middle;\">12 sec</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp; &nbsp; &nbsp; &nbsp; Activated PTT</td><td style=\"vertical-align:middle;\">26 sec</td></tr></tbody></table><p>Which of the following is the most appropriate next step in management of this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p><img  draggable=\"false\" id=\"6571\" src=\"https://www.uworld.com/media/highresdefault/L16455.jpg\"  ></p><p>This patient&#39;s acute <strong>abnormal uterine bleeding</strong> (AUB) is most likely due to ovulatory dysfunction and requires clinical intervention to prevent further bleeding.&nbsp; In <strong>adolescents</strong>, AUB is typically caused by an <strong>immature hypothalamic-pituitary-ovarian axis</strong>, resulting in anovulation and <strong>heavy, irregular bleeding</strong>.&nbsp; Without ovulation, there is persistent endometrial proliferation that results in heavy menses when ovulation does occur.&nbsp; Heavy menses is caused by exaggerated necrosis of the superficial layer of the endometrium, which eventually becomes denuded and continues to bleed due to lack of tissue stability.</p><p>Initial evaluation of patients presenting with acute vaginal bleeding includes a complete blood count, pregnancy test, and coagulation studies.&nbsp; In <strong>hemodynamically stable</strong> patients, acute uterine bleeding may be medically managed.&nbsp; First-line treatment includes intravenous estrogen (conjugated equine estrogen) or <strong>high-dose oral estrogen/progestin contraceptive pills</strong>.&nbsp; High-dose estrogen quickly stabilizes the denuded endometrium and stops menstrual bleeding.&nbsp; High-dose progestins may be given to patients with contraindications to estrogen (eg, history of thromboembolism).&nbsp; Progestins can also stabilize the endometrial lining and prevent further proliferation, but are not as effective as estrogen.</p><p><strong>(Choices A and D)</strong>&nbsp; In hemodynamically unstable, anemic patients (eg, tachycardia, hypotension), a dilation and curettage and/or a packed red blood cell transfusion may be indicated.&nbsp; A dilation and curettage removes the endometrium to quickly stop bleeding in an acute situation.&nbsp; This patient is hemodynamically stable.</p><p><strong>(Choice B)</strong>&nbsp; High-dose gonadotropin-releasing hormone (GnRH) agonists (eg, <a href=\"64343\">leuprolide</a>) create a hypoestrogenic state and are used to suppress symptoms of endometriosis and uterine leiomyoma.&nbsp; However, GnRH agonists do not work quickly enough to stop acute bleeding.&nbsp; In addition, GnRH agonists are not recommended for adolescents due to decreased bone mineral density caused by prolonged use.</p><p><strong>(Choice E)</strong>&nbsp; The most common inherited coagulation factor deficiencies include hemophilia A (factor VIII) and B (factor IX).&nbsp; Evaluation for these deficiencies is indicated in the settings of heavy bleeding and abnormal coagulation studies (eg, PT, PTT).&nbsp; This patient has normal coagulation studies and investigation for coagulation factor deficiency is not indicated. &nbsp;In addition, hemophilia is typically X-linked, making it unlikely in this patient.</p><p><strong>Educational objective:</strong><br>In adolescents, the immature hypothalamic-pituitary-ovarian axis causes anovulation and can result in heavy, irregular menstrual bleeding.&nbsp; In hemodynamically stable patients, heavy vaginal bleeding is managed with high-dose oral contraceptive therapy to stabilize the endometrium and stop the acute bleeding.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 104,
            "subject": "Pediatrics",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 17488,
            "topic": "Abnormal uterine bleeding",
            "titleId": 17488,
            "title": "Abnormal uterine bleeding",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "3",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Emergency dilation and curettage",
                    "choiceNumber": 1,
                    "correctTaken": 1402,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "High-dose gonadotropin-releasing hormone agonists",
                    "choiceNumber": 2,
                    "correctTaken": 1607,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "High-dose oral contraceptive therapy",
                    "choiceNumber": 3,
                    "correctTaken": 11553,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Packed red blood cell transfusion",
                    "choiceNumber": 4,
                    "correctTaken": 749,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Workup for inherited factor VII and VIII deficiencies",
                    "choiceNumber": 5,
                    "correctTaken": 1254,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "22946701",
                    "mediaDataId": 0,
                    "title": "Abnormal uterine bleeding and dysfunctional uterine bleeding in pediatric and adolescent gynecology.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/22946701",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 72,
            "notes": null,
            "peopleTaken": 16565,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 70,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 0,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 31,
            "questionId": 3120,
            "questionIndex": 3120,
            "questionText": "<p>A 46-year-old woman comes to the office for evaluation of heavy menstrual bleeding.&nbsp; The patient&#39;s menses previously occurred every 29 days and consisted of 4 days of moderate bleeding.&nbsp; However, for the past year her menses have occurred every 27 days and have become increasingly heavy, consisting of 5 days of heavy bleeding.&nbsp; During the first 2 days of her menstrual period, the patient changes her tampon every 1-2 hours and often soaks through her clothes.&nbsp; Her menses have also become increasingly painful and unrelieved by ibuprofen, and she now has constant, dull pelvic pain between menses.&nbsp; The patient has had 3 cesarean deliveries and a bilateral tubal ligation.&nbsp; Blood pressure is 110/70 mm Hg and pulse is 92/min.&nbsp; BMI is 28 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Bimanual examination reveals a soft, tender, globular uterus that measures 11 weeks in size.&nbsp; Urine pregnancy test is negative.&nbsp; Hemoglobin is 9.8 g/dL and platelets are 180,000/mm<font size=\"2\"><sup>3</sup></font>.&nbsp; Which of the following is the most likely cause of this patient&#39;s symptoms?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t35408\"><table class=\"table-default-style\" style=\"width:64.52%\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Adenomyosis </strong></p></td></tr><tr><td><p align=\"center\"><strong>Pathogenesis </strong></p></td><td><ul><li>Abnormal endometrial tissue within the uterine myometrium</li></ul></td></tr><tr><td><p align=\"center\"><strong>Risk factors </strong></p></td><td><ul><li>Age &gt;40</li><li>Multiparity</li><li>Prior uterine surgery (eg, myomectomy)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical features </strong></p></td><td><ul><li>Dysmenorrhea</li><li>Heavy menstrual bleeding</li><li>Chronic pelvic pain</li><li>Diffuse uterine enlargement (eg, globular uterus)</li><li>&plusmn; Uterine tenderness</li></ul></td></tr><tr><td><p align=\"center\"><strong>Diagnosis </strong></p></td><td><ul><li>Clinical presentation</li><li>MRI &amp; ultrasound: Thickened myometrium</li><li>Confirmation via pathology</li></ul></td></tr><tr><td><p align=\"center\"><strong>Treatment </strong></p></td><td><ul><li>Hysterectomy</li></ul></td></tr></tbody></table></div><p>This patient most likely has <strong>adenomyosis</strong> &ndash; a disorder caused by an abnormal collection of <a href=\"1210\">endometrial glands and stroma</a> within the uterine myometrium.&nbsp; Adenomyosis typically presents in multiparous women age &gt;40 with prior uterine surgery (eg, cesarean delivery).&nbsp; Clinical features of adenomyosis are as follows:</p><ul><li><p>New-onset <strong>dysmenorrhea</strong> due to cyclic accumulation of endometrial glands and stroma within the myometrium during menses.</p></li><li><p>Continued endometrial gland accumulation causes a <strong>symmetrically enlarged (globular) uterus</strong> that is boggy and tender but does not exceed 12 weeks in size.</p></li><li><p>The symmetrically enlarged uterus increases the endometrial cavity surface area, resulting in the concomitant <strong>heavy menstrual bleeding</strong> (eg, anemia) typically seen in these patients.</p></li></ul><p>As repeated menstrual cycles continue to cause endometrial shedding within the myometrium, patients often progress from dysmenorrhea to <strong>chronic</strong>, <strong>dull pelvic pain</strong>.&nbsp; Definitive diagnosis of adenomyosis is made histologically after hysterectomy, which is also the treatment for patients who do not improve with conservative management (eg, oral contraceptives).</p><p><strong>(Choice B)</strong>&nbsp; Endometrial hyperplasia typically presents with irregular menstrual or postmenopausal bleeding rather than heavy, regular menses and dysmenorrhea.</p><p><strong>(Choice C)</strong>&nbsp; <a href=\"1139\">Endometriosis</a> can cause chronic pelvic pain and dysmenorrhea.&nbsp; In contrast to this patient, those with endometriosis typically have a small, nontender uterus that is immobile (eg, fixed).</p><p><strong>(Choice D)</strong>&nbsp; Gestational trophoblastic disease (eg, hydatidiform mole, choriocarcinoma) can cause heavy menstrual bleeding and an enlarged uterus; however, patients typically have an elevated hCG (ie, positive pregnancy test), making this diagnosis less likely.</p><p><strong>(Choice E)</strong>&nbsp; Women going through menopause can have heavy menstrual bleeding; however, the bleeding pattern is irregular and there is no associated uterine tenderness.</p><p><strong>(Choice F)</strong>&nbsp; <a href=\"2335\">Leiomyomata uteri</a> (fibroids) commonly cause heavy menstrual bleeding.&nbsp; However, although patients may experience pelvic pressure, chronic pelvic pain is uncommon.&nbsp; In addition, fibroids cause a firm, irregularly enlarged uterus.</p><p><strong>Educational objective:</strong><br>Adenomyosis typically presents in women age &gt;40 with chronic pelvic pain, dysmenorrhea, and heavy menstrual bleeding.&nbsp; On physical examination, the uterus is symmetrically enlarged, boggy, globular, and tender.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 21040,
            "topic": "Dysmenorrhea",
            "titleId": 21040,
            "title": "Dysmenorrhea",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "1",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Adenomyosis",
                    "choiceNumber": 1,
                    "correctTaken": 10615,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Endometrial hyperplasia",
                    "choiceNumber": 2,
                    "correctTaken": 1114,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Endometriosis",
                    "choiceNumber": 3,
                    "correctTaken": 1024,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Gestational trophoblastic disease",
                    "choiceNumber": 4,
                    "correctTaken": 261,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Menopause",
                    "choiceNumber": 5,
                    "correctTaken": 112,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Uterine leiomyoma",
                    "choiceNumber": 6,
                    "correctTaken": 2801,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "48",
                    "mediaDataId": 0,
                    "title": "Adenomyosis",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "54",
                    "mediaDataId": 0,
                    "title": "Evaluation of abnormal uterine bleeding",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "23246186",
                    "mediaDataId": 0,
                    "title": "An update on adenomyosis.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/23246186",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "29566850",
                    "mediaDataId": 0,
                    "title": "Symptoms and classification of uterine adenomyosis, including the place of hysteroscopy in diagnosis.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/29566850",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 60,
            "notes": null,
            "peopleTaken": 15931,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 67,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 32,
            "questionId": 13408,
            "questionIndex": 14788,
            "questionText": "<p>A 34-year-old woman comes to the office for evaluation of amenorrhea.&nbsp; Since menarche at age 12, she has had regular menses with 3 or 4 days of bleeding.&nbsp; Last year, the patient had a suction curettage for a missed abortion; at her follow-up visit a few weeks later, a copper-containing intrauterine device (IUD) was placed.&nbsp; Following placement of the IUD, her menstrual periods were initially irregular and heavy, but the bleeding became progressively lighter.&nbsp; The patient has not had a menstrual period in 6 months.&nbsp; She has had no weight changes, vision changes, or galactorrhea.&nbsp; The patient has generalized anxiety disorder managed with therapy.&nbsp; Her older brother has severe intellectual disability due to fragile X syndrome.&nbsp; Vital signs are normal.&nbsp; BMI is 22 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Pelvic examination shows a small, mobile uterus with no adnexal masses.&nbsp; A urine pregnancy test is negative.&nbsp; TSH is normal and FSH is elevated.&nbsp; A progesterone withdrawal test is performed, and the patient has no withdrawal bleeding.&nbsp; Which of the following is the most likely diagnosis in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t31997\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Primary ovarian insufficiency </strong></p></td></tr><tr><td><p align=\"center\"><strong>Clinical features </strong></p></td><td><ul><li>Amenorrhea at age &lt;40</li><li>Hypoestrogenic symptoms (eg, hot flashes)</li><li>&uarr; FSH</li><li>&darr; Estrogen</li></ul></td></tr><tr><td><p align=\"center\"><strong>Major causes </strong></p></td><td><ul><li>Idiopathic</li><li>Turner syndrome (45,X)</li><li>Fragile X syndrome (<em>FMR1</em> premutation)</li><li>Autoimmune oophoritis</li><li>Anticancer drugs</li><li>Pelvic radiation</li><li>Galactosemia</li></ul></td></tr><tr><td><p align=\"center\"><strong>Management </strong></p></td><td><ul><li>Estrogen therapy (with progestin if intact uterus)</li></ul></td></tr><tr><td colspan=\"2\"><p style=\"margin-left:.1in;\"><strong><em>FMR1</em></strong> = fragile X messenger ribonucleoprotein 1.</p></td></tr></tbody></table></div><p>This patient has <strong>secondary amenorrhea</strong> (ie, lack of menses &#8805;3 months in women with previously regular cycles or &#8805;6 months in those with previously irregular cycles) and an <strong>elevated FSH level</strong>, findings suggestive of ovarian failure.&nbsp; In <strong>women age &lt;40</strong>, this is consistent with <strong>primary ovarian insufficiency (POI)</strong>.&nbsp; In POI, the lack of ovarian function results in <strong>low estrogen levels</strong> and loss of negative feedback in the hypothalamic-pituitary-ovarian axis, resulting in elevated FSH levels (ie, hypergonadotropic hypogonadism).&nbsp; The low estrogen levels limit endometrial proliferation; therefore, there is no withdrawal bleed after a <a href=\"21821\">progesterone withdrawal test</a>.</p><p>POI is common in women who are <strong>fragile X syndrome (</strong><em><strong>FMR1</strong></em>&nbsp;<strong>gene) premutation carriers</strong> (ie, those with 55-200 CGG repeats).&nbsp; These women often have associated neurobehavioral manifestations (eg, anxiety, autism) and a family history of fragile X syndrome, as in this patient.&nbsp; This premutation causes an <em>FMR1</em> mRNA overexpression, which likely has a cytotoxic effect on ovarian primordial follicles and results in <strong>accelerated follicle depletion</strong>.&nbsp; Due to this association, women with ovarian failure at age &lt;40 and with no other obvious cause for POI (eg, Turner syndrome) are tested for <em>FMR1</em> gene mutations.</p><p>Management of POI includes estrogen-containing therapy to reduce the risk of comorbidities associated with low estrogen levels (eg, osteoporosis).</p><p><strong>(Choice A)</strong>&nbsp; Functional hypothalamic amenorrhea typically occurs in women with a relative caloric deficiency (eg, athletes, eating disorders) due to decreased GnRH secretion.&nbsp; Patients have no withdrawal bleeding after a progesterone withdrawal test due to low estrogen levels; however, FSH levels are low.</p><p><strong>(Choice B)</strong>&nbsp; Intrauterine adhesions (Asherman syndrome) can cause secondary amenorrhea in patients who undergo intrauterine procedures (eg, suction curettage) due to endometrial damage and fibrous tissue formation.&nbsp; Patients with intrauterine adhesions have no withdrawal bleeding after a progesterone withdrawal test; however, they have normal FSH levels, which makes this diagnosis less likely.</p><p><strong>(Choice C)</strong>&nbsp; Levonorgestrel-releasing intrauterine devices (IUDs) can cause amenorrhea by thinning the endometrium.&nbsp; In contrast, copper-containing IUDs can cause heavy menstrual bleeding and dysmenorrhea.&nbsp; FSH levels are normal with both.</p><p><strong>(Choice D)</strong>&nbsp; Polycystic ovary syndrome can present with abnormal uterine bleeding and secondary amenorrhea.&nbsp; This diagnosis is unlikely because patients have normal estrogen levels and, therefore, would have withdrawal bleeding after a progesterone withdrawal test.</p><p><strong>Educational objective:</strong><br>Primary ovarian insufficiency (POI) occurs due to accelerated ovarian follicle depletion in women age &lt;40, resulting in secondary amenorrhea, elevated FSH, and low estrogen levels.&nbsp; A risk factor for POI is <em>FMR1</em> gene premutation for fragile X syndrome.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 23429,
            "topic": "Amenorrhea",
            "titleId": 23429,
            "title": "Amenorrhea",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "5",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Functional hypothalamic amenorrhea",
                    "choiceNumber": 1,
                    "correctTaken": 823,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Intrauterine adhesions",
                    "choiceNumber": 2,
                    "correctTaken": 3220,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Intrauterine device&ndash;induced amenorrhea",
                    "choiceNumber": 3,
                    "correctTaken": 2822,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Polycystic ovary syndrome",
                    "choiceNumber": 4,
                    "correctTaken": 115,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Primary ovarian insufficiency",
                    "choiceNumber": 5,
                    "correctTaken": 9714,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "55",
                    "mediaDataId": 0,
                    "title": "Primary ovarian insufficiency",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "700",
                    "mediaDataId": 0,
                    "title": "Evaluation of secondary amenorrhea",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "20708256",
                    "mediaDataId": 0,
                    "title": "Primary ovarian insufficiency.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/20708256",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "23703681",
                    "mediaDataId": 0,
                    "title": "Population-based estimates of the prevalence of FMR1 expansion mutations in women with early menopause and primary ovarian insufficiency.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/23703681",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25227694",
                    "mediaDataId": 0,
                    "title": "Genetics of primary ovarian insufficiency: a review.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25227694",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 71,
            "notes": null,
            "peopleTaken": 16694,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 58,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 33,
            "questionId": 15165,
            "questionIndex": 16589,
            "questionText": "<p>A 39-year-old woman, gravida 4 para 4, comes to the office for emergency contraception.&nbsp; The patient stopped breastfeeding a month ago and has not restarted her oral contraceptives because her husband is scheduled for a vasectomy in a few weeks.&nbsp; She had unprotected intercourse last night and is concerned she might get pregnant.&nbsp; The patient has no chronic medical conditions and takes no medications.&nbsp; She does not use tobacco, alcohol, or illicit drugs.&nbsp; Her last menstrual period was 9 days ago.&nbsp; Vital signs and physical examination are normal.&nbsp; Urine pregnancy test is negative.&nbsp; Which of the following is the best emergency contraceptive option for this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t32628\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"4\"><p align=\"center\"><strong>Emergency contraception</strong></p></td></tr><tr><td><p align=\"center\"><strong>Method</strong></p></td><td><p align=\"center\"><strong>Timing after<br />intercourse</strong></p></td><td><p align=\"center\"><strong>Efficacy</strong></p></td><td><p align=\"center\"><strong>Contraindications</strong></p></td></tr><tr><td><p align=\"center\"><strong>Copper-containing<br />intrauterine device</strong></p></td><td><p align=\"center\">0-120 hr</p></td><td><p align=\"center\">&gt;99%</p></td><td><ul><li>Wilson disease</li><li>Active pelvic infection</li><li>Severe uterine cavity distortion</li></ul></td></tr><tr><td><p align=\"center\"><strong>Progestin-releasing<br />intrauterine device</strong></p></td><td><p align=\"center\">0-120 hr</p></td><td><p align=\"center\">&gt;99%</p></td><td><ul><li>Breast cancer</li><li>Active pelvic infection</li><li>Severe uterine cavity distortion</li></ul></td></tr><tr><td><p align=\"center\"><strong>Ulipristal</strong></p></td><td><p align=\"center\">0-120 hr</p></td><td><p align=\"center\">98%-99%</p></td><td><ul><li>None</li></ul></td></tr><tr><td><p align=\"center\"><strong>Oral levonorgestrel</strong></p></td><td><p align=\"center\">0-72 hr</p></td><td><p align=\"center\">92%-98%</p></td><td><ul><li>None</li></ul></td></tr><tr><td><p align=\"center\"><strong>Oral contraceptives*</strong></p></td><td><p align=\"center\">0-72 hr</p></td><td><p align=\"center\">75%-89%</p></td><td><ul><li>None</li></ul></td></tr><tr><td colspan=\"4\"><p>*Combined estrogen/progestin oral contraceptive pills containing levonorgestrel or norgestrel.</p></td></tr></tbody></table></div><p>Patients who have had recent unprotected intercourse may be candidates for postcoital or <strong>emergency contraception (EC)</strong> for <strong>pregnancy prevention</strong>.&nbsp; Pregnancy status determines eligibility for EC use:</p><ul><li>Patients with a positive pregnancy test are not candidates for EC because implantation has already occurred.&nbsp;</li><li>In contrast, patients with a negative pregnancy test are still at risk for unintended pregnancy and are candidates for EC <strong>(Choice B)</strong>.</li></ul><p>A highly effective (ie, 98%-99%) EC option is the <strong>ulipristal</strong> pill, a progestin receptor blocker that prevents pregnancy by <strong>delaying ovulation</strong> and <strong>impairing implantation</strong>.&nbsp; Ulipristal can be taken up to 120 hours after unprotected intercourse; however, it should be administered as soon as possible because its effectiveness decreases with time.&nbsp; Other effective EC options include the copper-containing intrauterine device and oral levonorgestrel (ie, Plan B).</p><p><strong>(Choice A)</strong>&nbsp; Combination oral contraceptives, commonly used for precoital contraception, may also be used for EC by taking multiple pills simultaneously to achieve the progestin level required to delay ovulation.&nbsp; However, the high estrogen content typically causes intolerable side effects (eg, severe nausea), and this method is less effective (ie, 47%-89%) than ulipristal.</p><p><strong>(Choices C and E)</strong>&nbsp; A progestin-releasing subdermal implant is a long-acting, reversible contraceptive used for precoital contraception.&nbsp; Because it provides sustained release of low-dose progestin, it cannot achieve the acute increase in progestin levels required to delay ovulation for EC.&nbsp; Similarly, the transdermal estrogen-progestin patch is a slow-releasing combined hormonal contraceptive used only for precoital contraception.</p><p><strong>Educational objective:</strong><br>Ulipristal is a highly effective emergency contraception option that prevents pregnancy by delaying ovulation and impairing implantation.&nbsp; It can be taken up to 120 hours after unprotected intercourse.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 17805,
            "topic": "Contraception",
            "titleId": 17805,
            "title": "Contraception",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "4",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Combination oral contraceptives",
                    "choiceNumber": 1,
                    "correctTaken": 1043,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "None because pregnancy is unlikely",
                    "choiceNumber": 2,
                    "correctTaken": 1279,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Progestin-releasing subdermal implant",
                    "choiceNumber": 3,
                    "correctTaken": 1487,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Single dose of ulipristal acetate",
                    "choiceNumber": 4,
                    "correctTaken": 12778,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Transdermal estrogen-progestin patch",
                    "choiceNumber": 5,
                    "correctTaken": 169,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "75",
                    "mediaDataId": 0,
                    "title": "Emergency contraception",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25254919",
                    "mediaDataId": 0,
                    "title": "Emergency contraception review: evidence-based recommendations for clinicians.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25254919",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26287787",
                    "mediaDataId": 0,
                    "title": "Practice bulletin no. 152: emergency contraception.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26287787",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28766313",
                    "mediaDataId": 0,
                    "title": "Interventions for emergency contraception.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28766313",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 44,
            "notes": null,
            "peopleTaken": 16756,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 76,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 34,
            "questionId": 15060,
            "questionIndex": 16484,
            "questionText": "<p>A 34-year-old woman comes to the office to discuss the progestin-releasing intrauterine device.&nbsp; The patient previously used condoms for contraception but is interested in starting a more reliable method.&nbsp; Her menses occur every 8 to 12 weeks, with heavy vaginal bleeding and passage of clots, and she has intermittent light spotting in between.&nbsp; The patient&#39;s last menstrual period was 1 week ago.&nbsp; She has no chronic medical conditions and takes no daily medications.&nbsp; The patient was treated for <em>Trichomonas</em> vaginitis at age 16.&nbsp; Her maternal grandmother had metastatic breast cancer in her 70s.&nbsp; Blood pressure is 118/64 mm Hg and pulse is 80/min.&nbsp; BMI is 44 kg/m&sup2;.&nbsp; Pelvic examination shows a nulliparous cervix with scant physiologic discharge and a small, nontender uterus.&nbsp; Urine pregnancy test is negative.&nbsp; Which of the following is this patient&#39;s contraindication to a progestin-releasing intrauterine device?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t37375\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Contraindications to IUD placement</strong></p></td></tr><tr><td><p align=\"center\"><strong>Copper IUD &amp;<br />progestin IUD</strong></p></td><td><ul><li>Pregnancy</li><li>Endometrial or cervical cancer</li><li>Unexplained vaginal bleeding</li><li>Gestational trophoblastic disease</li><li>Severe uterine cavity distortion</li><li>Active pelvic infection (eg, PID, cervicitis)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Progestin IUD</strong></p></td><td><ul><li>Active liver disease</li><li>Current breast cancer</li></ul></td></tr><tr><td><p align=\"center\"><strong>Copper IUD</strong></p></td><td><ul><li>Wilson disease</li></ul></td></tr><tr><td colspan=\"2\"><p><strong>IUD</strong> = intrauterine device; <strong>PID</strong> = pelvic inflammatory disease.</p></td></tr></tbody></table></div><p>Long-acting, reversible contraceptives such as an intrauterine device (IUD) are highly effective for pregnancy prevention, easy to use, and rapidly reversible.&nbsp; IUDs may be used in patients of all ages and parity <strong>(Choices A and D)</strong>.&nbsp; However, one <strong>contraindication to IUD insertion</strong> (both copper-containing and progestin-releasing) is <strong>unexplained, abnormal vaginal bleeding</strong>, such as this patient&#39;s irregular menstrual bleeding pattern.&nbsp; Abnormal bleeding is often a symptom of an <strong>underlying condition</strong> that requires further evaluation before IUD insertion, such as:</p><ul><li>Infection (eg, cervicitis, pelvic inflammatory disease)</li><li>Endometrial polyp, which often causes intermenstrual bleeding</li><li><strong>Endometrial hyperplasia or cancer</strong>, particularly in patients with multiple risk factors for unopposed estrogen exposure (eg, obesity, chronic anovulation [as evidenced by this patient&#39;s irregular menses])</li></ul><p>IUD placement in patients with unexplained, abnormal vaginal bleeding can mask symptoms and delay diagnosis.&nbsp; Therefore, these patients <strong>require further evaluation</strong> prior to IUD insertion, which typically includes sexually transmitted infection testing, endometrial biopsy, and pelvic ultrasound.</p><p><strong>(Choice B)</strong>&nbsp; Progestin-releasing IUDs are contraindicated in patients with active breast cancer because breast cancers are often progesterone-sensitive.&nbsp; However, a family history of breast cancer, particularly in a second-degree relative, is not a contraindication.</p><p><strong>(Choice E)</strong>&nbsp; IUD insertion and removal is contraindicated during an active pelvic infection, which typically presents with pelvic pain, uterine tenderness, and abnormal vaginal discharge (not seen in this patient).&nbsp; A prior sexually transmitted infection, such as this patient&#39;s remote history of <em>Trichomonas</em> vaginitis, is not a contraindication.</p><p><strong>Educational objective:</strong><br>Unexplained, abnormal vaginal bleeding is a contraindication to intrauterine device insertion because it may indicate an underlying condition (eg, endometrial cancer).&nbsp; Patients with unexplained vaginal bleeding require further evaluation (eg, endometrial biopsy).</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 17805,
            "topic": "Contraception",
            "titleId": 17805,
            "title": "Contraception",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "3",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Age",
                    "choiceNumber": 1,
                    "correctTaken": 398,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Family history",
                    "choiceNumber": 2,
                    "correctTaken": 2652,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Menstrual bleeding pattern",
                    "choiceNumber": 3,
                    "correctTaken": 10341,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Nulliparity",
                    "choiceNumber": 4,
                    "correctTaken": 884,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Prior sexually transmitted infection",
                    "choiceNumber": 5,
                    "correctTaken": 2411,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "53",
                    "mediaDataId": 0,
                    "title": "Contraception",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27467196",
                    "mediaDataId": 0,
                    "title": "U.S. medical eligibility criteria for contraceptive use, 2016",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27467196",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27467319",
                    "mediaDataId": 0,
                    "title": "U.S. selected practice recommendations for contraceptive use, 2016.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27467319",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "30681544",
                    "mediaDataId": 0,
                    "title": "ACOG practice bulletin no. 206: use of hormonal contraception in women with coexisting medical conditions.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/30681544",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 59,
            "notes": null,
            "peopleTaken": 16686,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 62,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 35,
            "questionId": 12752,
            "questionIndex": 14038,
            "questionText": "<p>A 52-year-old woman comes to the office because she has not been sleeping well.&nbsp; For the past year, the patient has had no difficulty falling asleep, but has frequent sleep interruption and often awakens with her sheets soaked in sweat.&nbsp; She now has worsening fatigue that is affecting her ability to focus at work.&nbsp; The patient has not been sexually active in the last 6 months due to vaginal dryness and painful intercourse.&nbsp; She has no chronic medical conditions, and her only procedure has been a laparoscopic hysterectomy in her 40s for symptomatic uterine leiomyomata.&nbsp; The patient does not use tobacco, alcohol, or illicit drugs.&nbsp; Blood pressure is 116/78 mm Hg and pulse is 70/min.&nbsp; BMI is 24 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Pelvic examination shows pale, thin vulvovaginal tissues and a narrow vaginal introitus.&nbsp; The vaginal cuff is intact and without lesions.&nbsp; The remainder of the physical examination is normal.&nbsp; Which of the following is the most appropriate therapy for this patient&#39;s symptoms?</p>",
            "questionHeader": "",
            "explanationText": "<p><img draggable=\"false\" id=\"9766\" src=\"https://www.uworld.com/media/L33196.png\" ></p>&nbsp;<p><strong>Menopause</strong> occurs at a median age of 51 and is due to decreased estrogen production.&nbsp; It can present with sleep disturbance, worsening fatigue, and hot flashes, as in this patient.&nbsp; Painful intercourse due to vaginal dryness is also common.&nbsp; Diagnosis is usually clinical; on examination, <strong>vaginal atrophy</strong> (ie, pale, narrowed introitus) may be present due to <strong>hypoestrogenism</strong>.</p><p>Management of menopausal symptoms depends on the severity of vasomotor symptoms (ie, hot flashes).&nbsp; Mild hot flashes that do not interfere with daily activities are managed with lifestyle modification (eg, wearing layers, weight loss).&nbsp; In contrast, this patient has <strong>moderate to severe vasomotor symptoms</strong> (eg, awakening with sheets soaked in sweat) that may benefit from pharmacotherapy.</p><p>In patients with no contraindications to estrogen, <strong>menopausal hormone therapy</strong> (MHT) is first-line treatment.</p><ul><li><p>Patients with an intact uterus require estrogen-plus-progesterone MHT (eg, estrogen-progestin pills), which decreases the risk of endometrial cancer associated with unopposed estrogen <strong>(Choice B)</strong>.</p></li><li><p>In contrast, <strong>patients without a uterus</strong> (eg, prior hysterectomy) can receive <strong>estrogen-only</strong> MHT (eg, transdermal estrogen patch), which is preferred in these patients because estrogen-plus-progesterone MHT has a small increased risk of breast cancer with long-term (&gt;3-5 years) use.</p></li></ul><p><strong>(Choices A, C, and D)</strong>&nbsp; In patients with contraindications to estrogen (eg, breast cancer, venous thromboembolism), second-line treatment for vasomotor symptoms is paroxetine, a selective serotonin reuptake inhibitor that is typically well tolerated.&nbsp; In patients who have no relief from paroxetine or who cannot take paroxetine (eg, current tamoxifen use), clonidine or gabapentin may be used.&nbsp; However, these medications can be associated with intolerable side effects, including hypotension (clonidine) and headache/dizziness (gabapentin).</p><p><strong>Educational objective:</strong><br>In menopausal patients with moderate to severe vasomotor symptoms (ie, hot flashes), first-line treatment is with menopausal hormone therapy.&nbsp; Patients with a uterus require estrogen-plus-progesterone therapy.&nbsp; In contrast, patients without a uterus require estrogen-only therapy (eg, transdermal estrogen patch).</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 3188,
            "topic": "Menopause",
            "titleId": 3188,
            "title": "Menopause",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "5",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Clonidine",
                    "choiceNumber": 1,
                    "correctTaken": 182,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Estrogen-progestin pills",
                    "choiceNumber": 2,
                    "correctTaken": 5849,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Gabapentin",
                    "choiceNumber": 3,
                    "correctTaken": 158,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Paroxetine",
                    "choiceNumber": 4,
                    "correctTaken": 1205,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Transdermal estrogen patch",
                    "choiceNumber": 5,
                    "correctTaken": 9242,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "56",
                    "mediaDataId": 0,
                    "title": "Menopause",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "57",
                    "mediaDataId": 0,
                    "title": "Genitourinary syndrome of menopause",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25681847",
                    "mediaDataId": 0,
                    "title": "Hormonal and nonhormonal treatment of vasomotor symptoms.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25681847",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27929271",
                    "mediaDataId": 0,
                    "title": "Hormone therapy and other treatments for symptoms of menopause.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27929271",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 55,
            "notes": null,
            "peopleTaken": 16636,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 56,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 36,
            "questionId": 13748,
            "questionIndex": 15140,
            "questionText": "<p>A 16-year-old girl comes to the office for a routine health maintenance examination.&nbsp; The patient is in high school, is performing well academically, and plays on the tennis team.&nbsp; She has no concerns today.&nbsp; The patient has not reached menarche, but she says that her mother did not start menstruating until this age.&nbsp; The patient recently started wearing contact lenses for myopia and uses an over-the-counter cream for acne.&nbsp; She is at the 70th percentile for height and 25th percentile for weight.&nbsp; Blood pressure is 120/70 mm Hg and pulse is 60/min.&nbsp; Breast development is sexual maturity rating (Tanner stage) 4.&nbsp; Pelvic examination shows sexual maturity rating (Tanner stage) 4 pubic hair development and normal external genitalia.&nbsp; Speculum examination demonstrates a well-rugated vagina but no cervix.&nbsp; FSH level is within the normal pubertal range.&nbsp; Karyotype is 46,XX.&nbsp; Pelvic ultrasonography reveals that the uterus is absent.&nbsp; Which of the following is the best next step in management of this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p><img  draggable=\"false\" id=\"16860\" src=\"https://www.uworld.com/media/highresdefault/L39934.jpg\"  ></p><p>This patient has normal secondary sexual characteristics (eg, breasts, external genitalia), but the <strong>uterus and cervix are absent</strong>, findings consistent with <strong>m&uuml;llerian agenesis</strong> (ie, Mayer-Rokitansky-K&uuml;ster-Hauser syndrome), or abnormal paramesonephric (m&uuml;llerian) duct development.&nbsp; The ovaries and external genitalia develop independently of the m&uuml;llerian duct system; therefore, patients have normal FSH levels (ie, normal ovarian function), normal external genitalia, and the lower two-thirds of the vagina (ie, blind vaginal pouch).</p><p>In contrast, the <strong>internal genitalia</strong> derive from the intermediate mesoderm, which develops into the paramesonephric (m&uuml;llerian) and mesonephric (wolffian) ducts.</p><ul><li>The paramesonephric (m&uuml;llerian) duct forms the uterus, fallopian tubes, cervix, and upper third of the vagina.</li><li>The mesonephric (wolffian) duct forms the primitive kidney.&nbsp;</li></ul><p>Because of their <strong>common embryologic source</strong> and <strong>synchronous development</strong> in the first trimester, internal genital anomalies and <strong>renal abnormalities</strong> are often concurrent.&nbsp; Therefore, patients with m&uuml;llerian agenesis should undergo evaluation of the renal tract (ie, ureters, kidney) with <strong>renal ultrasonography</strong>.&nbsp; Common abnormalities include unilateral renal agenesis, pelvic kidneys, and duplications of the collecting system.</p><p><strong>(Choice A)</strong>&nbsp; Echocardiography is performed in patients with Turner syndrome to evaluate for cardiac malformations (eg, bicuspid aortic valve, aortic coarctation).&nbsp; This patient has a normal karyotype and FSH level (ie, normal ovarian function), making Turner syndrome unlikely.</p><p><strong>(Choice B)</strong>&nbsp; Dihydrotestosterone and testosterone levels are measured to diagnose 5-alpha reductase deficiency and androgen insensitivity syndrome (AIS).&nbsp; In 5-alpha reductase deficiency, genotypic males (46,XY) appear phenotypically female until puberty; elevated testosterone levels at puberty then cause virilization (eg, clitoromegaly) and lack of breast development, which are not seen in this patient.&nbsp; In AIS, genotypic males appear phenotypically female through puberty and have breast development.&nbsp; In contrast to this patient, those with AIS have no or minimal acne or pubic hair development due to an abnormal androgen receptor.</p><p><strong>(Choices C and D)</strong>&nbsp; TSH and prolactin levels are measured in patients with primary amenorrhea who have a uterus and a low or normal FSH.&nbsp; MRI of the head is indicated in patients with a low or normal FSH, high prolactin, or visual field defects to evaluate hypothalamic and pituitary causes (eg, sellar mass).</p><p><strong>Educational objective:</strong><br>M&uuml;llerian agenesis causes primary amenorrhea due to failed development of the uterus, cervix, and upper third of the vagina.&nbsp; Urogenital structures develop from a common embryologic source; therefore, renal malformations are common, so patients require evaluation with renal ultrasonography.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 23429,
            "topic": "Amenorrhea",
            "titleId": 23429,
            "title": "Amenorrhea",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "5",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Echocardiography",
                    "choiceNumber": 1,
                    "correctTaken": 1691,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Measurement of dihydrotestosterone and testosterone levels",
                    "choiceNumber": 2,
                    "correctTaken": 5185,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Measurement of TSH and prolactin levels",
                    "choiceNumber": 3,
                    "correctTaken": 790,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "MRI of the head",
                    "choiceNumber": 4,
                    "correctTaken": 410,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Renal ultrasonography",
                    "choiceNumber": 5,
                    "correctTaken": 8664,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "65",
                    "mediaDataId": 0,
                    "title": "Müllerian agenesis",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "703",
                    "mediaDataId": 0,
                    "title": "Evaluation of primary amenorrhea",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "24948340",
                    "mediaDataId": 0,
                    "title": "Mayer-Rokitansky-Kuster-Hauser syndrome: complications, diagnosis and possible treatment options: a review.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/24948340",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "29266078",
                    "mediaDataId": 0,
                    "title": "ACOG Committee opinion: no. 728: m&#252;llerian agenesis: diagnosis, management, and treatment.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/29266078",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 65,
            "notes": null,
            "peopleTaken": 16748,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 52,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 37,
            "questionId": 3744,
            "questionIndex": 3744,
            "questionText": "<p>A 57-year-old woman comes to the office for evaluation of vaginal pruritus, pain with urination, and increased urinary frequency.&nbsp; The patient&#39;s symptoms have been present for several months but have intensified recently.&nbsp; Her husband passed away 4 years ago, and the patient had not been sexually active until 6 months ago with a new partner.&nbsp; She has had some pain with intercourse and has tried over-the-counter, water-based lubricants with little relief.&nbsp; Her last menstrual period was 7 years ago.&nbsp; She has poorly controlled type 2 diabetes mellitus with a recent hemoglobin A1c of 8.4%.&nbsp; BMI is 28 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Vital signs are normal.&nbsp; Pelvic examination shows thin vulvar skin with reduced elasticity.&nbsp; The vagina appears pale, dry, and has multiple areas of petechiae.&nbsp; There is minimal clear discharge in the vault.&nbsp; Vaginal pH is 6.5.&nbsp; Urinalysis is normal.&nbsp; Which of the following is the best next step in management of this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t31153\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Genitourinary syndrome of menopause</strong></p></td></tr><tr><td><p align=\"center\"><strong>Symptoms</strong></p></td><td><ul><li>Vulvovaginal dryness, irritation, pruritus</li><li>Dyspareunia</li><li>Vaginal bleeding</li><li>Urinary incontinence, recurrent urinary tract infection</li><li>Pelvic pressure</li></ul></td></tr><tr><td><p align=\"center\"><strong>Physical<br />examination</strong></p></td><td><ul><li>Narrowed introitus</li><li>Pale mucosa, &darr;&nbsp;elasticity, &darr;&nbsp;rugae</li><li>Petechiae, fissures</li><li>Loss of labial volume</li></ul></td></tr><tr><td><p align=\"center\"><strong>Treatment</strong></p></td><td><ul><li>Vaginal moisturizer &amp; lubricant</li><li>Topical vaginal estrogen</li></ul></td></tr></tbody></table></div><p>This patient has <strong>genitourinary syndrome of menopause</strong> (or atrophic vaginitis), in which <strong>reduced estrogen levels</strong> associated with menopause cause decreased blood flow and reduced collagen and glycogen content in vulvovaginal tissues.&nbsp; This results in <strong>thin vulvar skin with reduced elasticity</strong> and loss of vaginal tissue pliability that cause <strong>vaginal pruritus</strong> and <strong>dyspareunia</strong>.&nbsp; Due to the proximity of the bladder to the vaginal epithelium, the bladder trigone and urethral epithelium may also atrophy, resulting in dysuria and urinary frequency (mimicking a urinary tract infection).&nbsp; Patients typically have a pale, dry vagina with petechiae (due to easily denuded epithelium) and <strong>minimal vaginal discharge with a pH &gt;4.5</strong> (due to decreased lactic acid production from low glycogen content).</p><p>The first-line management of atrophic vaginitis is vaginal moisturizers and lubricants.&nbsp; In patients with no symptom improvement, treatment is with <strong>vaginal estrogen</strong> (eg, cream, tablet, ring), which increases blood flow and glycogen content to the vulvovaginal tissues.</p><p><strong>(Choice A)</strong>&nbsp; Metronidazole treats trichomoniasis and bacterial vaginosis, which are associated with an increased vaginal pH (ie, &gt;4.5 pH).&nbsp; Patients with trichomoniasis may have cervical petechiae or punctate hemorrhages, but usually also have a copious, frothy green discharge (not seen in this patient).&nbsp; Patients with bacterial vaginosis typically have a malodorous, thin vaginal discharge with no other symptoms (eg, pruritus), making this diagnosis unlikely.</p><p><strong>(Choice B)</strong>&nbsp; Patients with urinary tract infections are typically treated with oral nitrofurantoin.&nbsp; Although this patient has dysuria and urinary frequency, her urinalysis is normal, making a urinary tract infection unlikely.</p><p><strong>(Choice C)</strong>&nbsp; Topical corticosteroid cream is used for vulvar <a href=\"2178\">lichen sclerosus</a>, which can present as vulvar pruritus and dyspareunia.&nbsp; However, patients have thin, white skin that forms into plaques, destroying the normal vulvar architecture.&nbsp; In addition, lichen sclerosus does not affect the vagina, making this diagnosis unlikely.</p><p><strong>(Choice D)</strong>&nbsp; Topical nystatin treats candida intertrigo, which can present with vulvar pruritis, particularly in patients with poorly controlled diabetes mellitus.&nbsp; However, candida intertrigo typically presents with erythematous plaques with satellite lesions involving the inguinal folds (not seen in this patient).</p><p><strong>Educational objective:</strong><br>Patients with the genitourinary syndrome of menopause (ie, atrophic vaginitis) can have vaginal pruritis, dyspareunia, thin vulvar skin with decreased elasticity, and a pale, dry vagina.&nbsp; First-line treatment is vaginal lubricants and moisturizers; those with no symptom improvement are treated with vaginal estrogen.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 3188,
            "topic": "Menopause",
            "titleId": 3188,
            "title": "Menopause",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "5",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Oral metronidazole",
                    "choiceNumber": 1,
                    "correctTaken": 1547,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Oral nitrofurantoin",
                    "choiceNumber": 2,
                    "correctTaken": 781,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Topical corticosteroid cream",
                    "choiceNumber": 3,
                    "correctTaken": 789,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Topical nystatin cream",
                    "choiceNumber": 4,
                    "correctTaken": 634,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Vaginal estrogen cream",
                    "choiceNumber": 5,
                    "correctTaken": 13014,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "57",
                    "mediaDataId": 0,
                    "title": "Genitourinary syndrome of menopause",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26707589",
                    "mediaDataId": 0,
                    "title": "Treating vulvovaginal atrophy/genitourinary syndrome of menopause:  how important is vaginal lubricant and moisturizer composition?",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26707589",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27929271",
                    "mediaDataId": 0,
                    "title": "Hormone therapy and other treatments for symptoms of menopause.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27929271",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "29202940",
                    "mediaDataId": 0,
                    "title": "Genitourinary syndrome of menopause:  management strategies for the clinician.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/29202940",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 56,
            "notes": null,
            "peopleTaken": 16765,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 78,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 38,
            "questionId": 11292,
            "questionIndex": 12447,
            "questionText": "<p>A 53-year-old woman comes to the office for a routine annual examination.&nbsp; Her last menstrual period was 2 years ago.&nbsp; The patient has hot flashes throughout the day.&nbsp; She awakens several times each night drenched with sweat.&nbsp; The patient has tried weight loss and over-the-counter medications to manage these symptoms, but they have not improved.&nbsp; She has hypertension and type 2 diabetes mellitus controlled with diet and exercise.&nbsp; The patient&#39;s mother had a bilateral hip replacement after a fall at age 77.&nbsp; Blood pressure is 124/80 mm Hg and pulse is 76/min.&nbsp; BMI is 28 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Cardiopulmonary examination is normal.&nbsp; On pelvic examination, the uterus is small and nontender, and there are no adnexal masses.&nbsp; The extremities have 2+ peripheral pulses.&nbsp; HbA1c is 6.9%.&nbsp; Which of the following is an indication for systemic estrogen/progestin replacement therapy in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t31500\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Menopause </strong></p></td></tr><tr><td><p align=\"center\"><strong>Clinical features </strong></p></td><td><ul><li>Vasomotor symptoms</li><li>Oligomenorrhea/amenorrhea</li><li>Sleep disturbances</li><li>Decreased libido</li><li>Depression</li><li>Cognitive decline</li><li>Vaginal atrophy</li></ul></td></tr><tr><td><p align=\"center\"><strong>Diagnosis </strong></p></td><td><ul><li>Clinical manifestations</li><li>&uarr; FSH</li></ul></td></tr><tr><td><p align=\"center\"><strong>Treatment </strong></p></td><td><ul><li>Topical vaginal estrogen</li><li>Systemic hormone&nbsp;replacement therapy</li></ul></td></tr></tbody></table></div><p><strong>Menopause</strong>, absent menses for 12 months, occurs at a median age of 51 when the loss of ovarian function leads to hypoestrogenemia and its sequelae: vasomotor symptoms (eg, hot flashes, night sweats, sleep disturbances), vulvovaginal atrophy, and osteoporosis.&nbsp; Management of hot flashes depends on symptom severity and patient risk factors.&nbsp; Patients with mild symptoms that do not interfere with daily activities are managed with lifestyle modification (eg, wearing layers, weight loss).&nbsp; Severe hot flashes typically require pharmacologic therapy, and <strong>hormone replacement therapy</strong> (HRT) is the first-line treatment <strong>(Choice E)</strong>.</p><p>The only current indication for HRT is <strong>vasomotor symptoms</strong> in women age &lt;60 who have undergone menopause within the past 10 years.&nbsp; HRT was previously used for chronic disease prevention, but it is no longer recommended in the prevention of coronary heart disease or osteoporosis due to the associated risks of HRT (eg, thromboembolism)&nbsp;<strong>(Choices A and C)</strong>.&nbsp; Contraindications to HRT include a personal history of coronary heart disease, thromboembolism, transient ischemic attack or stroke, breast cancer, and endometrial cancer.&nbsp; Patients with contraindications to HRT are typically managed with nonhormonal therapy (eg, selective serotonin reuptake inhibitors).</p><p><strong>(Choice B)</strong>&nbsp; HRT is not indicated for endometrial cancer risk reduction.&nbsp; The estrogen component of HRT treats menopausal symptoms, but if unopposed (ie, no progesterone), it can result in endometrial proliferation and hyperplasia.&nbsp; Therefore, in patients with a uterus, HRT with a progestin component is required for endometrial protection.</p><p><strong>Educational objective</strong>:<br>Hormone replacement therapy is indicated in the treatment of vasomotor symptoms (eg, hot flashes, night sweats) in women age &lt;60 who have undergone menopause within the past 10 years.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 3188,
            "topic": "Menopause",
            "titleId": 3188,
            "title": "Menopause",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "4",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Coronary heart disease prevention",
                    "choiceNumber": 1,
                    "correctTaken": 225,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Endometrial cancer risk reduction",
                    "choiceNumber": 2,
                    "correctTaken": 316,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Osteoporosis prevention",
                    "choiceNumber": 3,
                    "correctTaken": 2930,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Reduction of vasomotor symptoms",
                    "choiceNumber": 4,
                    "correctTaken": 10332,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "There is no indication",
                    "choiceNumber": 5,
                    "correctTaken": 2155,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "56",
                    "mediaDataId": 0,
                    "title": "Menopause",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26921929",
                    "mediaDataId": 0,
                    "title": "Managing the menopause: an update.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26921929",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26838086",
                    "mediaDataId": 0,
                    "title": "Hormone therapy for relieving postmenopausal vasomotor symptoms: a systematic review.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26838086",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 50,
            "notes": null,
            "peopleTaken": 15963,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 65,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 39,
            "questionId": 15190,
            "questionIndex": 16614,
            "questionText": "<p>A 14-year-old girl is brought to the office for a well-child examination.&nbsp; The patient&#39;s mother states that she is doing well in school and plays on the volleyball team.&nbsp; The patient sleeps 9 hours every night and often until noon on weekends.&nbsp; She drinks 2 glasses of 2% milk daily and her screen time is limited to 2 hours a day.&nbsp; She has no chronic medical conditions and takes no medications.&nbsp; At age 12, she received her first dose of human papillomavirus (HPV) vaccination, with another dose administered 6 months later.&nbsp; The patient underwent menarche at age 13, and her last menstrual period was 2 weeks ago.&nbsp; She has never been sexually active.&nbsp; The patient&#39;s mother has hypothyroidism, and her maternal grandmother recently died from complications of type 2 diabetes mellitus.&nbsp; Height and weight are at the 60th percentile.&nbsp; Blood pressure is 104/68 mm Hg and pulse is 60/min.&nbsp; Physical examination reveals an alert and engaged adolescent.&nbsp; Sexual maturity rating (Tanner) stage is 4.&nbsp; Cardiopulmonary examination is unremarkable.&nbsp; The abdomen is soft and nontender.&nbsp; The remainder of the examination is normal.&nbsp; Which of the following is the best next step in management of this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p>In addition to routine screening (eg, depression, substance use) and health care maintenance, the <strong>adolescent well-child visit</strong> is an opportunity to discuss preventive health care measures.&nbsp; Because many adolescents become sexually active during or immediately after the pubertal transition, the adolescent visit should include <strong>contraceptive counseling</strong> and <strong>discussion of safe sex practices</strong>.</p><p>Contraceptive counseling ideally takes place before the first sexual encounter.&nbsp; Adolescents are unique in that they have multiple potential barriers to contraception including confidentiality concerns, limited knowledge of reproduction, and misconceptions about contraceptive options.&nbsp; By addressing these concerns, a trusting health care provider&ndash;patient relationship can develop and may lead to higher contraception initiation rates.&nbsp; As a result, contraceptive counseling and discussion of safe sex practices can <strong>reduce unintended pregnancy</strong> and sexually transmitted infection rates.</p><p><strong>(Choice A)</strong>&nbsp; Annual <em>Chlamydia trachomatis</em> screening is indicated for all sexually active women age &lt;25 due to the increased incidence of infection in this patient population.&nbsp; For this reason, dual contraception with condoms plus another contraceptive method is recommended for adolescents.&nbsp; This patient has never been sexually active, and therefore does not require screening.</p><p><strong>(Choice C)</strong>&nbsp; Individuals age &#8805;15 require 3 doses of the human papillomavirus (HPV) vaccine to achieve immunity.&nbsp; In contrast, individuals age &lt;15, such as this patient, require only 2 doses administered 6 months apart to achieve equivalent immunity.&nbsp; This difference is likely attributable to a less mature immune system, which promotes increased antibody production and subsequent immunity with fewer doses.</p><p><strong>(Choice D)</strong>&nbsp; Hemoglobin A1c screening for type 2 diabetes mellitus is performed in individuals age &gt;45.&nbsp; Earlier screening may be indicated in patients with risk factors (eg, obesity, affected first-degree relative).&nbsp; This patient is at low risk.</p><p><strong>(Choice E)</strong>&nbsp; TSH levels are measured in patients with symptoms (eg, weight loss/gain, heat/cold intolerance) or concomitant disorders (eg, hypertension, dyslipidemia).&nbsp; This patient&#39;s sleep pattern is normal for adolescence and her family history is not a screening indication.</p><p><strong>(Choice F)</strong>&nbsp; Breast self-examination is no longer recommended for breast cancer screening in any age group; it increases the rate of false-positive results and unnecessary procedures (eg, biopsy) and does not affect outcomes.</p><p><strong>Educational objective:</strong><br>The adolescent well-child visit should include contraceptive counseling and discussion of safe sex practices.&nbsp; Contraceptive counseling is an opportunity to develop a trusting health care provider&ndash;patient relationship and to decrease the rates of unintended pregnancies and sexually transmitted infections.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 104,
            "subject": "Pediatrics",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 17805,
            "topic": "Contraception",
            "titleId": 17805,
            "title": "Contraception",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "2",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "<em>Chlamydia trachomatis</em> screening",
                    "choiceNumber": 1,
                    "correctTaken": 581,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Discuss contraception",
                    "choiceNumber": 2,
                    "correctTaken": 6471,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Give an additional HPV vaccination dose",
                    "choiceNumber": 3,
                    "correctTaken": 3529,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Hemoglobin A1c testing",
                    "choiceNumber": 4,
                    "correctTaken": 846,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Measure TSH level",
                    "choiceNumber": 5,
                    "correctTaken": 2206,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Teach breast self-examination",
                    "choiceNumber": 6,
                    "correctTaken": 2644,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28742675",
                    "mediaDataId": 0,
                    "title": "ACOG committee opinion no. 710: counseling adolescents about contraception",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28742675",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28426620",
                    "mediaDataId": 0,
                    "title": "ACOG committee opinion no 699: adolescent pregnancy, contraception, and sexual activity.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28426620",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28682927",
                    "mediaDataId": 0,
                    "title": "Contraception counseling for adolescents.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28682927",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 0,
            "othersAvgTimeSpent": 67,
            "notes": null,
            "peopleTaken": 16277,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 40,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 0,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 40,
            "questionId": 2388,
            "questionIndex": 2388,
            "questionText": "<p>A 14-year-old girl is brought to the office by her mother because she has not started menstruating.&nbsp; She is otherwise healthy, has no chronic medical conditions, and is performing well in her classes.&nbsp; The patient takes no daily medications and does not use tobacco, alcohol, or recreational drugs.&nbsp; She has never been sexually active.&nbsp; Her mother and older sister underwent menarche at age 13.&nbsp; Height is at the 15th percentile for age, and weight is at the 20th percentile.&nbsp; Vital signs are normal.&nbsp; On physical examination, heart sounds are normal without murmur.&nbsp; There is no breast development or axillary hair.&nbsp; The abdomen is soft, nontender, and nondistended.&nbsp; Pelvic examination reveals normal external female genitalia and no pubic hair.&nbsp; Ultrasonography confirms the presence of a uterus.&nbsp; Which of the following is the best next step in management of this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p><img  draggable=\"false\" id=\"16370\" src=\"https://www.uworld.com/media/highresdefault/L38795.jpg\"  ></p><p>This patient has <strong>primary amenorrhea</strong>, the absence of menarche in a girl <strong>age &#8805;13 with no secondary sexual characteristics</strong> (eg, axillary/pubic hair) (or &#8805;15 with secondary sexual characteristics).&nbsp; Initial evaluation with <strong>pelvic ultrasonography</strong> establishes the presence or absence of a uterus.&nbsp; If the patient has a uterus (as this patient does), the best next step is to measure the patient&#39;s <strong>FSH level</strong>, which helps distinguish between central and peripheral causes of amenorrhea in the hypothalamic-pituitary-ovarian (HPO) axis.</p><ul><li><p><strong>Central causes</strong> of amenorrhea (ie, hypothalamic, pituitary) result in <strong>low to normal FSH levels</strong> due to decreased production/secretion of either GnRH (hypothalamus) or FSH (anterior pituitary gland).</p></li><li><p><strong>Peripheral causes</strong> of amenorrhea (ie, ovarian) are associated with <strong>high FSH levels</strong>.&nbsp; High FSH levels occur due to a lack of ovarian estrogen and inhibin production; a lack of feedback inhibition to the hypothalamus and pituitary gland results in constant FSH production.&nbsp; Anatomic defects (eg, imperforate hymen) are also a peripheral cause of amenorrhea, but they do not affect the HPO axis and therefore are associated with normal FSH levels.</p></li></ul><p>Based on the FSH level, additional testing for a specific cause (eg, karyotype analysis, MRI of pituitary gland) is performed.</p><p><strong>(Choice A)</strong>&nbsp; Absent breast development indicates a lack of estrogen; determining this patient&#39;s estrogen level would provide no diagnostic information.</p><p><strong>(Choice C)</strong>&nbsp; A GnRH stimulation test can be used in the evaluation of precocious (not delayed) puberty to distinguish central precocious puberty from benign variants.&nbsp; It is not used in the evaluation of primary amenorrhea because it cannot distinguish between hypothalamic and pituitary causes and would provide no information to guide management.</p><p><strong>(Choice D)</strong>&nbsp; In contrast to this patient, a patient without a uterus would undergo karyotype analysis to evaluate for male (eg, androgen insensitivity [46,XY]) and female anatomic (eg, m&uuml;llerian agenesis [46,XX]) causes of amenorrhea.&nbsp; Karyotype analysis is also performed in a patient with a uterus and high FSH level to evaluate for Turner syndrome (45,XO).</p><p><strong>(Choice E)</strong>&nbsp; Reassurance and observation would be appropriate if the patient had primary amenorrhea with secondary sexual characteristics because this is normal until age 15.</p><p><strong>Educational objective:</strong><br>Primary amenorrhea is the absence of menarche in girls age &#8805;13 with no secondary sexual characteristics.&nbsp; In patients with a uterus, the best next step is an FSH level, which distinguishes between central (low/normal FSH) and peripheral (high FSH) causes of amenorrhea.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 104,
            "subject": "Pediatrics",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 212,
            "system": "Female Reproductive System & Breast",
            "topicId": 23429,
            "topic": "Amenorrhea",
            "titleId": 23429,
            "title": "Amenorrhea",
            "topicAttributeId": 330800,
            "topicAttribute": "Menstrual disorders and contraception",
            "correctAnswer": "2",
            "userAnswer": "0",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Estrogen level measurement",
                    "choiceNumber": 1,
                    "correctTaken": 1377,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "FSH level measurement",
                    "choiceNumber": 2,
                    "correctTaken": 6588,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "GnRH stimulation test",
                    "choiceNumber": 3,
                    "correctTaken": 1967,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Karyotype analysis",
                    "choiceNumber": 4,
                    "correctTaken": 2683,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Reassurance and observation",
                    "choiceNumber": 5,
                    "correctTaken": 3453,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": true,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "703",
                    "mediaDataId": 0,
                    "title": "Evaluation of primary amenorrhea",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "20840249",
                    "mediaDataId": 0,
                    "title": "Evaluation and management of adolescent amenorrhea.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/20840249",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 4,
            "othersAvgTimeSpent": 50,
            "notes": null,
            "peopleTaken": 16086,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 41,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 4,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        }
    ],
    "abstractList": null,
    "deckList": [
        {
            "deckId": 9788456,
            "deckName": "Notes",
            "deckColor": "#36c8a3",
            "isDefault": true,
            "dateCreated": "01/01/0001 12:00:00 AM",
            "noOfFlashCards": 4,
            "groupId": null,
            "studySettingsId": null,
            "lastStudyDate": null,
            "isCustomStudyDeck": false,
            "parentDeckId": null,
            "customStudySettings": null,
            "subscriptionId": 0
        }
    ],
    "newExamYearQuestionList": null,
    "flashCardList": null,
    "questionModes": [
        {
            "id": 1,
            "name": "UNUSED"
        }
    ],
    "subscriptionElapsedTime": 0.0,
    "isFacultyControlled": null,
    "endCATTest": null,
    "questionSourceIds": null
}